<SEC-DOCUMENT>0001140361-23-044141.txt : 20230915
<SEC-HEADER>0001140361-23-044141.hdr.sgml : 20230915
<ACCEPTANCE-DATETIME>20230915160137
ACCESSION NUMBER:		0001140361-23-044141
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20230912
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230915
DATE AS OF CHANGE:		20230915

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKET PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001281895
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36829
		FILM NUMBER:		231258613

	BUSINESS ADDRESS:	
		STREET 1:		350 FIFTH AVENUE
		STREET 2:		SUITE 7530
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118
		BUSINESS PHONE:		646-440-9100

	MAIL ADDRESS:	
		STREET 1:		350 FIFTH AVENUE
		STREET 2:		SUITE 7530
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10118

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOTEK PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20040226
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ny20010507x5_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:rckt="http://rocketpharma.com/20230912" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font: 10pt Times New Roman, Times, Serif">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_b57d0eff34e541809504538b1a174f93" contextRef="c20230912to20230912" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_5dee569895b346e0a1e954aa87aa725a" contextRef="c20230912to20230912">0001281895</ix:nonNumeric><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_7ef3f81ea73945c2946527de70834838" contextRef="c20230912to20230912">DE</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_d20f7e5cf5e1470aa0031ed39447f9ee" contextRef="c20230912to20230912">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="rckt-20230912.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20230912to20230912"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001281895</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-12</xbrli:startDate><xbrli:endDate>2023-09-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <p style="margin: 0"></p>
  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>UNITED STATES</b></span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>SECURITIES AND EXCHANGE COMMISSION</b></span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Washington, DC 20549</b></span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160; <br />
    </span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><b>FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_7b40ef2225874905be846709e250d01e" contextRef="c20230912to20230912">8-K</ix:nonNumeric></b></span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>CURRENT REPORT</b></span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</b></span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt">Date of Report (Date of earliest event reported):&#160; <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_c4ec690db7d84bc3a99069d3c153a40a" contextRef="c20230912to20230912" format="ixt:date-monthname-day-year-en">September 12, 2023</ix:nonNumeric></span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 0; margin-bottom: 0; text-align: center;">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>

  </div>

  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 24pt"><b><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_5ee4c53c90304400b1f6e481edd39637" contextRef="c20230912to20230912">Rocket Pharmaceuticals, Inc.</ix:nonNumeric><br />
      </b></span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">(Exact name of registrant as specified in its charter)</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 0; margin-bottom: 0; text-align: center;">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>

  </div>

  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">


  <tr style="font: 10pt Times New Roman, Times, Serif">

    <td style="width: 35%; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b><span style="-sec-ix-hidden:Fact_7ef3f81ea73945c2946527de70834838">Delaware</span><br />
            </b></span></td>

    <td style="width: 30%; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_2c7836dffed4401d9e0fccbcc90523c4" contextRef="c20230912to20230912">001-36829</ix:nonNumeric><br />
            </b></span></td>

    <td style="width: 35%; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_a8e140c6cd5c4cffb1938a216bf12c4d" contextRef="c20230912to20230912">04-3475813</ix:nonNumeric></span><br />
        </td>

  </tr>

  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(State or other jurisdiction of incorporation)</span></td>

    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(Commission File Number)</span></td>

    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(IRS Employer Identification No.)</span></td>

  </tr>


</table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 0; margin-bottom: 0; text-align: center;">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>

  </div>

  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">


  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="width: 50.57%; text-align: center; font: 10pt Times New Roman,Times,serif;"><span style="font-size: 10pt"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_4d771d266cef46d9bc81738f2e8109e9" contextRef="c20230912to20230912">9 Cedarbrook Drive</ix:nonNumeric>,
              <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_cced988fae7e4e8197f2e80664985e22" contextRef="c20230912to20230912">Cranbury</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_58d72708c1dc47179e33bedde4a2e64e" contextRef="c20230912to20230912">NJ</ix:nonNumeric></b></span></td>

    <td style="width: 49.43%; text-align: center; font: 10pt Times New Roman,Times,serif;"><span style="font-size: 10pt"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_97c314c10a114b9e88905dfc4b19ce54" contextRef="c20230912to20230912">08512</ix:nonNumeric><br />
            </b></span></td>

  </tr>

  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>(</b>Address of principal executive offices)</span></td>

    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(Zip Code)</span></td>

  </tr>


</table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 0; margin-bottom: 0; text-align: center;">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>

  </div>

  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">Registrant&#8217;s telephone number, including area code:&#160; (<ix:nonNumeric name="dei:CityAreaCode" id="Fact_36ef56850f9047d8b6c48c693ba42d42" contextRef="c20230912to20230912">646</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_97568cdcb17b41bb9d13c9d83e69321b" contextRef="c20230912to20230912">440-9100</ix:nonNumeric></span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 0; margin-bottom: 0; text-align: center;">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>

  </div>

  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Not applicable</b></span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">(Former name or former address, if changed since last report)</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
      following provisions (see General Instruction A.2):</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">


  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="width: 48px; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_d488bda2ed454bffa8cb95617738a787" contextRef="c20230912to20230912" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </span></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>

  </tr>


</table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">


  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="width: 48px; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_25a3b1b2479c4a6c90d2db814274a4a4" contextRef="c20230912to20230912" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </span></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>

  </tr>


</table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">


  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="width: 48px; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_b903dda86e524e22975cf8629ad77690" contextRef="c20230912to20230912" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </span></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>

  </tr>


</table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">


  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="width: 48px; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_98a6813b6b4c459280d27af7750bf7c4" contextRef="c20230912to20230912" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </span></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>

  </tr>


</table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span>&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">


  <tr style="font: 10pt Times New Roman, Times, Serif">

    <td style="white-space: nowrap; width: 34%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">Title of each class</span></td>

    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>

    <td style="width: 30%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">Trading</span></p>
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">Symbol(s)</span></p>
        </td>

    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>

    <td style="width: 34%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">Name of each exchange on which registered</span></p>
        </td>

  </tr>

  <tr style="font: 10pt Times New Roman, Times, Serif">

    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_de6de76c6b5e4726b161c221c9748838" contextRef="c20230912to20230912">Common stock, $0.01 par value</ix:nonNumeric><br />
          </span></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>

    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_23d4872fe63b4ee9a7fee65567e9a008" contextRef="c20230912to20230912">RCKT</ix:nonNumeric><br />
          </span></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>

    <td style="text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden:Fact_d20f7e5cf5e1470aa0031ed39447f9ee">The Nasdaq Global Market</span><br />
        </td>

  </tr>


</table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;
      230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-size: 10pt">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_86bb798c71fb45fc8bf31d5b0b06b35e" contextRef="c20230912to20230912" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
      revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea">&#160;</div>

    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" /> </div>

  </div>

  <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">


  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>Item 1.01</b></span></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>Entry into a Material Definitive Agreement.</b></span></td>

  </tr>


</table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b><i>&#160;</i></b></span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
  <div><span style="font-size: 10pt">On September 12, 2023, Rocket Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with J.P. Morgan Securities LLC, Morgan Stanley &amp; Co. LLC, Leerink Partners
      LLC and Cowen and Company, LLC, as representatives of the several underwriters named in Schedule A thereto (collectively, the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and sell up to (i) 7,812,500 shares of common stock (the
      &#8220;Shares&#8221;), and (ii) pre-funded warrants <span style="background-color: white">(the&#160;&#8220;Pre-Funded&#160;Warrants&#8221;) </span>to purchase 3,126,955 shares of common stock (the &#8220;Offering&#8221;). In addition, the Company granted the Underwriters a 30-day option to
      purchase up to an additional 1,640,918 shares of its common stock (the &#8220;Option Shares&#8221;).</span></div>

  <div>
<div><br /></div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Underwriters exercised their option to purchase the Option Shares in full, and the Offering closed on September 15, 2023.</div>

  </div>

  <div><span style="font-size: 10pt"> <br />
    </span></div>

  <div><span style="font-size: 10pt">The Shares and the Option Shares were sold in the Offering at the public offering price of $16.00 per share and were purchased by the Underwriters from the Company at a price of $15.04 per share. T<span style="background-color: white">he&#160;Pre-Funded&#160;Warrants were sold at a public offering price of $</span>15.99 <span style="background-color: white">per&#160;Pre-Funded&#160;Warrant, which represents the per share public offering price for the common stock
        less the $0.01 per share exercise price for each such&#160;Pre-Funded&#160;Warrant.</span></span> Each Pre-Funded Warrant is exercisable as of September 15, 2023 until fully exercised, subject to an ownership limitation pursuant to the Underwriting
    Agreement.</div>

  <div><span style="font-size: 10pt"><span style="background-color: white"> <br />
      </span></span></div>

  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">The Offering was made pursuant to the Company&#8217;s effective registration statement on Form S-3 (Registration No. 333-253756), which was previously filed with
      the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and declared effective on September 10, 2021.</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">The net proceeds from the Offering, after</span> (i) giving effect to the Underwriters&#8217; full exercise of their option to purchase the Option Shares and (ii)
    <span style="font-size: 10pt">deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, are expected to be approximately $188.9 million. The Company currently intends to use the net proceeds from the
      offering primarily to fund the further development of its pipeline of gene therapies for rare diseases, including the advancement of RP-A501 into a Phase 2 clinical trial and the continued clinical development of RP-A501, to accelerate the
      development of in-house manufacturing capabilities, and for general corporate purposes. The Company may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products. However, the Company currently
      has no agreements or commitments to complete any such transaction.</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <div><span style="font-size: 10pt">Pursuant to the Underwriting Agreement, the Company&#8217;s executive officers and directors, and certain other shareholders entered into agreements in substantially the form included as an exhibit to the Underwriting Agreement,
    providing for a 90-day &#8220;lock-up&#8221; period with respect to sales of the Company&#8217;s common stock, subject to certain exceptions.</span></div>

  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">The foregoing is a summary description of the Underwriting Agreement and is qualified in its entirety by the text of the Underwriting Agreement attached as
      Exhibit 1.1 to this Current Report on Form 8-K and incorporated herein by reference.</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt; background-color: white">The form of&#160;Pre-Funded&#160;Warrant is filed as Exhibit&#160;4.1 to this report and the description of the terms of the&#160;Pre-Funded&#160;Warrants is
      qualified in its entirety by reference to such exhibit.</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">A copy of the opinion of K&amp;L Gates LLP relating to the validity of the Shares, the Option Shares and the Pre-Funded Warrants issued in the Offering is
      filed herewith as Exhibit 5.1.</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span>&#160; </p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea">&#160;</div>

    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" /> </div>

  </div>

  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">


  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="width: 96px; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>Item 9.01</b></span></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></td>

  </tr>


</table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">


  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="width: 3%; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(d)</span></td>

    <td style="width: 97%; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Exhibits</span></td>

  </tr>


</table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">


  <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">

    <td style="white-space: nowrap; width: 96px; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>

    <td style="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>Description</b></span></td>

  </tr>

  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><a href="ny20010507x5_ex1-1.htm"><span style="font-size: 10pt">1.1</span></a></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Underwriting Agreement, dated September 12, 2023, among Rocket Pharmaceuticals, Inc. and J.P. Morgan Securities LLC, Morgan Stanley &amp; Co. LLC, Leerink Partners
            LLC and Cowen and Company, LLC, as representative of the several underwriters named in Schedule A thereto.</span></td>

  </tr>

  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><a href="ny20010507x5_ex4-1.htm"><span style="font-size: 10pt">4.1</span></a></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Form of Pre-Funded Warrant.</span></td>

  </tr>

  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><a href="ny20010507x5_ex5-1.htm"><span style="font-size: 10pt">5.1</span></a></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Opinion of K&amp;L Gates LLP.</span></td>

  </tr>

  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><a href="ny20010507x5_ex5-1.htm"><span style="font-size: 10pt">23.1</span></a></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Consent of K&amp;L Gates LLP (contained in Exhibit 5.1).</span></td>

  </tr>

  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Exhibit 104</span></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td>

  </tr>


</table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea">&#160;</div>

    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" /> </div>

  </div>

  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>SIGNATURES</b></span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">


  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Date: September 15, 2023</span></td>

    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>Rocket Pharmaceuticals, Inc.</b></span></td>

  </tr>

  <tr style="font: 10pt Times New Roman, Times, Serif">

    <td style="width: 51%; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>

    <td style="width: 5%; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>

    <td style="width: 44%; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>

  </tr>

  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">By:</span></td>

    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">/s/ Gaurav Shah, MD</span></td>

  </tr>

  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Name:</span></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Gaurav Shah, MD</span></td>

  </tr>

  <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Title:</span></td>

    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Chief Executive Officer and Director</span></td>

  </tr>


</table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
  <div><br /></div>

  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" />
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ny20010507x5_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">
  <p style="margin: 0; text-align: right"></p>
  <!-- Field: Rule-Page -->
  <div align="LEFT">
    <div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin: 0; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit 1.1</b></font></p>
  <p style="margin: 0; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="margin: 0"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Execution Version</i></b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="margin: 0"></p>
  <p style="margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="margin: 0"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rocket Pharmaceuticals</b>, <b>Inc</b>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7,812,500 Shares of Common Stock</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Funded Warrants to Purchase 3,126,955 Shares of Common Stock</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>UNDERWRITING AGREEMENT</u></b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 12, 2023</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">J.P. Morgan Securities LLC &#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Morgan Stanley &amp; Co. LLC</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEERINK PARTNERS LLC&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COWEN AND COMPANY, LLC</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As Representatives of the several Underwriters</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o J.P. Morgan Securities LLC&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">383 Madison Avenue&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, New York 10179</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o Morgan Stanley &amp; Co. LLC&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1585 Broadway&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, New York 10036</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o Leerink Partners LLC&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1301 Avenue of the Americas, 12th Floor&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, New York 10019</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o Cowen and Company, LLC&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">599 Lexington Avenue&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, New York 10022</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear Sirs and Madams:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i>INTRODUCTORY</i>. Rocket Pharmaceuticals, Inc., a
      Delaware corporation (the &#8220;<b><i>Company</i></b>&#8221;), proposes to sell, pursuant to the terms of this Underwriting Agreement, to the several underwriters named in <u>Schedule A</u> hereto (the &#8220;<b><i>Underwriters</i></b>,&#8221; or, each, an &#8220;<b><i>Underwriter</i></b>&#8221;),




      an aggregate of (a) 7,812,500 shares of Common Stock, par value $0.01 per share (the &#8220;<b><i>Common Stock</i></b>&#8221;), of the Company (the &#8220;<b><i>Firm Stock</i></b>&#8221;) and (b) pre-funded warrants to purchase up to 3,126,955 shares of Common Stock in a
      form to be mutually agreed upon by the Company and the Representatives (as defined below) (the &#8220;<b><i>Warrants</i></b>&#8221;). The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section&#160;3 hereof, up to an
      additional 1,640,918 shares of Common Stock (the &#8220;<b><i>Optional Stock</i></b>&#8221;). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the &#8220;<b><i>Stock</i></b>.&#8221; The Stock and the Warrants are herein referred to as the &#8220;<b><i>Securities</i></b>.&#8221;





      The shares of Common Stock issuable upon exercise of the Warrants are herein referred to as the &#8220;<b><i>Warrant Stock</i></b>.&#8221; J.P. Morgan Securities LLC, Morgan Stanley &amp; Co. LLC, Leerink Partners LLC and Cowen and Company, LLC are acting as
      representatives of the several Underwriters and in such capacity are hereinafter referred to as the &#8220;<b><i>Representatives</i></b>.&#8221;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i>REPRESENTATIONS AND WARRANTIES OF THE COMPANY</i>. The
      Company represents and warrants to the several Underwriters, as of the date hereof and as of each Closing Date (as defined below), and agrees with the several Underwriters, that:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A registration statement of the Company on Form&#160;S-3 (File
      No.&#160;333-253756) (including all amendments thereto, the &#8220;<b><i>Initial Registration Statement</i></b>&#8221;) in respect of the Stock has been filed with the Securities and Exchange Commission (the &#8220;<b><i>Commission</i></b>&#8221;) pursuant to Rule 415 under the
      Securities Act of 1933, as amended (the &#8220;<b><i>Securities Act</i></b>&#8221;). The Company meets the requirements for use of Form S-3 under the Securities Act and the rules and regulations of the Commission thereunder (the &#8220;<b><i>Rules and Regulations</i></b>&#8221;).




      The Initial Registration Statement and any post-effective amendment thereto, each in the form heretofore delivered to you, and, excluding exhibits thereto, to you for each of the other Underwriters, have been declared effective by the Commission in
      such form and meet the requirements of the Securities Act, and the Rules and Regulations. The proposed offering of the Securities and the Warrant Stock may be made pursuant to General Instruction I.B.1. of Form S-3. Other than (i)&#160;the Initial
      Registration Statement, (ii)&#160;a registration statement, if any, increasing the size of the offering filed pursuant to Rule 462(b) under the Securities Act and the Rules and Regulations (a &#8220;<b><i>Rule 462(b) Registration Statement</i></b>&#8221;), (iii)&#160;any
      Preliminary Prospectus (as defined below), (iv)&#160;the Prospectus (as defined below) contemplated by this Agreement to be filed pursuant to Rule 424(b) of the Rules and Regulations in accordance with Section&#160;4(a) hereof and (v)&#160;any Issuer Free Writing
      Prospectus (as defined below), no other document with respect to the offer and sale of the Securities has heretofore been filed with the Commission. No stop order suspending the effectiveness of the Initial Registration Statement, any post-effective
      amendment thereto or the Rule&#160;462(b) Registration Statement, if any, has been issued and no proceeding for that purpose or pursuant to Section&#160;8A of the Securities Act has been initiated or, to the Company&#8217;s knowledge, threatened by the Commission
      (any preliminary prospectus included in the Initial Registration Statement or filed with the Commission pursuant to Rule&#160;424 of the Rules and Regulations is hereinafter called a &#8220;<b><i>Preliminary Prospectus</i></b>&#8221;). The Initial Registration
      Statement including all exhibits thereto and including the information contained in the Prospectus filed with the Commission pursuant to Rule&#160;424(b) of the Rules and Regulations and deemed by virtue of Rules&#160;430A and 430B under the Securities Act to
      be part of the Initial Registration Statement at the time it became effective is hereinafter collectively called the &#8220;<b><i>Registration Statement</i></b>.&#8221; If the Company has filed a Rule&#160;462(b) Registration Statement, then any reference herein to
      the term &#8220;<b><i>Registration Statement</i></b>&#8221; shall be deemed to include such Rule&#160;462 Registration Statement. The base prospectus included in the Initial Registration Statement at the time of effectiveness thereof, as supplemented by the final
      prospectus supplement relating to the offer and sale of the Securities, in the form filed pursuant to and within the time limits described in Rule&#160;424(b) under the Rules and Regulations, is hereinafter called the &#8220;<b><i>Prospectus</i></b>.&#8221;</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">&#160;</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any reference herein to the Registration Statement, Preliminary
      Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein. Any reference to any amendment or supplement to any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include
      any documents filed after the date of such Preliminary Prospectus or the Prospectus under the Securities Exchange Act of 1934, as amended (the &#8220;<b><i>Exchange Act</i></b>&#8221;), and incorporated by reference in such Preliminary Prospectus or Prospectus,
      as the case may be. Any reference to any amendment to the Registration Statement shall be deemed to refer to and include any annual report of the Company filed pursuant to Section&#160;13(a) or 15(d) of the Exchange Act after the date of this Agreement
      that is incorporated by reference in the Registration Statement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As of the Applicable Time (as defined below) and as of the
      Closing Date or the Option Closing Date (as defined below), as the case may be, neither (i)&#160;the Pricing Prospectus (as defined below) and the information included on <u>Schedule&#160;C </u>hereto, all considered together (collectively, the &#8220;<b><i>General




          Disclosure Package</i></b>&#8221;), (ii)&#160;any individual Limited Use Free Writing Prospectus (as defined below), nor (iii)&#160;the bona fide electronic road show (as defined in Rule&#160;433(h)(5) of the Rules and Regulations); when considered together with the
      General Disclosure Package, included or will include any untrue statement of a material fact or omitted or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
      made, not misleading; <i>provided</i>, <i>however</i>, that the Company makes no representations or warranties as to information contained in or omitted from the Pricing Prospectus or any Issuer Free Writing Prospectus (as defined below), in
      reliance upon, and in conformity with, written information furnished to the Company through the Representatives by or on behalf of any Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the
      Underwriters&#8217; Information (as defined below). As used in this paragraph (b)&#160;and elsewhere in this Agreement:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Applicable Time</i></b>&#8221; means 8:30 P.M., New York City time, on
      the date of this Agreement or such other time as agreed to by the Company and the Representatives.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>General Use Free Writing Prospectus</i></b>&#8221; means any Issuer Free
      Writing Prospectus that is identified on <u>Schedule B</u> to this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Issuer Free Writing Prospectus</i></b>&#8221; means any &#8220;issuer free
      writing prospectus,&#8221; as defined in Rule&#160;433 of the Rules and Regulations relating to the Securities in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&#8217;s records pursuant
      to Rule&#160;433(g) of the Rules and Regulations.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Limited Use Free Writing Prospectuses</i></b>&#8221; means any Issuer
      Free Writing Prospectus that is not a General Use Free Writing Prospectus.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Pricing Prospectus</i></b>&#8221; means the Preliminary Prospectus
      relating to the Securities that is included in the Registration Statement immediately prior to the Applicable Time, including any document incorporated by reference therein.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">2</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b><i>Written Testing-the-Waters Communication</i></b>&#8221; means any
      Testing-the-Waters Communication (as defined below) that is a written communication within the meaning of Rule 405 of the Rules and Regulations.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No order preventing or suspending the use of any
      Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus relating to the proposed offering of the Securities has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&#160;8A of the Securities Act has
      been instituted or, to the Company&#8217;s knowledge, threatened by the Commission, and each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Securities Act and the Rules and Regulations,
      and did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; <i>provided</i>,
      <i>however</i>, that the Company makes no representations or warranties as to information contained in or omitted from any Preliminary Prospectus, in reliance upon, and in conformity with, written information furnished to the Company through the
      Representatives by or on behalf of any Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters&#8217; Information.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; At the respective times the Registration Statement and any
      amendments thereto became or become effective as to the Underwriters and at each Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and the
      Rules and Regulations and did not and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any
      amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at each Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and the Rules and
      Regulations and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading; <i>provided</i>,
      <i>however</i>, that the foregoing representations and warranties in this paragraph (d)&#160;shall not apply to information contained in or omitted from the Registration Statement or the Prospectus or any amendment or supplement thereto, in reliance upon,
      and in conformity with, written information furnished to the Company through the Representatives by or on behalf of any Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters&#8217;
      Information.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each Issuer Free Writing Prospectus, as of its issue date
      and at all subsequent times through the completion of the public offer and sale of the Securities or until any earlier date that the Company notified or notifies the Representatives as described in Section&#160;4(f) hereof, did not, does not and will not
      include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Pricing Prospectus or the Prospectus including any document incorporated by reference therein and any prospectus
      supplement deemed to be a part thereof that has not been superseded or modified, or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact required to be stated therein or necessary in order
      to make the statements therein, in the light of the circumstances under which they were made, not misleading <i>provided</i>, <i>however</i>, that the foregoing representations and warranties in this paragraph (e)&#160;shall not apply to information
      contained in or omitted from the Registration Statement, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, in reliance upon, and in conformity with, written information furnished to the Company through the
      Representatives by or on behalf of any Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters&#8217; Information.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The documents incorporated by reference in the
      Prospectus, when they were filed with the Commission conformed in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder and none of such
      documents contained any untrue statement of a material fact or omitted to state any material fact required to be stated therein, or necessary to make the statements therein, in the light of the circumstances under which they were made, not
      misleading; and any further documents so filed and incorporated by reference in the Prospectus, when such documents are filed with Commission will conform in all material respects to the requirements of the Securities Act or the Exchange Act, as
      applicable, and the rules and regulations of the Commission thereunder and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the
      light of the circumstances under which they were made, not misleading.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except as disclosed in the General Disclosure Package,
      the Company has not, directly or indirectly, distributed and will not distribute any offering material in connection with the offering and sale of the Securities other than any Preliminary Prospectus, the Prospectus, the form of Warrant and other
      materials, if any, permitted under the Securities Act and consistent with Section&#160;4(c) below. The Company will file with the Commission all Issuer Free Writing Prospectuses (other than a &#8220;road show&#8221; as described in Rule&#160;433(d)(8) of the Rules and
      Regulations) in the time and manner required under Rules&#160;163(b)(2) and 433(d) of the Rules and Regulations.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">3</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; [<i>Reserved</i>].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At the time of filing the Initial Registration Statement,
      any Rule&#160;462(b) Registration Statement and any post-effective amendments thereto, and at the date hereof, the Company was not, and the Company currently is not, an &#8220;ineligible issuer,&#8221; as defined in Rule&#160;405 of the Rules and Regulations.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as disclosed in the General Disclosure Package,
      the Company (a) has not engaged in any Testing-the-Waters Communication and (b) has not authorized anyone to engage in Testing-the-Waters Communications, in each case in respect of the offering of the Securities. The Company has not distributed any
      Written Testing-the-Waters Communications in connection with the offering of the Securities. &#8220;<b><i>Testing-the-Waters Communication</i></b>&#8221; means any oral or written communication with potential investors undertaken in reliance on Rule 163B under
      the Securities Act.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company has been duly organized and is validly
      existing as a corporation (or the foreign equivalent thereof) under the laws of the State of Delaware. The Company is duly qualified to do business and is in good standing as a foreign corporation or other legal entity in each jurisdiction in which
      its respective ownership or lease of property or the conduct of its business requires such qualification and has all power and authority (corporate or other) necessary to own or hold its properties and to conduct the business in which it is engaged,
      except where the failure to so qualify or have such power or authority would not (i)&#160;have, singularly or in the aggregate, a material adverse effect on the business, properties, management, financial condition, stockholders&#8217; equity, results of
      operations or prospects of the Company and its subsidiaries taken as a whole, or (ii)&#160;impair in any material respect the ability of the Company to perform its obligations under this Agreement or to consummate any transactions contemplated by this
      Agreement, the General Disclosure Package or the Prospectus (any such effect as described in clauses (i)&#160;or (ii), a &#8220;<b><i>Material Adverse Effect</i></b>&#8221;). The Company does not own or control, directly or indirectly, any interest in any
      corporation, partnership, limited liability corporation, association or other entity other than Rocket Pharmaceuticals, Ltd., an exempted company with limited liability organized under the laws of the Cayman Islands, Inotek Securities Corporation, a
      corporation organized under the laws of the Commonwealth of Massachusetts, Rocket Foundation, Inc., a corporation organized under the laws of Delaware, Spacecraft Seven, LLC, a limited liability company organized under the laws of Delaware, Zebrafish
      Merger Sub II, Inc., a corporation organized under the laws of Delaware, Renovacor Holdings, Inc., a corporation organized under the laws of Delaware, Rocket Pharmaceuticals B.V., a private limited company organized under the laws of the Netherlands,
      Rocket Pharmaceuticals GmbH, a limited liability company organized under the laws of Switzerland, and Rocket Pharmaceuticals UK Limited, a limited company organized under the laws of the United Kingdom.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each of the Company&#8217;s &#8220;subsidiaries&#8221; (for purposes of
      this Agreement, as defined in Rule&#160;405 under the Securities Act) has been duly organized and is validly existing in good standing (where such concept exists) under the laws of the jurisdiction of its organization and has the power and authority to
      own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus.&#160;Each of the Company&#8217;s subsidiaries is duly qualified to transact business and is in good
      standing (where such concept exists) in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where failure to be so qualified or in good standing could
      not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.&#160;All of the issued and outstanding share capital or other equity or ownership interests of each of the Company&#8217;s subsidiaries has been duly authorized and
      validly issued, is fully paid and nonassessable (where such concept exists) and is owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim, except as
      disclosed in the Registration Statement, the General Disclosure Package and the Prospectus.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Agreement has been duly authorized, executed and
      delivered by the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Securities to be issued and sold by the Company to the
      Underwriters hereunder has been duly and validly authorized and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued, fully paid and non-assessable and will conform to the descriptions thereof in the
      Registration Statement, the General Disclosure Package and the Prospectus; and the issuance of the Securities is not subject to any preemptive or similar rights.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">4</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; All of the outstanding shares of capital stock of the
      Company have been duly and validly authorized and issued, are fully paid and non-assessable, have been issued in compliance with federal and state securities laws, and conform in all material respects to the description thereof contained in the
      General Disclosure Package and the Prospectus under the heading &#8220;Description of Capital Stock.&#8221; All of the Company&#8217;s options, warrants and other rights to purchase or exchange any securities for shares of the Company&#8217;s capital stock have been duly
      authorized and validly issued and were issued in compliance with federal and state securities laws. None of the outstanding shares of Common Stock was issued in violation of any preemptive rights, rights of first refusal or other similar rights to
      subscribe for or purchase securities of the Company other than those which have been waived or satisfied. As of the date set forth in the General Disclosure Package and the Prospectus, there are no authorized or outstanding shares of capital stock,
      options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company other than those described above or
      accurately described in the General Disclosure Package. Since such date, the Company has not issued any securities other than Common Stock issued pursuant to the exercise of warrants or upon the exercise of stock options or other awards outstanding
      under the Company&#8217;s stock option plans, options or other securities granted or issued pursuant to the Company&#8217;s existing equity compensation plans or other plans, and the issuance of Common Stock pursuant to employee stock purchase plans. The
      description of the Company&#8217;s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, as described in the General Disclosure Package and the Prospectus, accurately and fairly present in all
      material respects the information required to be shown with respect to such plans, arrangements, options and rights.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The execution, delivery and performance of this Agreement
      and the Warrants by the Company, the issue and sale of the Securities by the Company and the consummation of the transactions contemplated hereby will not (with or without notice or lapse of time or both) (i)&#160;conflict with or result in a breach or
      violation of any of the terms or provisions of, constitute a default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, encumbrance, security interest, claim or charge upon any property
      or assets of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its
      subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject, (ii)&#160;result in any violation of the provisions of the charter or by-laws (or analogous governing instruments, as applicable) of the
      Company or any of its subsidiaries or (iii)&#160;result in the violation of any law, statute, rule, regulation, judgment, order or decree of any court or governmental or regulatory agency or body, domestic or foreign, having jurisdiction over the Company
      or any of its subsidiaries or their properties or assets except, in the case of clauses (i)&#160;and (iii)&#160;above, for any such conflict, breach, violation or default that would not, individually or in the aggregate, reasonably be expected to have a
      Material Adverse Effect. A &#8220;<b><i>Debt Repayment Triggering Event</i></b>&#8221; means any event or condition that gives, or with the giving of notice or lapse of time would give the holder of any note, debenture or other evidence of indebtedness (or any
      person acting on such holder&#8217;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except for the registration of the Securities under the
      Securities Act, and applicable state securities laws, and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority (&#8220;<b><i>FINRA</i></b>&#8221;) and The Nasdaq
      Global Market in connection with the purchase and distribution of the Securities by the Underwriters, no consent, approval, authorization or order of, or filing, qualification or registration (each an &#8220;<b><i>Authorization</i></b>&#8221;) with, any court,
      governmental or regulatory agency or body, foreign or domestic, which has not been made, obtained or taken and is not in full force and effect, is required for the execution, delivery and performance of this Agreement by the Company, the issuance and
      sale of the Securities or the consummation of the transactions contemplated hereby; and no event has occurred that allows or results in, or after notice or lapse of time or both would allow or result in, revocation, suspension, termination or
      invalidation of any such Authorization or any other impairment of the rights of the holder or maker of any such Authorization. All corporate approvals (including those of stockholders) necessary for the Company to consummate the transactions
      contemplated by this Agreement have been obtained and are in effect.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; EisnerAmper LLP, who has certified certain financial
      statements of the Company and its subsidiaries included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, is an independent registered public accounting firm with respect to the Company
      within the meaning of Article 2-01 of Regulation S-X and the Public Company Accounting Oversight Board (United States) (the &#8220;<b><i>PCAOB</i></b>&#8221;).</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">5</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The financial statements, together with the related
      notes, included or incorporated by reference in the General Disclosure Package, the Prospectus and in the Registration Statement fairly present in all material respects the consolidated financial position of, respectively, the Company and its
      subsidiaries, and their respective results of operations and changes in cash flows at the respective dates or for the respective periods therein specified. Such statements and related notes have been prepared in accordance with the generally accepted
      accounting principles in the United States (&#8220;<b><i>GAAP</i></b>&#8221;) applied on a consistent basis throughout the periods involved except as may be set forth in the related notes included or incorporated by reference in the General Disclosure Package.
      The financial statements, together with the related notes, included or incorporated by reference in the General Disclosure Package and the Prospectus comply in all material respects with Regulation S-X. No other financial statements or supporting
      schedules or exhibits are required by Regulation S-X to be described or included in the Registration Statement, the General Disclosure Package or the Prospectus. The summary and selected financial data included or incorporated by reference in the
      General Disclosure Package, the Prospectus and the Registration Statement fairly present in all material respects the information shown therein as at the respective dates and for the respective periods specified and are derived from the consolidated
      financial statements set forth in the Registration Statement, the Pricing Prospectus and the Prospectus. The interactive data in eXtensible Business Reporting Language (&#8220;<b><i>XBRL</i></b>&#8221;) included or incorporated by reference in the Registration
      Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company and its subsidiaries, taken as a whole, have
      not sustained, since the date of the latest audited consolidated financial statements included or incorporated by reference in the General Disclosure Package, (i)&#160;any material loss or interference with its business from fire, explosion, flood or
      other calamity, whether or not covered by insurance, or from any labor dispute or action, order or decree of any court or governmental or regulatory authority, otherwise than as set forth or contemplated in the General Disclosure Package; or (ii)&#160;any
      change in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options and warrants described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the
      Registration Statement, the General Disclosure Package and the Prospectus) or long-term debt of the Company, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or
      any material adverse changes, or any development involving a prospective material adverse change, in or affecting the business, properties, assets, general affairs, management, financial position, prospects, stockholders&#8217; equity or results of
      operations of the Company and its subsidiaries taken as a whole, otherwise than as set forth or contemplated in the General Disclosure Package.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except as set forth in the General Disclosure Package,
      there is no legal or governmental proceeding to which the Company or any of its subsidiaries is a party or of which any property or assets of the Company or any of its subsidiaries is the subject, including any proceeding before the United States
      Food and Drug Administration of the U.S. Department of Health and Human Services (&#8220;<b><i>FDA</i></b>&#8221;) or comparable federal, state, local or foreign governmental bodies (it being understood that the interaction between the Company and the FDA and
      such comparable governmental bodies relating to the clinical development and product approval process shall not be deemed proceedings for purposes of this representation), which is required to be described in the Registration Statement, the General
      Disclosure Package or the Prospectus or a document incorporated by reference therein and is not described therein, or which, singularly or in the aggregate, if determined adversely to the Company, would reasonably be expected to have a Material
      Adverse Effect; and to the Company&#8217;s knowledge, no such proceedings are threatened, by governmental authorities or others. The Company and its subsidiaries are and have been in compliance with all applicable federal, state, local and foreign laws,
      regulations, orders and decrees governing its business as prescribed by the FDA, or any other federal, state or foreign agencies or bodies engaged in the regulation of pharmaceuticals or biohazardous substances or materials, including without
      limitation, the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), the Public Health Service Act (42 U.S.C. &#167;&#167; 201 et seq.) and the regulations promulgated thereunder, except where noncompliance would not, singly or in the aggregate,
      have a Material Adverse Effect. All preclinical and clinical studies conducted by or on behalf of the Company or its subsidiaries to support approval for commercialization of the Company&#8217;s products have been conducted by the Company or its
      subsidiaries, or to the Company&#8217;s knowledge by third parties, in compliance with all applicable federal, state or foreign laws, rules, orders and regulations, except for such failure or failures to be in compliance which would not reasonably be
      expected to have, singly or in the aggregate, a Material Adverse Effect.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company and its subsidiaries are not in (i)&#160;violation
      of their respective charters or by-laws (or analogous governing instrument, as applicable), (ii)&#160;default in any respect, and no event has occurred which, with notice or lapse of time or both, would constitute such a default, in the due performance or
      observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which they are a party or by which they are bound or to which any of their property or assets
      is subject or (iii)&#160;violation in any respect of any law, ordinance, governmental rule, regulation or court order, decree or judgment to which they or their property or assets may be subject (including, without limitation, those administered by the
      FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA) except, in the case of clauses (ii)&#160;and (iii)&#160;above, for any such violation or default that would not,
      singularly or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">6</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company and its subsidiaries possess all licenses,
      certificates, exemptions, authorizations, approvals and permits issued by, and have made all declarations and filings with, the appropriate local, state, federal or foreign governmental or regulatory agencies or bodies (including, without limitation,
      the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA) that are necessary for the ownership or lease of their respective properties or the conduct of their
      business as described in the General Disclosure Package and the Prospectus (collectively, the &#8220;<b><i>Governmental Permits</i></b>&#8221;) except where any failures to possess or make the same would not, singularly or in the aggregate, reasonably be
      expected to have a Material Adverse Effect. The Company and its subsidiaries are in compliance with all such Governmental Permits and all such Governmental Permits are valid and in full force and effect, except for such non-compliance, validity or
      failure to be in full force and effect that would not, singularly or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries have not received notification of any revocation, modification,
      suspension, termination or invalidation (or proceedings related thereto) of any such Governmental Permit and the Company has no reason to believe that any such Governmental Permit will not be renewed. The Company, and to the Company&#8217;s knowledge, its
      and its subsidiaries respective directors, officers, employees or agents, are and have been in compliance in all material respects with applicable federal, state, local and foreign health care regulatory laws, including without limitation, laws
      related to (1) fraud and abuse, including the Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal false claims Law (42 U.S.C. &#167; 1320a-7b(a)), 18 U.S.C. Sections 286 and 287,
      the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996 (&#8220;<b><i>HIPAA</i></b>&#8221;) (42 U.S.C. Section 1320d et seq.), the exclusion laws (42 U.S.C. &#167; 1320a-7), and the civil monetary penalties law
      (42 U.S.C. &#167; 1320a-7a); (2) payment transparency, including the Physician Payments Sunshine Act (42 U.S.C. &#167; 1320a-7h); (3) privacy and security of protected health information, including HIPAA, as amended by the Health Information Technology for
      Economic and Clinical Health Act (the &#8220;<b><i>HITECH Act</i></b>&#8221;) (42 U.S.C. Section 17921 et seq.); and (4) the Medicare and Medicaid statutes (Titles XVIII and XIX of the Social Security Act); each together with their implementing regulations
      (collectively, &#8220;<b><i>Health Care Laws</i></b>&#8221;). The Company and its subsidiaries have not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court, arbitrator or
      governmental or regulatory authority or third party alleging that the Company, any of its subsidiaries or any of their respective personnel has violated any applicable Health Care Law, nor to the Company&#8217;s knowledge has any such claim, action, suit,
      proceeding, hearing, enforcement, investigation, arbitration or other action been threatened. Neither the Company nor any of its subsidiaries is a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreements,
      deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any governmental or regulatory authority. Additionally, none of the Company, any of its
      subsidiaries or, to the knowledge of the Company, any of their respective employees, officers or directors has been excluded, suspended or debarred from participation in any federal health care program.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The studies, tests and preclinical or clinical trials
      conducted by or on behalf of the Company and its subsidiaries that are described in the General Disclosure Package and the Prospectus (the &#8220;<b><i>Company Studies and Trials</i></b>&#8221;) were and, if still pending, are being, conducted in all material
      respects in accordance with the experimental protocols established for such studies, test, or trials, and all applicable laws rules and regulations, including without limitation, 21 C.F.R. Parts 50, 54, 56, 58 and 312; the descriptions of the results
      of the Company Studies and Trials contained in the General Disclosure Package and Prospectus are accurate in all material respects; the Company has no knowledge of any other studies or trials not described in the General Disclosure Package and the
      Prospectus, the results of which are inconsistent with or call in question the results described or referred to in the General Disclosure Package and the Prospectus; and the Company and its subsidiaries have not received any notices or correspondence
      with the FDA or any foreign, state or local governmental body exercising comparable authority requiring the termination, suspension or material modification of any Company Studies or Trials that would reasonably be expected to have a Material Adverse
      Effect and, to the Company&#8217;s knowledge, there are no reasonable grounds for the same. In using or disclosing patient information received by the Company in connection with the Company Studies and Trials, the Company and its subsidiaries have complied
      in all material respects with all applicable laws and regulatory rules or requirements, including, without limitation, the Health Insurance Portability and Accountability Act of 1996 and the rules and regulations thereunder. To the Company&#8217;s
      knowledge, the manufacturing facilities and operations of its suppliers are operated in compliance in all material respects with all applicable statutes, rules, regulations and policies of the FDA and comparable regulatory agencies outside of the
      United States to which the Company and its subsidiaries are subject.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">7</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company is not or, after giving effect to the offering
      of the Securities and the application of the proceeds thereof as described in the General Disclosure Package and the Prospectus, will not be required to register as an &#8220;investment company&#8221; or an entity &#8220;controlled&#8221; by an &#8220;investment company&#8221; within
      the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Neither the Company, nor any of its subsidiaries, nor any
      of its or their officers, directors or, to the Company&#8217;s knowledge, affiliates, has taken, directly or indirectly, any action designed or intended to stabilize or manipulate the price of any security of the Company, or which caused or resulted in, or
      which might in the future reasonably be expected to cause or result in, stabilization or manipulation of the price of any security of the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company and its subsidiaries own or possess the right
      to use all (i)&#160;patents, patent applications, trademarks, trademark registrations, service marks, service mark registrations, Internet domain name registrations, copyrights, copyright registrations, licenses, trade secret rights (&#8220;<b><i>Intellectual
          Property Rights</i></b>&#8221;) and (ii)&#160;inventions, software, works of authorships, trademarks, service marks, trade names, databases, formulae, know how, Internet domain names and other intellectual property (including trade secrets and other
      unpatented and/or unpatentable proprietary confidential information, systems, or procedures) (collectively, &#8220;<b><i>Intellectual Property Assets</i></b>&#8221;) necessary to conduct its business as currently conducted, and as proposed to be conducted and
      described in the General Disclosure Package and the Prospectus. The Company and its subsidiaries have not received any opinion from their legal counsel concluding that any of their business activities infringes, misappropriates, or otherwise
      violates, valid and enforceable Intellectual Property Rights of any other person, and have not received written notice of any challenge, which is to the Company&#8217;s knowledge still pending, by any other person to the rights of the Company and its
      subsidiaries with respect to any Intellectual Property Rights or Intellectual Property Assets owned or used by the Company and its subsidiaries. To the Company&#8217;s knowledge, the business of the Company and its subsidiaries as now conducted do not give
      rise to any infringement of, any misappropriation of, or other violation of, any valid and enforceable Intellectual Property Rights of any other person. All licenses for the use of the Company&#8217;s Intellectual Property Rights described in the General
      Disclosure Package and the Prospectus are valid, binding upon, and enforceable by or against the Company and its subsidiaries, and to the Company&#8217;s knowledge, the other parties thereto in accordance with its terms in all material respects. The
      Company and its subsidiaries have complied in all material respects with, and are not in breach nor have received any asserted or threatened claim of breach of any Intellectual Property license, and the Company has no knowledge of any breach or
      anticipated breach by any other person of any Intellectual Property license. Except as described in the General Disclosure Package, no claim has been made or is pending against the Company or any of its subsidiaries alleging the infringement by the
      Company or its subsidiaries of any patent, trademark, service mark, trade name, copyright, trade secret, license in or other intellectual property right or franchise right of any person. The Company and its subsidiaries have taken all reasonable
      steps to protect, maintain and safeguard their Intellectual Property Rights, including the execution of appropriate nondisclosure and confidentiality agreements. The consummation of the transactions contemplated by this Agreement will not result in
      the loss or impairment of or payment of any additional amounts with respect to, nor require the consent of any other person in respect of, the Company&#8217;s right to own, use, or hold for use any of the Intellectual Property Rights as owned, used or held
      for use in the conduct of the business as currently conducted. The Company and its subsidiaries have taken all reasonable actions to obtain ownership of all works of authorship and inventions made by their employees, consultants and contractors
      during the time they were employed by them or under contract with them and which relate to the Company and its subsidiaries&#8217; business. All key employees have signed confidentiality and invention assignment agreements with the Company and its
      subsidiaries.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company and its subsidiaries have good and marketable
      title in fee simple (in the case of real property) to, or have valid and marketable rights to lease or otherwise use, all items of real or personal property, other than with respect to intellectual property assets which are addressed exclusively in
      Section&#160;2(aa) above, which are material to the business of the Company and its subsidiaries taken as a whole, in each case free and clear of all liens, encumbrances, security interests, claims and defects that do not, singularly or in the aggregate,
      materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company or its subsidiaries; and all of the leases and subleases material to the business of the Company and its
      subsidiaries, and under which the Company and its subsidiaries hold properties described in the General Disclosure Package and the Prospectus, are in full force and effect in all material respects and the Company and its subsidiaries have not
      received any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or its subsidiaries under any of the leases or subleases mentioned above, or affecting or questioning the rights of the
      Company or its subsidiaries to the continued possession of the leased or subleased premises under any such lease or sublease.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">8</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There is (A)&#160;no unfair labor practice complaint pending
      against the Company or any of its subsidiaries, nor to the Company&#8217;s knowledge, threatened against it or any of its subsidiaries, before the National Labor Relations Board, any state or local labor relation board or any foreign labor relations board,
      and no significant grievance or significant arbitration proceeding arising out of or under any collective bargaining agreement is so pending against the Company or its subsidiaries, or, to the Company&#8217;s knowledge, threatened against it or any of its
      subsidiaries and (B)&#160;no labor disturbance by or dispute with, employees of the Company or any of its subsidiaries exists or, to the Company&#8217;s knowledge, is contemplated or threatened, and the Company is not aware of any existing or imminent labor
      disturbance by the employees of any of its principal suppliers, manufacturers, customers or contractors, that would be expected, singularly or in the aggregate, to have a Material Adverse Effect. The Company is not aware that any key employee or
      significant group of employees of the Company or any of its subsidiaries plans to terminate employment with the Company or any such subsidiary.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No &#8220;prohibited transaction&#8221; (as defined in Section&#160;406 of
      the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (&#8220;<b><i>ERISA</i></b>&#8221;), or Section&#160;4975 of the Internal Revenue Code of 1986, as amended from time to time (the &#8220;<b><i>Code</i></b>&#8221;))




      or &#8220;accumulated funding deficiency&#8221; (as defined in Section&#160;302 of ERISA) or any of the events set forth in Section&#160;4043(b) of ERISA (other than events with respect to which the thirty (30)-day notice requirement under Section&#160;4043 of ERISA has been
      waived) has occurred or would reasonably be expected to occur with respect to any employee benefit plan of the Company or its subsidiaries which would, singularly or in the aggregate, reasonably be expected to have a Material Adverse Effect. Each
      employee benefit plan of the Company and its subsidiaries is in compliance in all material respects with applicable law, including ERISA and the Code. The Company and its subsidiaries have not incurred and would not reasonably be expected to incur
      liability under Title IV of ERISA with respect to the termination of, or withdrawal from, any pension plan (as defined in ERISA). Each pension plan for which the Company or its subsidiaries would have any liability that is intended to be qualified
      under Section&#160;401(a) of the Code is so qualified, and to the Company&#8217;s knowledge, nothing has occurred, whether by action or by failure to act, which would, singularly or in the aggregate, reasonably be expected to cause the loss of such
      qualification.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company and its subsidiaries are in compliance in all
      material respects with all foreign, federal, state and local rules, laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety or the environment which are
      applicable to the Company&#8217;s and its subsidiaries&#8217; business (&#8220;<b><i>Environmental Laws</i></b>&#8221;). There has been no storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other
      wastes or other hazardous substances by, due to, or caused by the Company or any of its subsidiaries (or, to the Company&#8217;s knowledge, any other entity for whose acts or omissions the Company or any of its subsidiaries is or may otherwise be liable)
      upon any of the property now or previously owned or leased by the Company or its subsidiaries, or upon any other property, in violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which would, under any law,
      statute, ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any liability; and there has been no disposal, discharge, emission or other release of any kind onto such property or into the
      environment surrounding such property of any toxic or other wastes or other hazardous substances.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company and its subsidiaries (i)&#160;have timely filed all
      necessary federal, state, local and foreign tax returns (or timely filed extensions with respect to such returns), and all such returns were true, complete and correct, (ii)&#160;have paid all federal, state, local and foreign taxes, assessments,
      governmental or other charges due and payable for which they are liable, including, without limitation, all sales and use taxes and all taxes which they are obligated to withhold from amounts owing to employees, creditors and third parties, and
      (iii)&#160;do not have any tax deficiency or claims outstanding or assessed or, to the Company&#8217;s knowledge, proposed against any of them, except those, in each of the cases described in clauses (i), (ii)&#160;and (iii)&#160;above, that would not, singularly or in
      the aggregate, reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries have not engaged in any transaction which is a corporate tax shelter or which could be characterized as such by the Internal Revenue Service or
      any other taxing authority. The accruals and reserves on the books and records of the Company and its subsidiaries in respect of tax liabilities for any taxable period not yet finally determined are adequate to meet any assessments and related
      liabilities for any such period, and since December&#160;31, 2017 the Company and its subsidiaries have not incurred any liability for taxes other than in the ordinary course.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">9</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company and its subsidiaries carry or are covered by,
      insurance in such amounts and covering such risks as they reasonably believe is adequate for the conduct of the Company&#8217;s and its subsidiaries&#8217; business and the value of their properties and as is customary for companies engaged in similar businesses
      in similar industries. The Company and its subsidiaries do not have any reason to believe that they will not be able to renew their existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as
      may be necessary to continue their business at a cost that would not reasonably be expected to have a Material Adverse Effect. All policies of insurance owned by the Company and its subsidiaries are, to the Company&#8217;s knowledge, in full force and
      effect and the Company and its subsidiaries are in compliance in all material respects with the terms of such policies. The Company and its subsidiaries have not received written notice from any insurer, agent of such insurer or the broker that any
      material capital improvements or any other material expenditures (other than premium payments) are required or necessary to be made in order to continue such insurance. Except for customary deductibles, the Company and its subsidiaries do not insure
      risk of loss through any captive insurance, risk retention group, reciprocal group or by means of any fund or pool of assets specifically set aside for contingent liabilities other than as described in the General Disclosure Package.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company maintains a system of &#8220;internal control over
      financial reporting&#8221; (as such term is defined in Rule 13a-15(f) of the General Rules and Regulations under the Exchange Act (the &#8220;<b><i>Exchange Act Rules</i></b>&#8221;)) that is designed to comply with the requirements of the Exchange Act and has been
      designed by its principal executive and principal financial officers, or under their supervision, to provide reasonable assurances that (i)&#160;transactions are executed in accordance with management&#8217;s general or specific authorizations;
      (ii)&#160;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (iii)&#160;access to assets is permitted only in accordance with management&#8217;s general or specific
      authorization; (iv)&#160;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences and (v)&#160;the interactive data in XBRL included or incorporated by
      reference in the Registration Statement is in conformity with generally accepted accounting principles and is updated as necessary to comply in all material respects with the requirements of the Securities Act, the Rules and Regulations and
      guidelines applicable thereto and the Exchange Act and present fairly the financial position, results of operations and changes in financial position of the Company on the basis stated in the Registration Statement at the respective dates or for the
      respective periods to which they apply. There has been (A)&#160;no material weakness in the Company&#8217;s internal control over financial reporting (whether or not remediated) and (B)&#160;no change in the Company&#8217;s internal control over financial reporting that
      has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company&#8217;s internal control over financial reporting is overseen by the Audit Committee of the Board of Directors of
      the Company (the &#8220;<b><i>Audit Committee</i></b>&#8221;) in accordance with the Exchange Act Rules. Except as described in the General Disclosure Package and the Prospectus, the Company has not publicly disclosed or reported to the Audit Committee or to the
      Board, and within the next 90 days the Company does not reasonably expect to publicly disclose or report to the Audit Committee or the Board, material weakness, change in internal control over financial reporting or fraud involving management or
      other employees who have a significant role in the internal control over financial reporting (each an &#8220;<b><i>Internal Control Event</i></b>&#8221;) or any material violation of, or failure to comply in all material respects with, U.S. federal securities
      laws.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; A member of the Audit Committee has confirmed to the
      Chief Executive Officer or Principal Financial Officer of the Company that, except as set forth in the General Disclosure Package, the Audit Committee is not reviewing or investigating, and neither the Company&#8217;s independent auditors nor its internal
      auditors is currently recommending that the Audit Committee review or investigate, (i)&#160;adding to, deleting, changing the application of or changing the Company&#8217;s disclosure with respect to, any of the Company&#8217;s material accounting policies, (ii)&#160;any
      matter which could result in a restatement of the Company&#8217;s financial statements for any annual or interim period during the current or prior three fiscal years, or (iii)&#160;any Internal Control Event.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company maintains disclosure controls and procedures
      (as such is defined in Rule 13a-15(e) of the Exchange Act Rules) that are designed to comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure that information required to be disclosed by
      the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms, including controls and procedures designed to ensure that
      such information is accumulated and communicated to the Company&#8217;s management to allow timely decisions regarding disclosures. The Company has conducted evaluations of the effectiveness of their disclosure controls as required by Rule 13a-15 of the
      Exchange Act.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">10</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The minute books of the Company have been made available to
      counsel for the Underwriters, and such books (i)&#160;contain a complete summary in all material respects of all meetings and actions of the board of directors (including each board committee) and stockholders of the Company (or analogous governing bodies
      and interest holders, as applicable) since the time of its incorporation or organization through the date of the latest meeting and action, and (ii)&#160;accurately in all material respects reflect all transactions referred to in such minutes.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There is no franchise agreement, lease, contract, or
      other agreement or document required by the Securities Act or by the Rules and Regulations to be described in the General Disclosure Package or to be filed as an exhibit to the Registration Statement which is not so described or filed therein as
      required; and all descriptions of any such franchise agreements, leases, contracts, or other agreements or documents contained in the General Disclosure Package are accurate and complete descriptions of such documents in all material respects. Other
      than as described in the General Disclosure Package, no such franchise agreement, lease, contract or other agreement has been suspended or terminated for convenience or default by the Company, its subsidiaries or any of the other parties thereto, and
      the Company and its subsidiaries have not received notice of and do not have knowledge of any such pending or threatened suspension or termination.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)&#160;&#160;&#160;&#160;&#160;&#160;&#160; No relationship, direct or indirect, exists between or among
      the Company or any of its subsidiaries on the one hand, and the directors, officers, stockholders (or analogous interest holders), customers or suppliers of the Company or its subsidiaries or any of its affiliates on the other hand, which is required
      to be described in the General Disclosure Package and the Prospectus and which is not so described.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No person or entity has the right to require registration of
      shares of Common Stock or other securities of the Company because of the filing or effectiveness of the Registration Statement or otherwise, except for persons and entities who have expressly waived such right in writing or who have been given timely
      and proper written notice and have failed to exercise such right within the time or times required under the terms and conditions of such right. Except as described in the General Disclosure Package, there are no persons with registration rights or
      similar rights to have any securities registered by the Company under the Securities Act.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company does not own any &#8220;margin securities&#8221; as that
      term is defined in Regulation U of the Board of Governors of the Federal Reserve System (the &#8220;<b><i>Federal Reserve Board</i></b>&#8221;), and none of the proceeds of the sale of the Securities will be used, directly or indirectly, for the purpose of
      purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any of the Securities to be
      considered a &#8220;purpose credit&#8221; within the meanings of Regulation T, U or X of the Federal Reserve Board.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Other than this Agreement, neither the Company nor any of
      its subsidiaries is a party to any contract, agreement or understanding with any person that would give rise to a valid claim against the Company or the Underwriters for a brokerage commission, finder&#8217;s fee or like payment in connection with the
      offering and sale of the Securities or any transaction contemplated by this Agreement, the Registration Statement, the General Disclosure Package or the Prospectus.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The exercise price of each option issued under the stock
      option or other employee benefit plans of the Company and its subsidiaries has been no less than the fair market value of a share of Common Securities as determined on the date of grant of such option. All grants of options were validly issued and
      properly approved by the board of directors of the Company (or a duly authorized committee thereof) in material compliance with all applicable laws and regulations and recorded in the Company&#8217;s consolidated financial statements in accordance with
      GAAP and, to the Company&#8217;s knowledge, no such grants involved &#8220;back dating,&#8221; &#8220;forward dating&#8221; or similar practice with respect to the effective date of grant.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Since the date as of which information is given in the
      General Disclosure Package through the date hereof, and except for the obligations created by this Agreement and as set forth in the Pricing Prospectus or as disclosed in the General Disclosure Package, the Company and its subsidiaries, as
      applicable, have not (i)&#160;issued or granted any securities other than shares of Common Stock issued or issuable upon the conversion of the Company&#8217;s outstanding preferred stock and options to purchase common stock pursuant to the Company&#8217;s stock
      option plan, (ii)&#160;incurred any material liability or obligation, direct or contingent, other than liabilities and obligations which were incurred in the ordinary course of business, (iii)&#160;entered into any material transaction other than in the
      ordinary course of business or (iv)&#160;declared or paid any dividend on its capital stock.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">11</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If applicable, all of the information provided to the
      Underwriters or to counsel for the Underwriters by the Company, its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with letters, filings or other
      supplemental information provided to FINRA pursuant to FINRA Rule 5110 or 5121 is, to the Company&#8217;s knowledge with respect to all other persons except for the Company, true, correct and complete in all material respects as of the date hereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No forward-looking statement (within the meaning of
      Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act) contained in either the General Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(uu)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company is subject to and in compliance in all material
      respects with the reporting requirements of Section&#160;13 or Section&#160;15(d) of the Exchange Act. The Common Stock is registered pursuant to Section&#160;12(b) or 12(g) of the Exchange Act and is listed on The Nasdaq Global Market, and the Company has taken no
      action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from the Exchange, nor has the Company received any notification that the Commission
      or the FINRA is contemplating terminating such registration or listing.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There is and has been no failure on the part of the company
      or, to the Company&#8217;s knowledge, any of the Company&#8217;s officers or directors, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith (the &#8220;<b><i>Sarbanes-Oxley




          Act</i></b>&#8221;), including Section&#160;402 related to loans and Sections 302 and 906 related to certifications.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ww)&#160;&#160;&#160;&#160;&#160;&#160;&#160; None of the Company, any of its subsidiaries or, to the
      knowledge of the Company, any director, officer, agent, employee or affiliate of the Company or any of its subsidiaries is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign
      Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &#8220;<b><i>FCPA</i></b>&#8221;), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of
      an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any &#8220;foreign official&#8221; (as such term is defined in the FCPA) or any
      foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA; and the Company and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA,
      and have instituted and maintained and will continue to institute and maintain policies and procedures reasonably designed to promote and achieve compliance therewith.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There are no transactions, arrangements or other
      relationships between and/or among the Company, its subsidiaries or any of its affiliates (as such term is defined in Rule 405 of the Rules and Regulations) and any unconsolidated entity, including, but not limited to, any structured finance, special
      purpose or limited purpose entity that would reasonably be expected to materially affect the Company&#8217;s liquidity or the availability of or requirements for its capital resources required to be described in the General Disclosure Package and the
      Prospectus which have not been described as required.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(yy)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There are no outstanding loans, advances (except normal
      advances for business expenses in the ordinary course of business) or guarantees of indebtedness by the Company and its subsidiaries to or for the benefit of any of the officers or directors of the Company or its subsidiaries or any of their
      respective family members, except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus. All transactions by the Company and its subsidiaries with office holders or control persons of the Company and its
      subsidiaries have been duly approved by the board of directors of the Company and its subsidiaries, or duly appointed committees or officers thereof, if and to the extent required under U.S. law.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(zz)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The statistical and market related data included or
      incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate, and such data agree with the sources from which
      they are derived.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aaa)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The operations of the Company and its subsidiaries are and
      have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the U.S. Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable
      jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency in jurisdictions where the Company and its subsidiaries conduct business
      (collectively, the &#8220;<b><i>Anti-Money Laundering Laws</i></b>&#8221;); and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the
      Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">12</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bbb)&#160;&#160;&#160;&#160;&#160;&#160;&#160; None of the Company, any of its subsidiaries or, to the
      knowledge of the Company, any director, officer, agent, employee, affiliate or representative of the Company or any of its subsidiaries is an individual or entity (&#8220;<b><i>Person</i></b>&#8221;) that is, or is owned or controlled by one or more Persons that
      are, currently the subject or target of any sanctions administered or enforced by the United States government, including, without limitation, the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control, the United Nations Security
      Council, the European Union, His Majesty&#8217;s Treasury, or other relevant sanctions authority (collectively, &#8220;<b><i>Sanctions</i></b>&#8221;), nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions; and
      the Company will not directly or indirectly use the proceeds of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, (i)&#160;to fund any activities of or
      business with any Person, or in any country or territory, that, at the time of such funding, is the subject of Sanctions or (ii)&#160;in any other manner that will result in a violation by any Person (including any Person participating in the transaction,
      whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and will not engage in, any dealings or transactions with
      any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ccc)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Neither the Company nor any of its subsidiaries nor, to the
      Company&#8217;s knowledge, any of its affiliates (within the meaning of FINRA Rule 5121(f)(1)) directly or indirectly controls, is controlled by, or is under common control with, or is an associated person (within the meaning of Article I, Section&#160;1(rr) of
      the By-Laws of FINRA) of, any of the Underwriters.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ddd)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except as described in the General Disclosure Package and the
      Prospectus, no subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on
      such subsidiary&#8217;s capital stock, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#8217;s properties or assets to the Company or any other subsidiary of the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(eee)&#160;&#160;&#160;&#160;&#160;&#160;&#160; (i)(x) There has been no security breach or attack or other
      compromise of or relating to any of the Company&#8217;s and its subsidiaries&#8217; information technology and computer systems, networks, hardware, software, data (including the data of their respective customers, employees, suppliers, vendors and any third
      party data maintained by or on behalf of them), equipment or technology (&#8220;<b><i>IT Systems and Data</i></b>&#8221;) and (y) the Company and its subsidiaries have not been notified of, and have no knowledge of any event or condition that would reasonably be
      expected to result in, any security breach, attack or compromise to their IT Systems and Data, (ii) the Company and its subsidiaries have complied, and are presently in compliance, with, all applicable laws, statutes or any judgment, order, rule or
      regulation of any court or arbitrator or governmental or regulatory authority and all industry guidelines, standards, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of
      such IT Systems and Data from unauthorized use, access, misappropriation or modification, and (iii) the Company and its subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices, except, in
      each case with respect to clauses (i) through (iii) hereof, as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(fff)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Neither the Company nor any of its subsidiaries has any
      securities rated by any &#8220;nationally recognized statistical rating organization,&#8221; as such term is defined in Section 3(a)(62) of the Exchange Act.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ggg)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company and each of its subsidiaries are, and at all
      prior times since January 1, 2010 were, in material compliance with all applicable data privacy and security laws and regulations (collectively, &#8220;<b><i>Privacy Laws</i></b>&#8221;). The Company and each of its subsidiaries have in place, comply with, and
      take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling and analysis of Personal Data (as
      defined below) (the &#8220;<b><i>Policies</i></b>&#8221;). Where required by applicable Privacy Laws, the Company provides accurate notice of its Policies to data subjects from whom it collects Personal Data. The Policies provide accurate and sufficient notice
      of the Company&#8217;s then-current privacy practices relating to its subject matter and such Policies do not contain any material omissions of the Company&#8217;s then-current privacy practices. &#8220;<b><i>Personal Data</i></b>&#8221; means (i) a natural persons&#8217; name,
      street address, telephone number, email address, photograph, social security number, bank information, or customer or account number; (ii) any information which would qualify as &#8220;personally identifying information&#8221; under the Federal Trade Commission
      Act, as amended; (iii) Protected Health Information as defined by HIPAA; (iv) &#8220;personal data&#8221; as defined by GDPR; and (v) any other piece of information that allows the identification of such natural person, or his or her family, or permits the
      collection or analysis of any data related to an identified person&#8217;s health or sexual orientation. None of such disclosures made or contained in any of the Policies have been inaccurate, misleading, deceptive or in violation of any Privacy Laws or
      Policies in any material respect. The execution, delivery and performance of this Agreement or any other agreement referred to in this Agreement will not result in a material breach of any Privacy Laws or Policies. Neither the Company nor any of its
      subsidiaries, (i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result
      in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposed any
      obligation or liability under any Privacy Law.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">13</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hhh)&#160;&#160;&#160;&#160;&#160;&#160; The Warrants have been duly authorized and, when executed and
      delivered by the Company in accordance with this Agreement, will be valid and legally binding agreements of the Company, enforceable against the Company in accordance with their terms except as the enforcement thereof maybe limited by applicable
      bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors orby general equitable principles. The Warrant Stock to be issued by the Company upon exercise of the Warrants in
      accordance therewith have been duly authorized and will be reserved for issuance upon exercise of the Warrants in a number sufficient to meet the current exercise requirements. The Warrant Stock, when issued and delivered upon exercise of the
      Warrants in accordance therewith, will be validly issued, fully paid and nonassessable, and the issuance of the Warrant Stock is not subject to any preemptive or similar rights not otherwise validly waived or satisfied.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any certificate signed by or on behalf of the Company and delivered to
      the Representatives or to counsel for the Underwriters shall be deemed to be a representation and warranty by the Company to each Underwriter as to the matters covered thereby.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<i>PURCHASE</i>, <i>SALE AND DELIVERY OF OFFERED
        SECURITIES</i>. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company agrees to sell to the Underwriters, and the Underwriters agree, severally and not
      jointly, to purchase from the Company the respective numbers of shares of Firm Securities set forth opposite the names of the Underwriters in <u>Schedule A</u> hereto.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The purchase price per share to be paid by the Underwriters to the
      Company for the Stock will be $15.04 per share (the &#8220;<b><i>Purchase Price</i></b>&#8221;) and the purchase price per Warrant to be paid by the Underwriters to the Company for the Warrant will be $15.03 per Warrant (the &#8220;<b><i>Warrant Purchase Price</i></b>&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will deliver the Firm Securities to the Representatives for
      the respective accounts of the several Underwriters, through the facilities of The Depository Trust Company, in each such case, issued in such names and in such denominations as the Representatives may direct by notice in writing to the Company given
      at or prior to 12:00 Noon, New York time, at least one full business day preceding the Closing Date against payment of the aggregate Purchase Price or Warrant Purchase Price, as applicable, therefor by wire transfer in federal (same day) funds to an
      account specified by the Company payable to the order of the Company for the Firm Stock sold by them all at the offices of Latham &amp; Watkins LLP, 1271 Avenue of the Americas, New York, New York 10020. Time shall be of the essence, and delivery at
      the time and place specified pursuant to this Agreement is a further condition of the obligations of each Underwriter hereunder. The time and date of the delivery and closing shall be at 10:00 A.M., New York time, on September 15, 2023, in accordance
      with Rule 15c6-1 of the Exchange Act. The time and date of such payment and delivery are herein referred to as the &#8220;<b><i>Closing Date</i></b>.&#8221; The Closing Date and the location of delivery of, and the form of payment for, the Firm Securities may be
      varied by agreement between the Company and the Representatives.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Underwriters may purchase all or less than all of the Optional
      Stock. The price per share to be paid for the Optional Stock shall be the Purchase Price, less an amount per share equal to any dividends or distributions declared by the Company and payable on the Firm Stock but not payable on the Optional Stock.
      The Company agrees to sell to the Underwriters the number of shares of Optional Stock specified in the written notice delivered by the Representatives to the Company described below and the Underwriters agree, severally and not jointly, to purchase
      such shares of Optional Stock. Such shares of Optional Stock shall be purchased from the Company for the account of each Underwriter in the same proportion as the number of shares of Firm Stock set forth opposite such Underwriter&#8217;s name on <u>Schedule




        A</u> bears to the total number of shares of Firm Stock (subject to adjustment by the Representatives to eliminate fractions). The option granted hereby may be exercised as to all or any part of the Optional Stock at any time, and from time to
      time, not more than thirty (30)&#160;days subsequent to the date of this Agreement. No Optional Stock shall be sold and delivered unless the Firm Stock previously has been, or simultaneously is, sold and delivered. The right to purchase the Optional Stock
      or any portion thereof may be surrendered and terminated at any time upon notice by the Representatives to the Company.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">14</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The option granted hereby may be exercised by written notice being given
      to the Company by the Representatives setting forth the number of shares of the Optional Stock to be purchased by the Underwriters and the date and time for delivery of and payment for the Optional Stock. Each date and time for delivery of and
      payment for the Optional Stock (which may be the Closing Date, but not earlier) is herein called an &#8220;<b><i>Option Closing Date</i></b>&#8221; and shall in no event be earlier than two (2)&#160;business days nor later than five (5)&#160;business days after written
      notice is given. The Option Closing Date or Dates, if any, and the Closing Date are herein called the &#8220;<b><i>Closing Dates</i></b>.&#8221;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will deliver the Optional Stock to the Representatives for
      the respective accounts of the several Underwriters through the facilities of The Depository Trust Company or, at the election of the Representatives, in the form of definitive certificates, in each such case, issued in such names and in such
      denominations as the Representatives may direct by notice in writing to the Company given at or prior to 12:00&#160;Noon, New York time, at least one full business day preceding the Option Closing Date against payment of the aggregate Purchase Price
      therefor by wire transfer in federal (same day) funds to an account at a bank specified by the Company payable to the order of the Company, at the offices of Latham &amp; Watkins LLP, 1271 Avenue of the Americas, New York, New York 10020. Time shall
      be of the essence, and delivery at the time and place specified pursuant to this Agreement is a further condition of the obligations of each Underwriter hereunder. The Option Closing Date and the location of delivery of, and the form of payment for,
      the Optional Stock may be varied by agreement between the Company and the Representatives.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the foregoing, the Company and the Representatives shall
      instruct purchasers of the Warrants in the public offering to make payment for the Warrants on the Closing Date to the Company by wire transfer in immediately available funds to the account specified by the Company at a purchase price of $15.99 per
      Warrant, in lieu of payment by the Underwriters for such Warrants, and the Company shall deliver such Warrants to such purchasers on the Closing Date in definitive form against such payment, in lieu of the Company&#8217;s obligation to deliver such
      Warrants to the Underwriters; provided that, the underwriting discounts and commissions in respect of the Warrants, as calculated by subtracting the Warrant Purchase Price from the Offering Price of Warrants set forth on Schedule C hereto, shall be
      deducted and withheld from the amount otherwise payable by the Representatives to the Company for the Stock as set forth in this Section 3. The Warrants will be made available for inspection by the Representative on the day prior to the Closing Date.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event that the purchasers of the Warrants in the public offering
      fail to make payment to the Company for all or part of the Warrants on the Closing Date, the Representatives may elect, by written notice to the Company, to receive shares of Common Stock in lieu of all or a portion of such Warrants to be delivered
      to the Underwriters under this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The several Underwriters propose to offer the Securities for sale upon
      the terms and conditions set forth in the Prospectus.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>FURTHER AGREEMENTS OF THE COMPANY</i>. The Company
      agrees with the several Underwriters:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To prepare the Rule 462(b) Registration Statement, if
      necessary, in a form approved by the Representatives and file such Rule 462(b) Registration Statement with the Commission by 10:00 P.M., New York time, on the date hereof, and the Company shall at the time of filing either pay to the Commission the
      filing fee for the Rule 462(b) Registration Statement or give irrevocable instructions for the payment of such fee pursuant to Rule 111(b) under the Rules and Regulations; to prepare the Prospectus in a form approved by the Representatives containing
      information previously omitted at the time of effectiveness of the Registration Statement in reliance on Rules 430A or 430B of the Rules and Regulations and to file such Prospectus pursuant to Rule 424(b) of the Rules and Regulations not later than
      the second business (2nd)&#160;day following the execution and delivery of this Agreement or, if applicable, such earlier time as may be required by the Securities Act; to notify the Representatives promptly of the Company&#8217;s intention to file or prepare
      any supplement or amendment to the Registration Statement or to the Prospectus and to make no amendment or supplement to the Registration Statement, the General Disclosure Package or to the Prospectus to which the Representatives shall reasonably
      object by notice to the Company after a reasonable period to review; to advise the Representatives, promptly after it receives notice thereof, of the time when any amendment to the Registration Statement has been filed or becomes effective or any
      supplement to the General Disclosure Package or the Prospectus or any amended Prospectus or any Issuer Free Writing Prospectus has been filed and to furnish the Underwriters with copies thereof; to file promptly all material required to be filed by
      the Company with the Commission pursuant to Rules 433(d) or 163(b)(2) of the Rules and Regulations, as the case may be; to file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the
      Commission pursuant to Section&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules and
      Regulations) is required in connection with the offering or sale of the Securities; to advise the Representatives, promptly after it receives notice thereof, of the issuance by the Commission of any stop order or of any order preventing or suspending
      the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus, of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any
      such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement, the General Disclosure Package or the Prospectus or for additional information; and, in the event of the issuance of any stop order or
      of any order preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus or suspending any such qualification, and promptly to use its commercially reasonable efforts to obtain the withdrawal
      of such order.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">15</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; [<i>Reserved</i>].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company represents and agrees that, unless it obtains
      the prior consent of the Representatives, and each Underwriter represents and agrees that, unless it obtains the prior consent of the Company and the Representatives, it has not made and will not, make any offer relating to the Securities that would
      constitute a &#8220;free writing prospectus&#8221; as defined in Rule 405 of the Rules and Regulations (each, a &#8220;<b><i>Permitted Free Writing Prospectus</i></b>&#8221;); <i>provided</i> that the prior written consent of the Representatives hereto shall be deemed to
      have been given in respect of the Issuer Free Writing Prospectuses included in <u>Schedule&#160;B</u> hereto. The Company represents that it has treated and agrees that it will treat each Permitted Free Writing Prospectus as an Issuer Free Writing
      Prospectus, comply with the requirements of Rules 164 and 433 of the Rules and Regulations applicable to any Issuer Free Writing Prospectus, including the requirements relating to timely filing with the Commission, legending and record keeping and
      will not take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) of the Rules and Regulations a free writing prospectus prepared by or on behalf of such Underwriter that
      such Underwriter otherwise would not have been required to file thereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If at any time prior to the date when a prospectus relating
      to the Securities is required to be delivered (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules and Regulations) any event occurs or condition exists as a result of which the Prospectus as then amended or supplemented would
      include any untrue statement of a material fact, or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made when the Prospectus is delivered (or in lieu thereof, the notice
      referred to in Rule 173(a) of the Rules and Regulations), not misleading, or if it is necessary at any time to amend or supplement the Registration Statement or to file under the Exchange Act any document incorporated by reference in the Prospectus
      to comply with the Securities Act, that the Company will promptly notify the Representatives thereof and upon their request will prepare an appropriate amendment or supplement or upon their request make an appropriate filing pursuant to Section&#160;13 or
      14 of the Exchange Act in form and substance satisfactory to the Representatives which will correct such statement or omission or effect such compliance and will use its commercially reasonable efforts to have any amendment to the Registration
      Statement declared effective as soon as possible. The Company will furnish without charge to each Underwriter and to any dealer in securities as many copies as the Representatives may from time to time reasonably request of such amendment or
      supplement. In case any Underwriter is required to deliver a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules and Regulations) relating to the Securities, the Company upon the request of the Representatives will
      prepare promptly an amended or supplemented Prospectus as may be necessary to permit compliance with the requirements of Section&#160;10(a)(3) of the Securities Act and deliver to such Underwriter as many copies as such Underwriter may request of such
      amended or supplemented Prospectus complying with Section&#160;10(a)(3) of the Securities Act.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If the General Disclosure Package is being used to solicit
      offers to buy the Securities at a time when the Prospectus is not yet available to prospective purchasers and any event shall occur as a result of which, in the judgment of the Company or in the reasonable opinion of the Underwriters, it becomes
      necessary to amend or supplement the General Disclosure Package in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, or to make the statements therein not conflict with the information contained
      or incorporated by reference in the Registration Statement then on file and not superseded or modified, or if it is necessary at any time to amend or supplement the General Disclosure Package to comply with any law, the Company promptly will either
      (i)&#160;prepare, file with the Commission (if required) and furnish to the Underwriters and any dealers an appropriate amendment or supplement to the General Disclosure Package or (ii)&#160;prepare and file with the Commission an appropriate filing under the
      Exchange Act which shall be incorporated by reference in the General Disclosure Package so that the General Disclosure Package as so amended or supplemented will not, in the light of the circumstances then prevailing, be misleading or conflict with
      the Registration Statement then on file, or so that the General Disclosure Package will comply with law.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">16</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If at any time following issuance of an Issuer Free
      Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or will conflict with the information contained in the Registration Statement, Pricing Prospectus or Prospectus,
      including any document incorporated by reference therein and any prospectus supplement deemed to be a part thereof and not superseded or modified or included or would include an untrue statement of a material fact or omitted or would omit to state a
      material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances prevailing at the subsequent time, not misleading, the Company has promptly notified or will promptly notify the
      Representatives so that any use of the Issuer Free Writing Prospectus may cease until it is amended or supplemented and has promptly amended or will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or
      correct such conflict, untrue statement or omission. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus in reliance upon, and in conformity with, written information furnished to the Company
      through the Representatives by or on behalf of any Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters&#8217; Information.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To the extent not available on the Commission&#8217;s Electronic
      Data Gathering, Analysis and Retrieval system or any successor system (&#8220;<b><i>EDGAR</i></b>&#8221;), upon the request of the Representatives, to furnish promptly to the Representatives and to counsel for the Underwriters a signed copy of the Registration
      Statement as originally filed with the Commission, and of each amendment thereto filed with the Commission, including all consents and exhibits filed therewith.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Upon request of the Representatives, to the extent not
      available on EDGAR, to deliver promptly to the Representatives in New York City such number of the following documents as the Representatives shall reasonably request: (i)&#160;conformed copies of the Registration Statement as originally filed with the
      Commission (excluding exhibits), (ii)&#160;each Preliminary Prospectus, (iii)&#160;any Issuer Free Writing Prospectus, (iv)&#160;the Prospectus (the delivery of the documents referred to in clauses (i), (ii), (iii)&#160;and (iv)&#160;of this paragraph (i)&#160;to be made not
      later than 10:00 A.M., New York time, on the business day following the execution and delivery of this Agreement), (v)&#160;conformed copies of any amendment to the Registration Statement (excluding exhibits), (vi)&#160;any amendment or supplement to the
      General Disclosure Package or the Prospectus (the delivery of the documents referred to in clauses (v)&#160;and (vi)&#160;of this paragraph (i)&#160;to be made not later than 10:00 A.M., New York City time, on the business day following the date of such amendment
      or supplement) and (vii)&#160;any document incorporated by reference in the General Disclosure Package or the Prospectus (excluding exhibits thereto) (the delivery of the documents referred to in clause (vi)&#160;of this paragraph (i)&#160;to be made not later than
      10:00 A.M., New York City time, on the business day following the date of such document).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To make generally available to its stockholders as soon
      as practicable, but in any event not later than sixteen (16)&#160;months after the effective date of the Registration Statement (as defined in Rule 158(c) of the Rules and Regulations), an earnings statement of the Company and its subsidiaries (which need
      not be audited) complying with Section&#160;11(a) of the Securities Act (including, at the option of the Company, Rule 158). The Company, during the period when a Prospectus relating to the Securities is (or, but for the exception afforded by Rule 172 of
      the Rules and Regulations, would be) required to be delivered under the Securities Act, will file all documents required to be filed with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and the rules
      and regulations promulgated thereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To take promptly from time to time such actions as the
      Representatives may reasonably request to qualify the Securities for offering and sale under the securities or Blue Sky laws of such jurisdictions (domestic or foreign) as the Representatives may designate and to continue such qualifications in
      effect, and to comply with such laws, for so long as required to permit the offer and sale of Securities in such jurisdictions; <i>provided</i> that neither the Company nor any of its subsidiaries shall be obligated to (i)&#160;qualify as a foreign
      corporation in any jurisdiction in which it is not so qualified, (ii)&#160;file a general consent to service of process in any jurisdiction or (iii)&#160;subject itself to taxation in any such jurisdiction if it is not otherwise so subject.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">17</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Upon request, during the period of five (5)&#160;years from the
      date hereof, to deliver to each of the Underwriters, (i)&#160;as soon as they are available, copies of all reports or other communications (financial or other) furnished to stockholders, and (ii)&#160;as soon as they are available, copies of any reports and
      financial statements furnished or filed with the Commission or any national securities exchange on which the Securities are listed. However, so long as the Company is subject to the reporting requirements of either Section&#160;13 or Section&#160;15(d) of the
      Exchange Act and is timely filing reports with the Commission on EDGAR, it is not required to furnish such reports or statements to the Underwriters.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the period commencing on and including the date
      hereof and ending on and including the ninetieth (90th)&#160;day following the date of this Agreement (as the same may be extended as described below, the &#8220;<b><i>Lock-Up Period</i></b>&#8221;) the Company will not, without the prior written consent of J.P.
      Morgan Securities LLC and Morgan Stanley &amp; Co. LLC (which consent may be withheld at the sole discretion of J.P. Morgan Securities LLC and Morgan Stanley &amp; Co. LLC), directly or indirectly offer, sell (including, without limitation, any short
      sale), assign, transfer, lend, pledge, contract to sell, establish an open &#8220;put equivalent position&#8221; within the meaning of Rule 16a-1(h) under the Exchange Act, or otherwise dispose of, or announce the offering of, or file any registration statement
      under the Securities Act in respect of, any Common Stock, options, rights or warrants to acquire Common Stock or securities exchangeable or exercisable for or convertible into Common Stock (other than as contemplated by this Agreement with respect to
      the Securities) or publicly announce any intention to do any of the foregoing; <i>provided</i>, however, that the Company may (i)&#160;sell the Securities, including, for the avoidance of doubt, the issuance by the Company of Warrant Shares upon the
      exercise of the Warrants, pursuant to this Agreement and as otherwise disclosed in the General Disclosure Package, (ii)&#160;issue Common Stock and options to purchase Common Stock, shares of Common Stock underlying options granted, and other securities,
      each pursuant to any director or employee stock option plan, stock ownership plan or dividend reinvestment plan of the Company in effect on the date hereof and described in the General Disclosure Package, (iii)&#160;issue Common Stock pursuant to the
      conversion of securities or the exercise of warrants, which securities or warrants are outstanding on the date hereof and described in the General Disclosure Package; (iv)&#160;file a registration statement on Form&#160;S-8&#160;relating to shares of Common Stock
      granted pursuant to the Company&#8217;s equity incentive plans in effect as of the date hereof; or (v) issue Common Stock or securities convertible into or exercisable for shares of Common Stock in connection with any acquisition, collaboration, licensing,
      consulting arrangement or other strategic transaction or any debt financing transaction; <i>provided</i>, that in the case of this clause (v), such issuances shall not be greater than 10% of the total outstanding shares of Common Stock outstanding
      immediately after the completion of this offering (after giving effect to the Warrant Shares issuable upon exercise of the Warrants) and each recipient of shares of Common Stock, or securities exchangeable or exercisable for or convertible into
      Common Stock, shall be contractually prohibited, pursuant to an agreement substantially in the form of Exhibit I hereto, from selling, offering, disposing of or otherwise transferring any such shares or securities during the remainder of the Lock-Up
      Period.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To supply the Representatives with copies of all
      correspondence to and from, and all documents issued to and by, the Commission in connection with the registration of the Securities under the Securities Act or any of the Registration Statement, any Preliminary Prospectus or the Prospectus, or any
      amendment or supplement thereto or document incorporated by reference therein.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Prior to the latest of the Closing Dates, not to issue any
      press release or other communication directly or indirectly or hold any press conference with respect to the Company, its condition, financial or otherwise, or earnings, business affairs or business prospects (except for routine oral marketing
      communications in the ordinary course of business and consistent with the past practices of the Company and of which the Representatives are notified), without the prior written consent of the Representatives, unless in the judgment of the Company
      and its counsel, and after notification to the Representatives, such press release or communication is required by law.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Until the Representatives shall have notified the Company
      of the completion of the resale of the Securities, that the Company will not, and will use its reasonable best efforts to cause its affiliated purchasers (as defined in Regulation M under the Exchange Act) not to, either alone or with one or more
      other persons, bid for or purchase, for any account in which it or any of its affiliated purchasers has a beneficial interest, any Securities, or attempt to induce any person to purchase any Securities; and not to, and to use its reasonable best
      efforts to cause its affiliated purchasers not to, make bids or purchase for the purpose of creating actual, or apparent, active trading in or of raising the price of the Securities.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">18</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Not to take any action prior to the latest of the Closing
      Dates which would require the Prospectus to be amended or supplemented pursuant to Section&#160;4(d).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To at all times comply in all material respects with all
      applicable provisions of the Sarbanes-Oxley Act in effect from time to time.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To maintain, at its expense, a registrar and transfer
      agent for the Securities.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To apply the net proceeds from the sale of the Securities
      as set forth in the Registration Statement, the General Disclosure Package and the Prospectus under the heading &#8220;<b><i>Use of Proceeds</i></b>,&#8221; and except as disclosed in the General Disclosure Package, the Company does not intend to use any of the
      proceeds from the sale of the Securities hereunder to repay any outstanding debt owed to any affiliate of any Underwriter. The Company shall manage its affairs and investments in such a manner as not to be or become an &#8220;investment company&#8221; within the
      meaning of the Investment Company Act and the rules and regulations thereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To use its reasonable best efforts to list, subject to
      notice of issuance, the Securities on The Nasdaq Global Market.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To use its reasonable best efforts to do and perform all
      things required to be done or performed under this Agreement by the Company prior to each Closing Date and to satisfy all conditions precedent to the delivery of the Firm Securities and the Optional Stock.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Upon request of any Underwriter, to furnish, or cause to be
      furnished, to such Underwriter an electronic version of the Company&#8217;s trademarks, service marks and corporate logo for use on the website, if any, operated by such Underwriter for the purpose of facilitating the on-line offering of the Securities
      (the &#8220;<b><i>License</i></b>&#8221;); <i>provided</i>, <i>however</i> that the License shall be used solely for the purpose described above, is granted without any fee and may not be assigned or transferred.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; At all times while any Warrants are outstanding, to reserve
      and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Stock upon exercise of such Warrants, the number of Warrant Stock that are initially
      issuable and deliverable upon the exercise of the then-outstanding Warrants.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>PAYMENT OF EXPENSES</i>. The Company agrees to pay, or
      reimburse if paid by any Underwriter, whether or not the transactions contemplated hereby are consummated or this Agreement is terminated: (a)&#160;the costs incident to the authorization, issuance, sale, preparation and delivery of the Securities and any
      taxes payable in that connection; (b)&#160;the costs incident to the registration of the Securities under the Securities Act; (c)&#160;the costs incident to the preparation, printing and distribution of the Registration Statement, any Preliminary Prospectus,
      any Issuer Free Writing Prospectus, the General Disclosure Package, the Prospectus, any amendments, supplements and exhibits thereto or any document incorporated by reference therein; (d)&#160;the fees and expenses (including reasonable related fees and
      expenses of counsel for the Underwriters in an amount not to exceed an aggregate amount of $15,000) incurred in connection with securing any required review by FINRA of the terms of the sale of the Securities and any filings made with FINRA relating
      to the offering of the Securities; (e)&#160;any applicable listing or other fees; (f)&#160;the fees and expenses (including related fees and expenses of counsel to the Underwriters) of qualifying the Securities under the securities laws of the several
      jurisdictions as provided in Section&#160;4(j) and of preparing, printing and distributing wrappers, Blue Sky Memoranda and Legal Investment Surveys; (g)&#160;the cost of preparing and printing stock certificates; (h)&#160;all fees and expenses of the registrar and
      transfer agent of the Securities; (i)&#160;the costs and expenses (including, without limitation, any damages or other amounts payable in connection with the legal or contractual liability) associated with the reforming of any contracts for sale of the
      Securities made by the Underwriters caused by a breach of the representation contained in Section&#160;2(b); (j)&#160;the costs and expenses of the Company relating to investor presentations on any &#8220;road show&#8221; undertaken in connection with the marketing of the
      offering of the Securities, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any
      consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the officers of the Company and such consultants; <i>provided</i>, that the Company shall be responsible for
      50% of the cost of any aircraft chartered in connection with the road show and the Underwriters shall be responsible for the balance; (k)&#160;all other costs and expenses of the Company incident to the offering of the Securities or the performance of the
      obligations of the Company under this Agreement (including, without limitation, the fees and expenses of the Company&#8217;s counsel and the Company&#8217;s independent accountants); and (l) the costs of reproducing and distributing each of the Warrants; <i>provided</i>
      that, except to the extent otherwise provided in this Section&#160;5 and in Sections 9 and 10, the Underwriters shall pay their own costs and expenses, including the fees and expenses of their counsel not contemplated herein, any transfer taxes on the
      resale of any Securities by them and the expenses of advertising any offering of the Securities made by the Underwriters.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">19</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>CONDITIONS OF UNDERWRITERS&#8217; OBLIGATIONS</i>. The
      respective obligations of the several Underwriters hereunder are subject to the accuracy, when made and as of the Applicable Time and on each Closing Date, of the representations and warranties of the Company contained herein, to the accuracy of the
      statements of the Company made in any certificates pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder, and to each of the following additional terms and conditions:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Registration Statement has become effective under the
      Securities Act, and no stop order suspending the effectiveness of the Registration Statement or any part thereof, preventing or suspending the use of any Preliminary Prospectus, the Prospectus or any Permitted Free Writing Prospectus or any part
      thereof shall have been issued and no proceedings for that purpose or pursuant to Section&#160;8A under the Securities Act shall have been initiated or threatened by the Commission, and all requests for additional information on the part of the Commission
      (to be included or incorporated by reference in the Registration Statement or the Prospectus or otherwise) shall have been complied with to the reasonable satisfaction of the Representatives; the Rule 462(b) Registration Statement, if any, each
      Issuer Free Writing Prospectus and the Prospectus shall have been filed with, the Commission within the applicable time period prescribed for such filing by, and in compliance with, the Rules and Regulations and in accordance with Section&#160;4(a), and
      the Rule 462(b) Registration Statement, if any, shall have become effective immediately upon its filing with the Commission; and FINRA shall have raised no unresolved objection to the fairness and reasonableness of the terms of this Agreement or the
      transactions contemplated hereby (or the offering shall be otherwise exempt from filing with FINRA under FINRA Rule 5110(h)(1).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; None of the Underwriters shall have discovered and
      disclosed to the Company on or prior to such Closing Date that the Registration Statement or any amendment or supplement thereto contains an untrue statement of a fact which, in the opinion of counsel for the Underwriters, is material or omits to
      state any fact which, in the opinion of such counsel, is material and is required to be stated therein or is necessary to make the statements therein not misleading, or that the General Disclosure Package, any Issuer Free Writing Prospectus or the
      Prospectus or any amendment or supplement thereto contains an untrue statement of fact which, in the opinion of such counsel, is material or omits to state any fact which, in the opinion of such counsel, is material and is necessary in order to make
      the statements, in the light of the circumstances in which they were made, not misleading.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; All corporate proceedings and other legal matters incident
      to the authorization, form and validity of each of this Agreement, the Securities, the Registration Statement, the General Disclosure Package, each Issuer Free Writing Prospectus and the Prospectus and all other legal matters relating to this
      Agreement and the transactions contemplated hereby shall be reasonably satisfactory in all material respects to counsel for the Underwriters, and the Company shall have furnished to such counsel all documents and information that they may reasonably
      request to enable them to pass upon such matters.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; K&amp;L Gates LLP shall have furnished to the
      Representative such counsel&#8217;s written opinion and negative assurance letter, as counsel to the Company, addressed to the Underwriters and dated as of such Closing Date, in form and substance reasonably satisfactory to the Representatives.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Cooley LLP shall have furnished to the Representatives such
      counsel&#8217;s written opinion, as intellectual property counsel to the Company, addressed to the Underwriters and dated such Closing Date, in form and substance reasonably satisfactory to the Representatives.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Representatives shall have received from Latham &amp;
      Watkins LLP, counsel for the Underwriters, such opinion or opinions, dated as of such Closing Date, with respect to such matters as the Underwriters may reasonably require, and the Company shall have furnished to such counsel such documents as they
      request for enabling them to pass upon such matters.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; At the time of the execution of this Agreement, the
      Representatives shall have received from EisnerAmper LLP a letter, addressed to the Underwriters, executed and dated such date, in form and substance satisfactory to the Representatives (i)&#160;confirming that they are an independent registered
      accounting firm with respect to the Company and its subsidiaries within the meaning of the Securities Act and the Rules and Regulations and PCAOB and (ii)&#160;stating the conclusions and findings of such firm, of the type ordinarily included in
      accountants&#8217; &#8220;comfort letters&#8221; to underwriters, with respect to the financial statements and certain financial information contained or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">20</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; On the effective date of any post-effective amendment to
      the Registration Statement and on such Closing Date, the Representatives shall have received a letter (the &#8220;<b><i>bring-down letter</i></b>&#8221;) from EisnerAmper LLP addressed to the Underwriters and dated such Closing Date confirming, as of the date of
      the bring-down letter (or, with respect to matters involving changes or developments since the respective dates as of which specified financial information is given in the General Disclosure Package and the Prospectus, as the case may be, as of a
      date not more than three (3)&#160;business days prior to the date of the bring-down letter), the conclusions and findings of each firm, of the type ordinarily included in accountants&#8217; &#8220;comfort letters&#8221; to underwriters, with respect to the financial
      information and other matters covered by its letter delivered to the Representatives concurrently with the execution of this Agreement pursuant to paragraph (g)&#160;of this Section&#160;6.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall have furnished to the Representatives a
      certificate, dated such Closing Date, of its Chief Executive Officer or President and its Principal Financial Officer stating in their respective capacities as officers of the Company on behalf of the Company and not in their individual capacities
      that (i)&#160;no stop order suspending the effectiveness of the Registration Statement (including, for avoidance of doubt, any Rule 462(b) Registration Statement), or any post-effective amendment thereto, shall be in effect and no proceedings for such
      purpose shall have been instituted or, to their knowledge, threatened by the Commission, (ii)&#160;for the period from and including the date of this Agreement through and including such Closing Date, there has not occurred any Material Adverse Effect,
      (iii)&#160;to their knowledge, after reasonable investigation, as of such Closing Date, the representations and warranties of the Company in this Agreement that are qualified by materiality are true and correct and the representations and warranties of
      the Company not qualified by materiality are true and correct in all material respects, and the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to such Closing Date,
      and (iv)&#160;there has not been, subsequent to the date of the most recent audited consolidated financial statements included or incorporated by reference in the General Disclosure Package, any Material Adverse Effect in the financial position or results
      of operations of the Company, or any change or development that, singularly or in the aggregate, would reasonably be expected to involve a Material Adverse Effect, except as set forth in the General Disclosure Package and the Prospectus.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Since the date of the latest audited consolidated
      financial statements included in or incorporated by reference in the General Disclosure Package, (i)&#160;the Company and its subsidiaries shall not have sustained any loss or interference with its business from fire, explosion, flood or other calamity,
      whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as set forth in the General Disclosure Package, and (ii)&#160;there shall not have been any change in the capital stock or
      long-term debt of the Company or any of its subsidiaries, or any change, or any development involving a prospective change, in or affecting the business, general affairs, management, financial position, stockholders&#8217; equity or results of operations
      of the Company or any of its subsidiaries, otherwise than as set forth in the General Disclosure Package or the Prospectus, the effect of which, in any such case described in clause (i)&#160;or (ii)&#160;of this paragraph (k)&#160;is, in the judgment of the
      Representatives, so material and adverse as to make it impracticable or inadvisable to proceed with the sale or delivery of the Securities on the terms and in the manner contemplated in the General Disclosure Package.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No action shall have been taken and no law, statute, rule,
      regulation or order shall have been enacted, adopted or issued by any governmental agency or body which would prevent the issuance or sale of the Securities or materially and adversely affect or potentially materially and adversely affect the
      business or operations of the Company or any of its subsidiaries; and no injunction, restraining order or order of any other nature by any federal or state court of competent jurisdiction shall have been issued which would prevent the issuance or
      sale of the Securities or materially and adversely affect or potentially materially and adversely affect the business or operations of the Company or any of its subsidiaries.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subsequent to the execution and delivery of this
      Agreement there shall not have occurred any of the following: (i)&#160;trading in any of the Company&#8217;s securities shall have been suspended or materially limited by the Commission or the Exchange, or trading in securities generally on the New York Stock
      Exchange, The Nasdaq Global Select Market, The Nasdaq Global Market, The Nasdaq Capital Market or the NYSE MKT LLC or in the over-the-counter market, or trading in any securities of the Company on any exchange or in the over-the-counter market, shall
      have been suspended or materially limited, or minimum or maximum prices or maximum range for prices shall have been established on any such exchange or such market by the Commission, by such exchange or market or by any other regulatory body or
      governmental authority having jurisdiction, (ii)&#160;a banking moratorium shall have been declared by Federal or state authorities or a material disruption has occurred in commercial banking or securities settlement or clearance services in the United
      States, (iii)&#160;the United States shall have become engaged in hostilities, or the subject of an act of terrorism, or there shall have been an outbreak of or escalation in hostilities involving the United States, or there shall have been a declaration
      of a national emergency or war by the United States or (iv)&#160;there shall have occurred such a material adverse change in general economic, political or financial conditions (or the effect of international conditions on the financial markets in the
      United States shall be such) as to make it, in the judgment of the Representatives, impracticable or inadvisable to proceed with the sale or delivery of the Securities on the terms and in the manner contemplated in the General Disclosure Package and
      the Prospectus.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">21</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall have filed a Notification: Listing of
      Additional shares with The Nasdaq Global Market and shall have received no objection thereto from The Nasdaq Global Market.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Representatives shall have received on and as of such
      Closing Date satisfactory evidence of the good standing of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing as foreign entities in such other jurisdictions as the Representatives may
      reasonably request, in each case in writing or any standard form of telecommunication from the appropriate Governmental Authorities of such jurisdictions</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Representatives shall have received the written
      agreements, substantially in the form of Exhibit I hereto, of the officers, directors and certain holders of the Company&#8217;s capital stock, as set forth in Schedule D hereto.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall have furnished to the Representatives a
      Secretary&#8217;s Certificate of the Company, in form and substance reasonably satisfactory to counsel for the Underwriters and customary for the type of offering contemplated by this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; [<i>Reserved</i>].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On or prior to such Closing Date, the Company shall have
      furnished to the Representatives such further certificates and documents as the Representatives may reasonably request.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Representatives shall have received a form of Warrant
      in form and substance reasonably acceptable to the Representatives.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All opinions, letters, evidence and certificates mentioned above or
      elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>INDEMNIFICATION AND CONTRIBUTION</i>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall indemnify and hold harmless: (i)&#160;each
      Underwriter, its affiliates, directors, officers, managers, members, employees, representatives and agents and each person, if any, who controls any Underwriter within the meaning of Section&#160;15 of the Securities Act or Section&#160;20 of the Exchange Act
      (collectively the &#8220;<b><i>Underwriter Indemnified Parties</i></b>,&#8221; and each an &#8220;<b><i>Underwriter Indemnified Party</i></b>&#8221;) against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding in respect
      thereof), joint or several, to which such Underwriter Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding arises out of or is based
      upon (A)&#160;any untrue statement or alleged untrue statement of a material fact contained in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#8220;issuer information&#8221; filed or required to be filed pursuant to Rule&#160;433(d) of the Rules and
      Regulations, the Registration Statement, the Prospectus, or in any amendment or supplement thereto or document incorporated by reference therein or in any materials or information provided to investors by, or with the approval of, the Company in
      connection with the marketing of the offering of the Common Stock, including any roadshow or investor presentations made to investors by the Company (whether in person or electronically) (&#8220;<b><i>Marketing Materials</i></b>&#8221;) or (B)&#160;the omission or
      alleged omission to state in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#8220;issuer information&#8221; filed or required to be filed pursuant to Rule 433(d) of the Rules and Regulations, the Registration Statement or the Prospectus, or
      in any amendment or supplement thereto or document incorporated by reference therein, or in any Marketing Materials, a material fact required to be stated therein or necessary to make the statements therein not misleading, and shall reimburse each
      Underwriter Indemnified Party promptly upon demand for any legal fees or other expenses reasonably incurred by that Underwriter Indemnified Party in connection with investigating, or preparing to defend, or defending against, or appearing as a third
      party witness in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding, as such fees and expenses are incurred; <i>provided</i>, <i>however</i>, that the Company
      shall not be liable in any such case to the extent that any such loss, claim, damage, expense or liability arises out of or is based upon an untrue statement or alleged untrue statement in, or omission or alleged omission from any Preliminary
      Prospectus, the Registration Statement or the Prospectus, or any such amendment or supplement thereto, any Issuer Free Writing Prospectus or any Marketing Materials made in reliance upon and in conformity with written information furnished to the
      Company through the Representatives by or on behalf of any Underwriter specifically for use therein, which information the parties hereto agree is limited to the Underwriters&#8217; Information; and (ii)&#160;each indemnity agreement in this Section&#160;7(a) is not
      exclusive and is in addition to each other indemnity agreement in this Section&#160;7(a) and each other liability which the Company might have under this Agreement or otherwise, and shall not limit any rights or remedies which may otherwise be available
      under this Agreement, at law or in equity to any Underwriter Indemnified Party.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">22</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each Underwriter, severally and not jointly, shall
      indemnify and hold harmless the Company and its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&#160;15 of the Securities Act or Section&#160;20 of the Exchange Act
      (collectively the &#8220;<b><i>Company Indemnified Parties</i></b>&#8221; and each a &#8220;<b><i>Company Indemnified Party</i></b>&#8221;) against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding in respect thereof),
      joint or several, to which such Company Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding arises out of or is based upon (i)&#160;any
      untrue statement or alleged untrue statement of a material fact contained in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#8220;issuer information&#8221; filed or required to be filed pursuant to Rule&#160;433(d) of the Rules and Regulations,
      the Registration Statement or the Prospectus, or in any amendment or supplement thereto, or (ii)&#160;the omission or alleged omission to state in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#8220;issuer information&#8221; filed or required
      to be filed pursuant to Rule&#160;433(d) of the Rules and Regulations, the Registration Statement or the Prospectus, or in any amendment or supplement thereto, a material fact required to be stated therein or necessary to make the statements therein not
      misleading, but in each case only to the extent that the untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with written information furnished to the Company through the
      Representatives by or on behalf of that Underwriter specifically for use therein, which information the parties hereto agree is limited to the Underwriters&#8217; Information, and shall reimburse the Company Indemnified Parties for any legal or other
      expenses reasonably incurred by such party in connection with investigating or preparing to defend or defending against or appearing as third party witness in connection with any such loss, claim, damage, liability, action, investigation or
      proceeding, as such fees and expenses are incurred. This indemnity agreement is not exclusive and will be in addition to any liability which the Underwriters might otherwise have and shall not limit any rights or remedies which may otherwise be
      available under this Agreement, at law or in equity to the Company Indemnified Parties.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Promptly after receipt by an indemnified party under this
      Section&#160;7 of notice of the commencement of any action, the indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party under this Section&#160;7, notify such indemnifying party in writing of the commencement of that
      action; <i>provided</i>, <i>however</i>, that the failure to notify the indemnifying party shall not relieve it from any liability which it may have under this Section&#160;7 except to the extent it has been materially prejudiced by such failure; and <i>provided</i>,
      <i>further</i>, that the failure to notify an indemnifying party shall not relieve it from any liability which it may have to an indemnified party otherwise than under this Section&#160;7. If any such action shall be brought against an indemnified party,
      and it shall notify the indemnifying party thereof, the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party (which counsel shall not, except with the written consent of the
      indemnified party, be counsel to the indemnifying party) to represent the indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In
      any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel (other than reasonable costs of investigation) shall be at the expense of such indemnified party unless (i)&#160;the
      employment thereof has been specifically authorized in writing by the Company in the case of a claim for indemnification under Section&#160;7(a) or the Representatives in the case of a claim for indemnification under Section&#160;7(b), (ii)&#160;such indemnified
      party shall have been advised by its counsel that there may be one or more legal defenses available to it which are different from or additional to those available to the indemnifying party, or (iii)&#160;the indemnifying party has failed to employ
      counsel reasonably satisfactory to the indemnified party within a reasonable period of time after notice of the commencement of the action; <i>provided</i>, <i>however</i>, that the indemnifying party shall not, in connection with any one such
      action or separate but substantially similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances, be liable for the reasonable fees and expenses of more than one separate firm of attorneys at any
      time for all such indemnified parties (in addition to one local counsel), which firm shall be designated in writing by the Representatives if the indemnified parties under this Section&#160;7 consist of any Underwriter Indemnified Party or by the Company
      if the indemnified parties under this Section&#160;7 consist of any Company Indemnified Parties. Subject to this Section&#160;7(c), the amount payable by an indemnifying party under Section&#160;7 shall include, but not be limited to, (x)&#160;reasonable and documented
      legal fees and expenses of counsel to the indemnified party and any other expenses in investigating, or preparing to defend or defending against, or appearing as a third party witness in respect of, or otherwise incurred in connection with, any
      action, investigation, proceeding or claim, and (y)&#160;all amounts paid in settlement of any of the foregoing. No indemnifying party shall, without the prior written consent of the indemnified parties (which consent shall not be unreasonably withheld or
      delayed), settle or compromise or consent to the entry of judgment with respect to any pending or threatened action or any claim whatsoever, in respect of which indemnification or contribution could be sought under this Section&#160;7 (whether or not the
      indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i)&#160;includes an unconditional release of each indemnified party in form and substance reasonably satisfactory to such indemnified party from
      all liability arising out of such action or claim and (ii)&#160;does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. Subject to the provisions of the following sentence, no
      indemnifying party shall be liable for settlement of any pending or threatened action or any claim whatsoever that is effected without its written consent (which consent shall not be unreasonably withheld or delayed), but if settled with its written
      consent, if its consent has been unreasonably withheld or delayed or if there be a judgment for the plaintiff in any such matter, the indemnifying party agrees to indemnify and hold harmless any indemnified party from and against any loss or
      liability by reason of such settlement or judgment. In addition, if at any time an indemnified party shall have requested that an indemnifying party reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees that
      it shall be liable for any settlement of the nature contemplated by Section&#160;7(a) effected without its written consent if (i)&#160;such settlement is entered into more than forty-five (45)&#160;days after receipt by such indemnifying party of the request for
      reimbursement, (ii)&#160;such indemnifying party shall have received notice of the terms of such settlement at least thirty (30)&#160;days prior to such settlement being entered into and (iii)&#160;such indemnifying party shall not have reimbursed such indemnified
      party in accordance with such request prior to the date of such settlement.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">23</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If the indemnification provided for in this Section&#160;7 is
      unavailable or insufficient to hold harmless an indemnified party under Section&#160;7(a) or 7(b), then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid, payable or otherwise incurred by such
      indemnified party as a result of such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof), as incurred, (i)&#160;in such proportion as shall be appropriate to reflect the relative benefits received by
      the Company on the one hand and the Underwriters on the other from the offering of the Securities, or (ii)&#160;if the allocation provided by clause (i)&#160;of this Section&#160;7(d) is not permitted by applicable law, in such proportion as is appropriate to
      reflect not only the relative benefits referred to in clause (i)&#160;of this Section&#160;7(d) but also the relative fault of the Company on the one hand and the Underwriters on the other with respect to the statements, omissions, acts or failures to act
      which resulted in such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof) as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and
      the Underwriters on the other with respect to such offering shall be deemed to be in the same proportion as the total net proceeds from the offering of the Securities purchased under this Agreement (before deducting expenses) received by the Company
      bear to the total underwriting discounts and commissions received by the Underwriters with respect to the Stock and Warrants purchased under this Agreement, in each case as set forth in the table on the cover page of the Prospectus. The relative
      fault of the Company on the one hand and the Underwriters on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material
      fact relates to information supplied by the Company on the one hand or the Underwriters on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement, omission,
      act or failure to act; <i>provided</i> that the parties hereto agree that the written information furnished to the Company through the Representatives by or on behalf of the Underwriters for use in the Preliminary Prospectus, any Registration
      Statement or the Prospectus, or in any amendment or supplement thereto, consists solely of the Underwriters&#8217; Information.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company and the Underwriters agree that it would not be
      just and equitable if contributions pursuant to Section&#160;7(d) above were to be determined by pro rata allocation or by any other method of allocation which does not take into account the equitable considerations referred to Section&#160;7(d) above. The
      amount paid or payable by an indemnified party as a result of the loss, claim, damage, expense, liability, action, investigation or proceeding referred to in Section&#160;7(d) above shall be deemed to include, subject to the limitations set forth above,
      any legal or other expenses reasonably incurred by such indemnified party in connection with investigating, preparing to defend or defending against or appearing as a third party witness in respect of, or otherwise incurred in connection with, any
      such loss, claim, damage, expense, liability, action, investigation or proceeding. Notwithstanding the provisions of this Section&#160;7, no Underwriter shall be required to contribute any amount in excess of the amount by which the total underwriting
      discounts and commissions received by such Underwriter with respect to the offering of the Securities exceeds the amount of any damages which the Underwriter has otherwise paid or become liable to pay by reason of any untrue or alleged untrue
      statement, omission or alleged omission, act or alleged act or failure to act or alleged failure to act. No person guilty of fraudulent misrepresentation (within the meaning of Section&#160;11(f) of the Securities Act) shall be entitled to contribution
      from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#8217; obligations to contribute as provided in this Section&#160;7 are several in proportion to their respective underwriting obligations and not joint.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">24</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>TERMINATION</i>. The obligations of the Underwriters
      hereunder may be terminated by the Representatives, in their absolute discretion by notice given to the Company prior to delivery of and payment for the Firm Securities if, prior to that time, any of the events described in Sections 6(j) or 6(l) have
      occurred or if the Underwriters shall decline to purchase the Securities for any reason permitted under this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>REIMBURSEMENT OF UNDERWRITERS&#8217; EXPENSES</i>.
      Notwithstanding anything to the contrary in this Agreement, if (a)&#160;this Agreement shall have been terminated pursuant to Section&#160;8 or 10, (b)&#160;the Company shall fail to tender the Securities for delivery to the Underwriters, or in the case of the
      Warrants, to the purchaser thereof, for any reason not permitted under this Agreement, (c)&#160;the Underwriters shall decline to purchase the Securities for any reason permitted under this Agreement or (d)&#160;the sale of the Securities is not consummated
      because any condition to the obligations of the Underwriters set forth herein is not satisfied or because of the refusal, inability or failure on the part of the Company to perform any agreement herein or to satisfy any condition or to comply with
      the provisions hereof, then in addition to the payment of amounts in accordance with Section&#160;5, the Company shall reimburse the Underwriters for the accountable fees and expenses of Underwriters&#8217; counsel and for such other out-of-pocket accountable
      expenses as shall have been actually incurred by them in connection with this Agreement and the proposed purchase of the Securities, including, without limitation, reasonable travel and lodging expenses of the Underwriters, and upon demand the
      Company shall pay the full amount thereof to the Representatives; <i>provided</i> that if this Agreement is terminated pursuant to Section&#160;10 by reason of the default of one or more Underwriters, the Company shall not be obligated to reimburse any
      defaulting Underwriter on account of expenses to the extent incurred by such defaulting Underwriter; <i>provided</i>, <i>further</i> that the foregoing shall not limit any reimbursement obligation of the Company to any non-defaulting Underwriter
      under this Section&#160;9.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>SUBSTITUTION OF UNDERWRITERS</i>. If any Underwriter or
      Underwriters shall default in its or their obligations to purchase shares of Securities hereunder on any Closing Date and the aggregate number of shares which such defaulting Underwriter or Underwriters agreed but failed to purchase does not exceed
      ten percent (10%)&#160;of the total number of shares to be purchased by all Underwriters on such Closing Date, the other Underwriters shall be obligated severally, in proportion to their respective commitments hereunder, to purchase the shares which such
      defaulting Underwriter or Underwriters agreed but failed to purchase on such Closing Date. If any Underwriter or Underwriters shall so default and the aggregate number of shares with respect to which such default or defaults occur is more than ten
      percent (10%)&#160;of the total number of shares to be purchased by all Underwriters on such Closing Date and arrangements satisfactory to the Representatives and the Company for the purchase of such shares by other persons are not made within forty-eight
      (48)&#160;hours after such default, this Agreement shall terminate.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the remaining Underwriters or substituted Underwriters are required
      hereby or agree to take up all or part of the shares of Securities of a defaulting Underwriter or Underwriters on such Closing Date as provided in this Section&#160;10, (i)&#160;the Company shall have the right to postpone such Closing Dates for a period of
      not more than five (5)&#160;full business days in order that the Company may effect whatever changes may thereby be made necessary in the Registration Statement or the Prospectus, or in any other documents or arrangements, and the Company agrees promptly
      to file any amendments to the Registration Statement or supplements to the Prospectus which may thereby be made necessary, and (ii)&#160;the respective numbers of shares to be purchased by the remaining Underwriters or substituted Underwriters shall be
      taken as the basis of their underwriting obligation for all purposes of this Agreement. Nothing herein contained shall relieve any defaulting Underwriter of its liability to the Company or the other Underwriters for damages occasioned by its default
      hereunder. Any termination of this Agreement pursuant to this Section&#160;10 shall be without liability on the part of any non-defaulting Underwriter or the Company, except that the representations, warranties, covenants, indemnities, agreements and
      other statements set forth in Section&#160;2, the obligations with respect to expenses to be paid or reimbursed pursuant to Sections 5 and 9 and the provisions of Section&#160;7 and Sections 11 through 21, inclusive, shall not terminate and shall remain in
      full force and effect.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">25</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>ABSENCE OF FIDUCIARY RELATIONSHIP</i>. The Company
      acknowledges and agrees that:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; each Underwriter&#8217;s responsibility to the Company is solely
      contractual in nature, the Representatives have been retained solely to act as underwriters in connection with the sale of the Securities and no fiduciary, advisory or agency relationship between the Company and the Representatives has been created
      in respect of any of the transactions contemplated by this Agreement, irrespective of whether any of the Representatives has advised or is advising the Company on other matters;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the price of the Securities set forth in this Agreement was
      established by the Company following discussions and arms-length negotiations with the Representatives, and the Company is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions
      contemplated by this Agreement;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; it has been advised that the Representatives and their
      affiliates are engaged in a broad range of transactions which may involve interests that differ from those of the Company and that the Representatives have no obligation to disclose such interests and transactions to the Company by virtue of any
      fiduciary, advisory or agency relationship;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the Underwriters have not provided any recommendation or
      investment advice nor have the Underwriters solicited any action from the undersigned with respect to the offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent
      deemed appropriate. Although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the offering of the Securities, the Representatives and the other Underwriters
      are not making a recommendation to you to enter into this Agreement, and nothing set forth in such disclosures is intended to suggest that the Representatives or any Underwriter is making such a recommendation. Furthermore, none of the activities of
      the Underwriters in connection with the transactions contemplated herein constitutes a recommendation, investment advice, or solicitation of any action by the Underwriters with respect to any entity or natural person; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; it waives, to the fullest extent permitted by law, any
      claims it may have against the Representatives for breach of fiduciary duty or alleged breach of fiduciary duty and agrees that the Representatives shall have no liability (whether direct or indirect) to the Company in respect of such a fiduciary
      duty claim or to any person asserting a fiduciary duty claim on behalf of or in right of the Company, including stockholders, employees or creditors of the Company.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>SUCCESSORS; PERSONS ENTITLED TO BENEFIT OF AGREEMENT</i>.
      This Agreement shall inure to the benefit of and be binding upon the several Underwriters, the Company and their respective successors and assigns. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person,
      other than the persons mentioned in the preceding sentence, any legal or equitable right, remedy or claim under or in respect of this Agreement, or any provisions herein contained, this Agreement and all conditions and provisions hereof being
      intended to be and being for the sole and exclusive benefit of such persons and for the benefit of no other person; except that the representations, warranties, covenants, agreements and indemnities of the Company contained in this Agreement shall
      also be for the benefit of the Underwriter Indemnified Parties and the indemnities of the several Underwriters shall be for the benefit of the Company Indemnified Parties. It is understood that each Underwriter&#8217;s responsibility to the Company is
      solely contractual in nature and the Underwriters do not owe the Company, or any other party, any fiduciary duty as a result of this Agreement. No purchaser of any of the Securities from any Underwriter shall be deemed to be a successor or assign by
      reason merely of such purchase.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>SURVIVAL OF INDEMNITIES</i>, <i>REPRESENTATIONS</i>, <i>WARRANTIES</i>,
      <i>ETC. </i>The respective indemnities, covenants, agreements, representations, warranties and other statements of the Company and the several Underwriters, as set forth in this Agreement or made by them respectively, pursuant to this Agreement,
      shall remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter, the Company or any person controlling any of them and shall survive delivery of and payment for the Securities. Notwithstanding any
      termination of this Agreement, including without limitation any termination pursuant to Section&#160;8 or Section&#160;10, the indemnities, covenants, agreements, representations, warranties and other statements forth in Sections 2, 5, 7 and 9 and Sections 11
      through 21, inclusive, of this Agreement shall not terminate and shall remain in full force and effect at all times.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">26</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>NOTICES</i>. All statements, requests, notices and
      agreements hereunder shall be in writing, and:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; if to the Underwriters, shall be delivered or sent by mail,
      telex or facsimile transmission to: J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) 622-8358); Attention: Equity Syndicate Desk; Morgan Stanley &amp; Co. LLC, 1585 Broadway, 29th Floor, New York, New York 10036,
      Attention: Equity Syndicate Desk; Leerink Partners LLC, 1301 Avenue of the Americas, 12th Floor, New York, New York 10019, Attention: Stuart Nayman; and Cowen&#160;and&#160;Company,&#160;LLC, 599 Lexington Avenue, New York, New York 10022, Attention: Head of Equity
      Capital Markets, with a copy to the General Counsel, Investment Banking;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; if to the Company shall be delivered or sent by mail,
      telex, facsimile transmission or email to Rocket Pharmaceuticals, Inc., 9 Cedar Brook Drive, Cranbury, NJ 08512, Attention: Gaurav Shah, Chief Executive Officer, Telephone: (646)&#160;440-9100, Email: gs@rocketpharma.com, with a copy to K&amp;L Gates LLP,
      Whitney J. Smith, Esq., Telephone: (212) 536-3930, Email: whitney.smith@klgates.com;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>provided</i>, <i>however</i>, that any notice to an Underwriter pursuant to Section&#160;7
      shall be delivered or sent by mail, or facsimile transmission to such Underwriter at its address set forth in its acceptance telex to the Representatives, which address will be supplied to any other party hereto by the Representatives upon request.
      Any such statements, requests, notices or agreements shall take effect at the time of receipt thereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>RECOGNITION OF THE U.S. SPECIAL RESOLUTION REGIMES</i>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event that any Underwriter that is a Covered Entity
      becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be
      effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event that any Underwriter that is a Covered Entity
      or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent
      than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For purposes of this Section 15, a &#8220;BHC Act Affiliate&#8221; has the meaning
      assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k). &#8220;Covered Entity&#8221; means any of the following: (i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;
      252.82(b); (ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). <b>&#8220;</b>Default
      Right&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. &#8220;U.S. Special Resolution Regime&#8221; means each of (i) the Federal Deposit Insurance Act and the regulations
      promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>DEFINITION OF CERTAIN TERMS</i>. For purposes of this
      Agreement, (a)&#160;&#8220;<b><i>affiliate</i></b>&#8221; has the meaning set forth in Rule 405 under the Securities Act, (b)&#160;&#8220;<b><i>business day</i></b>&#8221; means any day on which the New York Stock Exchange, Inc. is open for trading and (c)&#160;&#8220;<b><i>subsidiary</i></b>&#8221;
      has the meaning set forth in Rule&#160;405 of the Rules and Regulations.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>GOVERNING LAW AND JURISDICTION</i>. <b>This Agreement
        shall be governed by and construed in accordance with the laws of the State of New York, including without limitation Section&#160;5-1401 of the New York General Obligations</b>. The Company irrevocably (a)&#160;submits to the non-exclusive jurisdiction of
      the Federal and state courts in the Borough of Manhattan in The City of New York for the purpose of any suit, action or other proceeding arising out of this Agreement or the transactions contemplated by this Agreement, the Registration Statement and
      any Preliminary Prospectus or the Prospectus, (b)&#160;agrees that all claims in respect of any such suit, action or proceeding may be heard and determined by any such court, (c)&#160;waives to the fullest extent permitted by applicable law, any immunity from
      the jurisdiction of any such court or from any legal process, (d)&#160;agrees not to commence any such suit, action or proceeding other than in such courts, and (e)&#160;waives, to the fullest extent permitted by applicable law, any claim that any such suit,
      action or proceeding is brought in an inconvenient forum.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">27</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>UNDERWRITERS&#8217; INFORMATION</i>. The parties hereto
      acknowledge and agree that, for all purposes of this Agreement, the Underwriters&#8217; Information consists solely of the following information in the Prospectus:&#160;the statements concerning the Underwriters contained in the third, twelfth, thirteenth and
      fourteenth paragraphs under the heading &#8220;Underwriting&#8221; (the &#8220;<b><i>Underwriters&#8217; Information</i></b>&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>AUTHORITY OF THE REPRESENTATIVES</i>. In connection
      with this Agreement, the Representatives will act for and on behalf of the several Underwriters, and any action taken under this Agreement by the Representatives will be binding on all the Underwriters.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>PARTIAL UNENFORCEABILITY</i>. The invalidity or
      unenforceability of any section, paragraph, clause or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph, clause or provision hereof. If any section, paragraph, clause or provision of this
      Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>GENERAL</i>. This Agreement constitutes the entire
      agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. In this Agreement, the masculine, feminine and
      neuter genders and the singular and the plural include one another. The section headings in this Agreement are for the convenience of the parties only and will not affect the construction or interpretation of this Agreement. This Agreement may be
      amended or modified, and the observance of any term of this Agreement may be waived, only by a writing signed by the Company and the Representatives.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <i>COUNTERPARTS</i>. This Agreement may be executed by any
      one or more of the parties hereto in any number of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic
      mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and
      any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the foregoing is in accordance with your understanding of the
      agreement between the Company and the several Underwriters, kindly indicate your acceptance of this Agreement by signing in the space provided for that purpose below.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<i>Signature page follows</i>]</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center" class="BRPFPageNumberArea"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal">28</font></div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="margin: 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Very truly yours,</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">ROCKET PHARMACEUTICALS, INC.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 50%"></td>
        <td style="width: 3%; text-align: left; vertical-align: bottom">By:</td>
        <td style="text-align: center; width: 47%; border-bottom: Black 1pt solid"><img src="ny20010507x5_ex1-1img01.jpg" alt=""></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: right">Name: Martin Wilson</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: right">Title: General Counsel</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: right">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Signature Page to Underwriting Agreement]</p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
  &#160;
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted as of the date first above written:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="text-transform: uppercase">J.P. Morgan Securities LLC </font>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="text-transform: uppercase">Morgan Stanley &amp; Co. LLC</font>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">LEERINK PARTNERS LLC&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">COWEN AND COMPANY, LLC</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acting on their own behalf and as&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Representatives of several Underwriters listed&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">on <u>Schedule A</u> to this Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: J.P. MORGAN SECURITIES LLC</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">

      <tr style="vertical-align: top">
        <td style="width: 5%; text-align: left; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
        <td style="width: 45%; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<img src="ny20010507x5_ex1-1img02.jpg" alt="" style="height: 29px; width: 170px"></font></td>
        <td style="width: 50%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: David Ke</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Managing Director</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: <font style="text-transform: uppercase">Morgan Stanley &amp; Co. LLC</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
  <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">

      <tr style="vertical-align: top">
        <td style="width: 5%; text-align: left; vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">By:</font></td>
        <td style="width: 45%; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;<img src="ny20010507x5_ex1-1img03.jpg" alt="" style="height: 39px; width: 120px"></font></td>
        <td style="width: 50%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
        <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Name: Chirag D. Surti</font></td>
        <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
        <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Title: Executive Director</font></td>
        <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: LEERINK PARTNERS LLC</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
  <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">

      <tr style="vertical-align: top">
        <td style="width: 5%; text-align: left; vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">By:</font></td>
        <td style="width: 45%; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;<img src="ny20010507x5_ex1-1img04.jpg" alt="" style="height: 25px; width: 100px"></font></td>
        <td style="width: 50%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
        <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Name: Anurag Jindal</font></td>
        <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
        <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Title: Sr. Managing Director</font></td>
        <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
      </tr>

  </table>
  <br>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: COWEN AND COMPANY, LLC</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
  <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">

      <tr style="vertical-align: top">
        <td style="width: 5%; text-align: left; vertical-align: bottom"><font style="font: 10pt Times New Roman, Times, Serif">By:</font></td>
        <td style="width: 45%; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">&#160;<img src="ny20010507x5_ex1-1img05.jpg" alt=""></font></td>
        <td style="width: 50%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
        <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Name: Kunal Bhatia</font></td>
        <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
        <td style="padding-bottom: 1pt"><font style="font: 10pt Times New Roman, Times, Serif">Title: Managing Director</font></td>
        <td><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
  <p style="margin-top: 0; margin-bottom: 0; text-align: center">[Signature Page to Underwriting Agreement]</p>
  <p style="margin-top: 0; margin-bottom: 0; text-align: center"></p>
  <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" class="BRPFPageBreakArea">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div style="PAGE-BREAK-AFTER: always" class="BRPFPageBreak">
      <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
  </div>
  <!--PROfilePageNumberReset%Num%32%%%-->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="text-transform: uppercase"><b>Schedule A</b></font>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

      <tr style="vertical-align: bottom">
        <td>&#160;</td>
        <td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
        <td colspan="2" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares&#160;of&#160;Firm&#160;Stock to be Sold</td>
        <td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold">&#160;</td>
        <td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
        <td colspan="2" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Warrants to be Sold</td>
        <td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold">&#160;</td>
        <td style="font-size: 9pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
        <td colspan="2" style="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&#160;of&#160;Shares of Optional Stock to be Sold</td>
        <td style="padding-bottom: 1pt; font-size: 9pt; font-weight: bold">&#160;</td>
      </tr>
      <tr style="vertical-align: bottom">
        <td style="font-weight: bold; text-decoration: underline">Underwriter</td>
        <td>&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td style="text-align: right">&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td>&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td style="text-align: right">&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td>&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td style="text-align: right">&#160;</td>
        <td style="text-align: left">&#160;</td>
      </tr>
      <tr style="vertical-align: bottom">
        <td style="width: 55%; text-align: left">J.P. Morgan Securities LLC </td>
        <td style="width: 1%">&#160;</td>
        <td style="width: 1%; text-align: left">&#160;</td>
        <td style="width: 12%; text-align: right">2,343,750</td>
        <td style="width: 1%; text-align: left">&#160;</td>
        <td style="width: 1%">&#160;</td>
        <td style="width: 1%; text-align: left">&#160;</td>
        <td style="width: 12%; text-align: right">938,087</td>
        <td style="width: 1%; text-align: left">&#160;</td>
        <td style="width: 1%">&#160;</td>
        <td style="width: 1%; text-align: left">&#160;</td>
        <td style="width: 12%; text-align: right">492,276</td>
        <td style="width: 1%; text-align: left">&#160;</td>
      </tr>
      <tr style="vertical-align: bottom">
        <td style="text-align: left">Morgan Stanley &amp; Co. LLC </td>
        <td>&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td style="text-align: right">2,265,625</td>
        <td style="text-align: left">&#160;</td>
        <td>&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td style="text-align: right">906,817</td>
        <td style="text-align: left">&#160;</td>
        <td>&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td style="text-align: right">475,866</td>
        <td style="text-align: left">&#160;</td>
      </tr>
      <tr style="vertical-align: bottom">
        <td style="text-align: left">Leerink Partners LLC </td>
        <td>&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td style="text-align: right">1,328,125</td>
        <td style="text-align: left">&#160;</td>
        <td>&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td style="text-align: right">531,582</td>
        <td style="text-align: left">&#160;</td>
        <td>&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td style="text-align: right">278,956</td>
        <td style="text-align: left">&#160;</td>
      </tr>
      <tr style="vertical-align: bottom">
        <td style="text-align: left">Cowen and Company, LLC </td>
        <td>&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td style="text-align: right">1,328,125</td>
        <td style="text-align: left">&#160;</td>
        <td>&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td style="text-align: right">531,582</td>
        <td style="text-align: left">&#160;</td>
        <td>&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td style="text-align: right">278,956</td>
        <td style="text-align: left">&#160;</td>
      </tr>
      <tr style="vertical-align: bottom">
        <td style="text-align: left">LifeSci Capital LLC </td>
        <td>&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td style="text-align: right">546,875</td>
        <td style="text-align: left">&#160;</td>
        <td>&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td style="text-align: right">218,887</td>
        <td style="text-align: left">&#160;</td>
        <td>&#160;</td>
        <td style="text-align: left">&#160;</td>
        <td style="text-align: right">114,864</td>
        <td style="text-align: left">&#160;</td>
      </tr>
      <tr style="vertical-align: bottom">
        <td style="padding-bottom: 2.5pt">Total </td>
        <td style="padding-bottom: 2.5pt">&#160;</td>
        <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
        <td style="border-bottom: Black 2.5pt double; text-align: right">7,812,500</td>
        <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
        <td style="padding-bottom: 2.5pt">&#160;</td>
        <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
        <td style="border-bottom: Black 2.5pt double; text-align: right">3,126,955</td>
        <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
        <td style="padding-bottom: 2.5pt">&#160;</td>
        <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td>
        <td style="border-bottom: Black 2.5pt double; text-align: right">1,640,918</td>
        <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
      </tr>

  </table>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; font-style: normal;">32</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="text-transform: uppercase"><b>Schedule B</b></font>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">General Use Free Writing Prospectuses</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</p>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; font-style: normal;">33</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <!--PROfilePageNumberReset%Num%32%%%-->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="text-transform: uppercase"><b>Schedule C</b></font>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pricing Information</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Firm Stock to be sold: 7,812,500 shares</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Optional Stock to be sold: 1,640,918 shares</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Offering Price of Firm and Optional Stock: $16.00 per share</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Warrants to be sold: 3,126,955 warrants</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Offering Price of Warrants: $15.99 per Warrant</p>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; font-style: normal;">34</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <br>
  <!--PROfilePageNumberReset%Num%33%%%-->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="text-transform: uppercase"><b>Schedule D</b></font>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">List of Parties to Lock-up Agreements</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Roderick Wong&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carsten Boess&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pedro Granadillo&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gotham Makker&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gaurav Shah&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Southwell&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Naveen Yalamanchi&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Elisabeth Bj&#246;rk&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mark White&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Martin Wilson&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kinnari Patel&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">John Militello&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Fady Malik&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RTW Master Fund, Ltd.&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RTW Innovation Master Fund, Ltd.&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RTW Biotech Opportunities Ltd&#160;</p>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; font-style: normal;">35</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <!--PROfilePageNumberReset%Num%34%%%-->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit I</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form of Lock-Up Agreement</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">_________, 2023</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J.P. Morgan Securities LLC&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">383 Madison Avenue&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10179</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Morgan Stanley &amp; Co. LLC&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1585 Broadway&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10036</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leerink Partners LLC&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1301 Avenue of the Americas, 12th Floor&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10019</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cowen and Company LLC&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">599 Lexington Avenue&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10022</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As Representatives of the several Underwriters</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Re: Rocket Pharmaceuticals, Inc. &#8211; Registration Statement on Form S-3</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This agreement (the &#8220;<b><i>Lock-Up Agreement</i></b>&#8221;) is being delivered to you in connection with the proposed Underwriting Agreement (the &#8220;<b><i>Underwriting




        Agreement</i></b>&#8221;) between Rocket Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<b><i>Company</i></b>&#8221;), J.P. Morgan Securities LLC, Morgan Stanley &amp; Co. LLC, Leerink Partners LLC and Cowen and Company, LLC as representatives (the &#8220;<b><i>Representatives</i></b>&#8221;)




    of a group of underwriters (collectively, the &#8220;<b><i>Underwriters</i></b>&#8221;) to be named therein, and the other parties thereto (if any), relating to the proposed public offering (the &#8220;<b><i>Offering</i></b>&#8221;) of shares of common stock of the Company,
    par value $0.01 per share (the &#8220;<b><i>Common Stock</i></b>&#8221;).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to induce you and the other Underwriters to enter into the Underwriting Agreement, and in light of the benefits that the Offering will
    confer upon the undersigned in its capacity as a securityholder and/or an officer, director or employee of the Company, and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with
    each Underwriter that, during the period beginning on the date hereof through and including the date that is the 90th day after the date of the Underwriting Agreement (the &#8220;<b><i>Restricted Period</i></b>&#8221;), the undersigned will not, without the prior
    written consent of J.P. Morgan Securities LLC and Morgan Stanley &amp; Co. LLC, directly or indirectly:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)<font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>offer, pledge, sell, contract to sell, sell any
    option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or
    exercisable or exchangeable for Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and
    Exchange Commission and securities of the Company which may be issued upon exercise of a stock option or warrant or settlement of a restricted stock unit (&#8220;<b><i>RSU</i></b>&#8221;)) that are currently or hereafter owned by the undersigned (collectively, the
    &#8220;<b><i>Undersigned&#8217;s Shares</i></b>&#8221;), or publicly disclose the intention to make any such offer, sale, pledge, grant, transfer or disposition;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii)<font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>enter into any swap, short sale, hedge or other
    agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Undersigned&#8217;s Shares regardless of whether any such transaction described in clause (i)&#160;above or this clause (ii)&#160;is to be settled by delivery of Common
    Stock or such other securities, in cash or otherwise; or</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii)<font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>make any demand for or exercise any right with
    respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock.&#160;</p>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; font-style: normal;">36</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
  <!--PROfilePageNumberReset%Num%35%%%-->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The restrictions and obligations contemplated by this Lock-Up Agreement shall not apply to:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>transfers of the Undersigned&#8217;s Shares:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>if the undersigned is a natural
    person, (A)&#160;to any person related to the undersigned by blood or adoption who is an immediate family member of the undersigned, or by marriage or domestic partnership (a &#8220;<b><i>Family Member</i></b>&#8221;), or to a trust formed for the benefit of the
    undersigned or any of the undersigned&#8217;s Family Members, (B)&#160;to the undersigned&#8217;s estate, following the death of the undersigned, by will, intestacy or other operation of law, (C)&#160;as a <i>bona fide</i> gift to a charitable organization, (D)&#160;by
    operation of law pursuant to a qualified domestic order or in connection with a divorce settlement or (E)&#160;to any partnership, corporation or limited liability company which is controlled by the undersigned and/or by any such Family Member(s);</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>if the undersigned is a corporation,
    partnership or other business entity, (A)&#160;to another corporation, partnership or other business entity that is an affiliate (as defined under Rule 12b-2 of the Exchange Act of 1934, as amended (the &#8220;<b><i>Exchange Act</i></b>&#8221;)) of the undersigned,
    including investment funds or other entities under common control or management with the undersigned, (B)&#160;as a distribution or dividend to equity holders (including, without limitation, general or limited partners and members) of the undersigned
    (including upon the liquidation and dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned&#8217;s equity holders) or (C)&#160;as a <i>bona fide</i> gift to a charitable organization; or</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)<font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>if the undersigned is a trust, to any
    grantors or beneficiaries of the trust;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>provided</i> that, in the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value and each donee, heir, beneficiary or
    other transferee or distributee shall sign and deliver to the Representatives a lock-up agreement in the form of this Lock-Up Agreement with respect to the shares of Common Stock or such other securities that have been so transferred or distributed;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the exercise of an option (including a net or
    cashless exercise of an option) to purchase shares of Common Stock, and any related transfer of shares of Common Stock to the Company for the purpose of paying the exercise price of such options or for paying taxes (including estimated taxes) due as a
    result of the exercise of such options (or the disposition to the Company of any shares of restricted stock granted pursuant to the terms of any employee benefit plan or restricted stock purchase agreement); <i>provided</i> that, for the avoidance of
    doubt, the underlying shares of Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the sale of shares of Common Stock in order to
    pay any tax withholding obligations upon the vesting of RSUs; <i>provided</i> that, for the avoidance of doubt, (i) the underlying shares of Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement,
    (ii) no public disclosure or filing under Section 16(a) of the Exchange Act shall be voluntarily made during the Restricted Period and (iii) to the extent a filing under Section 16(a) of the Exchange Act is required during the Restricted Period as a
    result of transfers in this clause (c), it shall (A) clearly indicate that the filing relates to the circumstances described in this clause (c), including that the securities remain subject to the terms of this letter and (B) no securities were sold by
    the undersigned other than pursuant to this clause (c);</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the establishment of a trading plan pursuant to
    Rule 10b5-1 under the Exchange Act for the transfer of Common Stock (a &#8220;<b><i>10b5-1 Plan</i></b>&#8221;); <i>provided</i> that (1) such 10b5-1 Plan does not provide for any transfers of Common Stock during the Restricted Period and (2) to the extent a
    public announcement, report or filing under the Exchange Act, if any, is required by or on behalf of the undersigned or the Company regarding the establishment of such plan, such announcement, report or filing shall include a statement to the effect
    that no transfer, sale or other disposition of Common Stock of the Company may be made under such plan during the Restricted Period;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="background-color: white">the sale
      of shares of Common Stock pursuant to a </font>10b5-1 <font style="background-color: white">plan that complies with Rule 10b5-1 and that exists on the date of this Agreement, if any; <i>provided</i> that any Form 4 or Form 5 required to be filed
      under the Exchange Act if the undersigned is subject to Section 16 reporting with respect to the Company under the Exchange Act will indicate by footnote that such sale was made under the circumstances described in this clause; and <i>provided
        further</i> that no other filing under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with such sale during the Restricted Period; or</font>&#160;</p>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; font-style: normal;">37</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
  <!--PROfilePageNumberReset%Num%36%%%-->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)<font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>transfers by the undersigned of shares of Common
    Stock purchased by the undersigned on the open market following the Closing Date;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and <i>provided</i>, <i>further</i>, that, with respect to each of (b), (c) and (f)&#160;above, no filing by any party under the Exchange Act or other public
    announcement shall be required or shall be made voluntarily in connection with such transfer or disposition during the Restricted Period (other than in respect of a required filing under the Exchange Act in connection with the exercise of an option to
    purchase Common Stock following such individual&#8217;s termination of employment with the Company that would otherwise expire during the Restricted Period, <i>provided</i> that such filing shall include a note stating that such exercise is in connection
    with such termination of employment).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any attempted transfer in violation of this Lock-Up Agreement will be of no effect and null and void, regardless of whether the purported
    transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Lock-Up Agreement, and will not be recorded on the share register of the Company. In furtherance of the foregoing, the undersigned agrees that the
    Company and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this
    Lock-Up Agreement. The Company may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the undersigned&#8217;s ownership of Common Stock:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY OF WHICH IS
    ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement and that
    this Lock-Up Agreement has been duly authorized (if the undersigned is not a natural person), executed and delivered by the undersigned and is a valid and binding agreement of the undersigned. This Lock-Up Agreement and all authority herein conferred
    or agreed to be conferred and any obligations of the undersigned are irrevocable and shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. The undersigned understands that the Underwriters are proceeding
    with the Offering in reliance upon this Lock-Up Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any and all remedies herein expressly conferred upon the Underwriters will be deemed cumulative with and not exclusive of any other remedy
    conferred hereby, or by law or equity, and the exercise by the Underwriters of any one remedy will not preclude the exercise of any other remedy. The undersigned agrees that irreparable damage would occur to the Underwriters in the event that any
    provision of this Lock-Up Agreement were not performed in accordance with its specific terms or were otherwise breached. It is accordingly agreed that the Underwriters shall be entitled to an injunction or injunctions to prevent breaches of this
    Lock-Up Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which the Underwriters are entitled at law or in equity, and
    the undersigned waives any bond, surety or other security that might be required of the Company with respect thereto.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Lock-Up Agreement and any claim, controversy or dispute arising under or related to this Lock-Up Agreement shall be governed by and construed
    in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Lock-Up Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one
    and the same instrument. The delivery of this Lock-Up Agreement executed by the undersigned by facsimile or electronic transmission (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act,
    the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) in .pdf format (in counterparts or otherwise) shall be sufficient to bind the undersigned to the terms and conditions of this Lock-Up Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the Underwriters
    solicited any action from the undersigned with respect to the Offering of the Common Stock and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The undersigned further
    acknowledges and agrees that, although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Offering, the Representatives and the other Underwriters are not
    making a recommendation to you to enter into this Lock-up Agreement, and nothing set forth in such disclosures is intended to suggest that the Representatives or any Underwriter is making such a recommendation.&#160;</p>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; font-style: normal;">38</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
  <!--PROfilePageNumberReset%Num%37%%%-->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If (i)&#160;the Company notifies the Representatives in writing that it does not intend to proceed with the Offering, (ii)&#160;the Underwriting Agreement
    is not executed by September 30, 2023, or (iii)&#160;the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated for any reason prior to payment for and delivery of any securities to be sold
    thereunder, then this Agreement shall immediately be terminated and the undersigned shall automatically be released from all of his or her obligations under this Agreement. The undersigned acknowledges and agrees that whether or not the Offering
    actually occurs depends on a number of factors, including market conditions.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<i>Signature page follows</i>]</p>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; font-style: normal;">39</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <br>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt; text-align: right">Very truly yours,</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt; text-align: right">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt; text-align: right"></p>
  <!-- Field: Rule-Page -->
  <div align="RIGHT" style="margin-top: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt; text-align: right">(Name of Stockholder &#8211; Please Print)</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt; text-align: right">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt; text-align: right"></p>
  <!-- Field: Rule-Page -->
  <div align="RIGHT" style="margin-top: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt; text-align: right">(Signature)</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt; text-align: right">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt; text-align: right"></p>
  <!-- Field: Rule-Page -->
  <div align="RIGHT" style="margin-top: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt; text-align: right">(Name of Signatory if Stockholder is an entity &#8211; Please Print)</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt; text-align: right">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt; text-align: right"></p>
  <!-- Field: Rule-Page -->
  <div align="RIGHT" style="margin-top: 3pt">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt; text-align: right">(Title of Signatory if Stockholder is an entity &#8211; Please Print)</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt; text-align: right">&#160;</p>
  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 50%"></td>
        <td style="width: 6%;">Address:</td>
        <td style="width: 44%; border-bottom: Black 1pt solid;">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td>&#160;</td>
        <td>&#160;</td>
        <td style="border-bottom: Black 1pt solid;">&#160;</td>
      </tr>

  </table>
  <div> <br>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt"></p>
  <div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt"></p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ny20010507x5_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%--><font style="font-size: 10pt;">
  </font>
  <div>
    <div style="font-size: 10pt; text-align: right;">
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"><font style="font-weight: bold;">Exhibit 4.1</font><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), OR ANY
      APPLICABLE STATE SECURITIES LAWS.&#160; SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES AND MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT
      FILED BY THE ISSUER WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION COVERING SUCH SECURITIES UNDER THE SECURITIES ACT OR AN EXEMPTION FROM REGISTRATION.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ROCKET PHARMACEUTICALS, INC.</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zc00ba6b5851b40779c54aabe39e753de" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 54.91%; vertical-align: bottom; font-size: 10pt;">&#160;</td>
          <td style="width: 2.16%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 42.93%; vertical-align: top;">
            <div style="text-align: right;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Number of Shares: [</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">
                  ]</font></font></div>
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(subject to adjustment)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 54.91%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Warrant No.</div>
          </td>
          <td style="width: 2.16%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 42.93%; vertical-align: top;">
            <div style="text-align: right;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Original Issue Date: [</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;">]</font></font></div>
          </td>
        </tr>

    </table>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Rocket Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Company</font>&#8221;), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [RTW Innovation Master Fund, Ltd.] or its permitted registered assigns (the &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Holder</font>&#8221;), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [ ] shares of common stock, $0.01 par value per
      share (the &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Common Stock</font>&#8221;), of the Company (each such share, a &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Warrant
        Share</font>&#8221; and all such shares, the &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Warrant Shares</font>&#8221;) at an exercise price per share equal to $0.01 per share (as adjusted from time to time as
      provided in <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 9</u></font> herein, the &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Exercise Price</font>&#8221;), upon surrender of
      this Pre-Funded Warrant to Purchase Common Stock (including any Pre-Funded Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Warrant</font>&#8221;) at any time and from time to time on or after the date hereof (the &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Original Issue Date</font>&#8221;) and through the date on which this
      Warrant is exercised in full (the &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Expiration Date</font>&#8221;), and subject to the following terms and conditions:</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div>
      <div>
        <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 36pt;"><font style="font-family: 'Times New Roman', Times, serif; text-align: left;">1. </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u></u></font></div>
        <div style="margin: -12pt 0px 0px; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Definitions</u></font><font style="font-size: 10pt;">. For purposes of this Warrant, the following terms shall have the following meanings:</font></div>
      </div>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Affiliate</font>&#8221;
          means any Person directly or indirectly controlled by (including by a common investment manager), controlling or under common control with, a Holder, but only for so long as such control shall continue. For purposes of this definition, &#8220;control&#8221;
          (including, with correlative meanings, &#8220;controlled by,&#8221; &#8220;controlling&#8221; and &#8220;under common control with&#8221;) means, with respect to a Person, possession, direct or indirect, of (a) the power to direct or cause direction of the management and policies
          of such Person (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise), or (b) at least 50% of the voting securities (whether directly or pursuant to any option, warrant or other similar
          arrangement) or other comparable equity interests.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Commission</font>&#8221;
          means the United States Securities and Exchange Commission.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Closing
            Sale Price</font>&#8221; means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg Financial Markets, or, if such Principal Trading Market begins to
          operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the
          last trade price of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets, or, if no last trade price is reported for such security by Bloomberg Financial
          Markets, the average of the bid and ask prices, of any market makers for such security as reported in the &#8220;pink sheets&#8221; by Pink Sheets LLC. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing
          bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then
          the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&#8217; determination shall be binding upon all parties absent demonstrable error. All such determinations shall be
          appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</font></font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">1</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Principal
            Trading Market</font>&#8221; means the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be The Nasdaq Global Market.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Securities
            Act</font>&#8221; means the Securities Act of 1933, as amended.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Trading
            Day</font>&#8221; means any weekday on which the Principal Trading Market is open for trading.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(g)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;">&#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Transfer
            Agent</font>&#8221; means Continental Stock Transfer &amp; Trust Company, the Company&#8217;s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity.</font></font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Registration of Warrants</u></font>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Warrant Register</font>&#8221;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any registered assignee to which this Warrant is
          permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
          purposes, absent actual notice to the contrary.</font></font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Registration of Transfers</u></font>. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of
          all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially
          the form of this Warrant (any such new warrant, a &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">New Warrant</font>&#8221;) evidencing the portion of this Warrant so transferred shall be issued to the
          transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by
          such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#8217;s own expense any
          New Warrant under this <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 3</u></font>. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder
          for all purposes, and the Company shall not be affected by any notice to the contrary.</font></font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Exercise and Duration of Warrants</u></font>.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;">All or any part of this Warrant shall be exercisable by the registered Holder in any manner
          permitted by <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 10</u></font> of this Warrant at any time and from time to time on or after the Original Issue Date and through and including 5:30 P.M. New York City
          time, on the Expiration Date. At 5:30 P.M., New York City time, on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value and this Warrant shall be terminated and no longer
          outstanding.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;">The Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the
          form attached as <font style="font-family: 'Times New Roman',Times,serif;"><u>Schedule 1</u></font> hereto (the &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Exercise Notice</font>&#8221;),
          completed and duly signed, and (ii) payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a &#8220;cashless exercise&#8221; if so indicated in the Exercise Notice pursuant to <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 10</u></font> below), and the date on which the last of such items is delivered to the Company (as determined in accordance with the notice provisions hereof) is an &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Exercise Date</font>.&#8221; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the
          Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares.</font></font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Delivery of Warrant Shares</u></font>.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;">Upon exercise of this Warrant, the Company shall promptly (but in no event than two Trading Days
          after the Exercise Date or such shorter time period as then represents the standard settlement period for the Company&#8217;s primary trading market or quotation system with respect to the Common Stock that is in effect on the date of delivery of an
          applicable Exercise Notice), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&#8217;s or its designee&#8217;s balance account with The Depository
          Trust Company (&#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">DTC</font>&#8221;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated
          Securities Transfer Program (the &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">FAST Program</font>&#8221;) or if the certificates are required to bear a legend regarding restriction on transferability, issue
          and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the
          Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Person</font>&#8221;) permissibly so designated by the
          Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#8217;s DTC account or the date of delivery of
          the certificates evidencing such Warrant Shares, as the case may be.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;">If by the close of the fifth Trading Day after the Exercise Date, the Company fails to deliver to
          the Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 5(a)</u></font> or fails to credit the Holder&#8217;s balance
          account with DTC for such number of Warrant Shares to which the Holder is entitled, and if after such fifth Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares of
          Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Buy-In</font>&#8221;),
          then the Company shall, within two Trading Days after the Holder&#8217;s request and in the Holder&#8217;s sole discretion, either (1) pay in cash to the Holder an amount equal to the Holder&#8217;s total purchase price (including brokerage commissions, if any)
          for the shares of Common Stock so purchased, at which point the Company&#8217;s obligation to deliver such certificate (and to issue such Warrant Shares) shall terminate or (2) at the option of the Holder, either reinstate the portion of the Warrant
          and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or promptly honor its obligation to deliver to the Holder a certificate or certificates representing such
          Warrant Shares and pay cash to the Holder in an amount equal to the excess (if any) of Holder&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the Buy-In over the product of (A) the
          number of shares of Common Stock purchased in the Buy-In, <font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">times </font>(B) the Closing Sale Price of a share of Common Stock on the Exercise Date. The
          provisions of this Section 5(b) shall be the only remedy available to the Holder in the event the Company fails to deliver to the Holder the required number of Warrant Shares in the manner required pursuant to Section 5(a) and a Buy-In occurs.
          Irrespective of whether there is a Buy-In, no remedy shall be available, notwithstanding the requirements of Section 5(a), unless and until the Company fails to deliver to the Holder the required number of Warrant Shares by the close of the fifth
          Trading Day after the Exercise Date.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;">To the extent permitted by law and subject to <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 5(b)</u></font>, the Company&#8217;s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 11</u></font> below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the
          recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company
          or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares.
          Subject to <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 5(b)</u></font>, nothing herein shall limit the Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity, including,
          without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms
          hereof.</font></font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Charges, Taxes and Expenses</u></font>. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder
          for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; <font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">provided, however</font>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any
          certificates for Warrant Shares or this Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or
          receiving Warrant Shares upon exercise hereof.</font></font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Replacement of Warrant</u></font>. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon
          cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and
          reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as
          the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&#8217;s obligation to issue the New
          Warrant.</font></font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">8.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Reservation of Warrant Shares</u></font>. The Company covenants that it will at all times while this Warrant is outstanding reserve and keep available out of the aggregate of its
          authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and
          deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 9</u></font>). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms
          hereof, be duly and validly authorized, issued and fully paid and nonassessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation of
          any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed.</font></font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">9.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Certain Adjustments</u></font>. The number of Warrant Shares issuable upon exercise of this Warrant is subject to adjustment from time to time as set forth in this <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 9</u></font>.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Stock Dividends and Splits</u></font>.
          If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with
          the terms of such stock on the Original Issue Date or as amended, that is payable in shares of Common Stock, (ii) subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii) combines its outstanding
          shares of Common Stock into a smaller number of shares of Common Stock or (iv) issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such case the number of Warrant Shares then
          underlying this Warrant shall be divided by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock
          outstanding immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or
          distribution; provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the number of Warrant Shares shall be recomputed accordingly as of the close of business on such
          record date and thereafter the Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately
          after the effective date of such subdivision or combination.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Pro Rata Distributions</u></font>.
          If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the
          preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security, or (iv) cash or any other asset (in each case, &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Distributed Property</font>&#8221;),
          then, upon any exercise of this Warrant that occurs after the record date fixed for determination of stockholders entitled to receive such distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise issuable
          upon such exercise (if applicable), the Distributed Property that such Holder would have been entitled to receive in respect of such number of Warrant Shares had the Holder been the record holder of such Warrant Shares immediately prior to such
          record date without regard to any limitation on exercise contained therein.</font></font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">4</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Fundamental Transactions</u></font>.
          If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity or the stockholders of the Company immediately
          prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii) the Company effects any sale to another Person of all or
          substantially all of its assets in one transaction or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock who tender shares representing more
          than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a stock purchase agreement or other business combination
          (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for
          any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v) the Company effects any
          reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of
          shares of Common Stock covered by <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 9(a)</u></font> above) (in any such case, a &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Fundamental
            Transaction</font>&#8221;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon
          the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on
          exercise contained herein (the &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Alternate Consideration</font>&#8221;). The Company shall not effect any Fundamental Transaction in which the Company is not the
          surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration is solely cash and the Company provides for the simultaneous &#8220;cashless exercise&#8221; of this Warrant pursuant to <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 10</u></font> below or (ii) prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any
          purchaser of assets of the Company) shall assume the obligation to deliver to the Holder, such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this
          Warrant. The provisions of this paragraph (c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Calculations</u></font>.
          All calculations under this <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 9</u></font> shall be made to the nearest share.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Notice of Adjustments</u></font>.
          Upon the occurrence of each adjustment pursuant to this <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 9</u></font>, the Company at its expense will, at the written request of the Holder, promptly compute such
          adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted number or type of Warrant Shares or other securities issuable upon exercise of
          this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate
          to the Holder and to the Company&#8217;s transfer agent.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Notice of Corporate Events</u></font>.
          If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to
          subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary
          dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such
          transaction at least ten (10) days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; <font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">provided, however</font>, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if
          while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 9(c)</u></font>, other than a Fundamental Transaction under clause (iii) of <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 9(c)</u></font>, the Company shall deliver to the
          Holder a notice of such Fundamental Transaction at least thirty (30) days prior to the date such Fundamental Transaction is consummated. Holder agrees to maintain any information disclosed pursuant to this <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 9(f)</u></font> in confidence until such information is publicly available, and shall comply with applicable law with respect to trading in the Company&#8217;s securities following receipt any such
          information.</font></font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">5</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Payment of Exercise Price</u></font>. Notwithstanding anything contained herein to the contrary, the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise
          Price through a &#8220;cashless exercise,&#8221; in which event the Company shall issue to the Holder the number of Warrant Shares determined as follows:</font></font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"> <br>
        </font></font></div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">X = Y [(A-B)/A]</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 55.5pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">where:</div>
    <div style="text-align: left; text-indent: 55.5pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 55.5pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;X&#8221; equals the number of Warrant Shares to be issued to the Holder;</div>
    <div style="text-align: left; text-indent: 55.5pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 55.5pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;Y&#8221; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised;</div>
    <div style="text-align: left; text-indent: 55.5pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 55.5pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;A&#8221; equals the average of the Closing Sale Prices of the shares of Common Stock (as reported by Bloomberg Financial Markets) for the five
      (5) consecutive Trading Days ending on the date immediately preceding the Exercise Date; and</div>
    <div style="text-align: left; text-indent: 55.5pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 55.5pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;B&#8221; equals the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a &#8220;cashless
      exercise&#8221; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the Commission continues to take
      the position that such treatment is proper at the time of such exercise). Except as set forth in <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 12</u></font> (payment of cash in lieu of fractional shares), in no event
      will the exercise of this Warrant be settled in cash.</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">11.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Limitations on Exercise</u></font>.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;">Notwithstanding anything to the contrary contained in any Section herein, except for <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 15</u></font>, the number of Warrant Shares that may be acquired by the Holder upon any exercise of this Warrant (or otherwise in respect hereof) shall be limited to the
          extent necessary to ensure that, following such exercise (or other issuance), the total number of shares of Common Stock then beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock
          would be aggregated with the Holder&#8217;s for purposes of Section 13(d) of the Exchange Act, does not exceed 9.99% of the total number of then issued and outstanding shares of Common Stock (including for such purpose the shares of Common Stock
          issuable upon such exercise), it being acknowledged by the Holder that the Company is not representing to such Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and such Holder is solely responsible for any
          schedules required to be filed in accordance therewith. To the extent that the limitation contained in this <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 11(a)</u></font> applies, the determination of whether
          this Warrant is exercisable (in relation to other securities owned by such Holder) and of which a portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to
          be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by such Holder) and of which portion of this Warrant is exercisable, in each case subject to such aggregate percentage limitation, and the
          Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination under this <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 11(a)</u></font> as to any group
          status shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 11(a)</u></font>,
          in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company&#8217;s most recent Form 10-Q or Form 10-K, as the case may be, (y) a more recent
          public announcement by the Company or (z) any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall, within three (3) Trading
          Days, confirm orally and in writing to such Holder the number of shares of Common Stock then outstanding. By written notice to the Company, which will not be effective until the sixty-first (61<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup>) day after such notice is delivered to
          the Company, the Holder may increase the beneficial ownership limitation to such percentage of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this
          Warrant as the Holder shall determine, in its sole discretion, subject to <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 11(b)</u></font>, and the provisions of this <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 11(a)</u></font> shall continue to apply. Upon such a change by a Holder of the beneficial ownership limitation, the beneficial ownership limitation may not be further increased by such Holder without first
          providing the minimum notice required by this <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 11(a)</u></font>. Notwithstanding the foregoing, at any time following notice of a Fundamental Transaction under <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 9(f)(ii)</u></font> with respect to a <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 9(c)(iii)</u></font> Fundamental Transaction, the
          Holder may change the beneficial ownership limitation effective immediately upon written notice to the Company and may reinstitute a beneficial ownership limitation at any time thereafter effective immediately upon written notice to the Company.</font></font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">6</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;">This <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 11</u></font>
          shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as
          contemplated in <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 9</u></font> of this Warrant.</font></font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">12.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>No Fractional Shares</u></font>. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise
          be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares.</font></font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">13.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Notices</u></font>. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be
          deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via facsimile or confirmed e-mail at the facsimile number or e-mail address specified below prior to 5:30 P.M., New York City
          time, on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile or confirmed e-mail at the facsimile number or e-mail address specified below on a day that is not a
          Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (c) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (d) upon actual
          receipt by the Person to whom such notice is required to be given, if by hand delivery.</font></font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">14.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Warrant Agent</u></font>. The Company shall initially serve as warrant agent under this Warrant. Upon thirty (30) days&#8217; notice to the Holder, the Company may appoint a new warrant
          agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any
          new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of
          its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#8217;s last address as shown on the Warrant Register.</font></font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Miscellaneous</u></font>.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>No Rights as a Stockholder</u></font>.
          The Holder, solely in such Person&#8217;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be
          construed to confer upon the Holder, solely in such Person&#8217;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any
          reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of
          the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon
          exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.</font></font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">7</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Authorized Shares</u></font>.</font></font></div>
    <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i) </div>
    <div style="margin: -12pt 0px 0px 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action,
      including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to
      avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights
      of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (A) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
      to such increase in par value, (B) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (C) use commercially
      reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.</div>
    <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii) </div>
    <div style="margin: -12pt 0px 0px 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; text-indent: 72pt;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this
      Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Successors and Assigns</u></font>.
          Subject to the restrictions on transfer set forth in this Warrant and the restrictions on transfer set forth in this Warrant and compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be
          assigned by the Company without the written consent of the Holder except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective
          successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This
          Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Amendment and Waiver</u></font>.
          Except as otherwise provided herein, the provisions of the Warrants may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the
          written consent of the Holders of Warrants representing no less than a majority of the Warrant Shares obtainable upon exercise of the Warrants then outstanding.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Acceptance</u></font>.
          Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Governing Law;
              Jurisdiction</u></font>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD
          TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION
          OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO
          ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING
          SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE
          SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES
          ALL RIGHTS TO A TRIAL BY JURY.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(g)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Headings</u></font>. The
          headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.</font></font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(h)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></font></font></div>
    <div style="margin: -12pt 0px 0px; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;"><u>Severability</u></font>.
          In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired
          thereby, and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in
          this Warrant.</font></font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">8</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.</div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z684ee12d509849d2984dcbe3afddcf3a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" rowspan="1" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">ROCKET PHARMACEUTICALS, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; font-size: 10pt;" colspan="1">&#160;</td>
          <td style="width: 5%; vertical-align: middle; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: middle; font-size: 10pt; width: 45%;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">By:</div>
          </td>
          <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Name:</div>
          </td>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Title:</div>
          </td>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>

    </table>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">9</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><u>SCHEDULE 1</u></div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><u> <br>
      </u></div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">FORM OF EXERCISE NOTICE<br>
      <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">[To be executed by the Holder to purchase shares of Common Stock under the Warrant]<br>
      <br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ladies and Gentlemen:</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z06bd582e633e4f7e8b53b93eebfedf7d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">(1)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">The undersigned is the Holder of Warrant No. ___ (the &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Warrant</font>&#8221;)
                issued by Rocket Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">Company</font>&#8221;). Capitalized terms used herein and not otherwise defined herein
                have the respective meanings set forth in the Warrant.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z07e40eb57a6e42fcbda7fa4889315675" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">(2)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">The undersigned hereby exercises its right to purchase Warrant Shares pursuant to the Warrant.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z596f5c50b9d442baa333d70a158e4263" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">(3)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">The Holder intends that payment of the Exercise Price shall be made as (check one):</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z3b36f2d0dd3b4734b7b4102db1fc5adc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: middle; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 18pt; vertical-align: top; font-size: 10pt;">&#9744;</td>
          <td style="width: auto; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Cash Exercise</div>
          </td>
        </tr>

    </table>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="zee06b05104184983a8c057b2c2f19945" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; vertical-align: middle; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 18pt; vertical-align: top; font-size: 10pt;">&#9744;</td>
          <td style="width: auto; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">&#8220;Cashless Exercise&#8221; under <u><font style="font-family: 'Times New Roman',Times,serif;">Section 10</font></u> of the Warrant</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z91b2765d12d44cb6b7a9a824215d8856" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">(4)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in immediately available funds to the Company in accordance
                with the terms of the Warrant.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z0914dcdd52a8463db2731e1af5848c24" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">(5)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zad86c7e91640406fafb5e12aa89e5941" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">(6)</div>
            </td>
            <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the
                Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 11(a)</u></font> or <font style="font-family: 'Times New Roman',Times,serif;"><u>Section 11(b)</u></font>, as applicable, of the Warrant to which this notice relates.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z18c181c3110a4dbf858bdd347afea531" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Dated:</div>
          </td>
          <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="vertical-align: top; font-size: 10pt; width: 10%; padding-bottom: 2px;" rowspan="1">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Name of Holder:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">By:</div>
          </td>
          <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Name:</div>
          </td>
          <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Title:</div>
          </td>
          <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
        </tr>

    </table>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </font><font style="font-size: 10pt;"><br>
      </font></div>
  </div>
  <font style="font-size: 10pt;">
  </font>
  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">10</font>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>ny20010507x5_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">Exhibit 5.1</div>
    <div><br>
    </div>
    <div>
      <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">September 15, 2023</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Rocket Pharmaceuticals, Inc.</div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9 Cedar Brook Drive</div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cranbury, NJ 08512</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ladies and Gentlemen:</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have acted as counsel to Rocket Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Company</u></font>&#8221;), in connection with the issuance and sale of (i) an aggregate of 9,453,418 shares (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Offered Shares</u></font>&#8221;) of the
        Company&#8217;s common stock, par value $0.01 per share (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Common Stock</u></font>&#8221;), (ii) pre-funded warrants (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Pre-Funded Warrants</u></font>&#8221;) to purchase an aggregate of 3,126,955 shares of Common Stock, and (iii) up to an aggregate of 3,126,955 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Warrant Shares</u></font>&#8221; and, together with the Offered Shares, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Shares</u></font>&#8221;),
        pursuant to an Underwriting Agreement, dated September 12, 2023 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Underwriting Agreement</u></font>&#8221;), by and among the Company and J.P. Morgan Securities LLC,
        Morgan Stanley &amp; Co. LLC, Leerink Partners LLC, and Cowen and Company LLC, as representatives of the several underwriters named therein. In accordance with the Securities Act of 1933, as amended (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Securities Act</u></font>&#8221;), and the rules and regulations promulgated thereunder, the Company has prepared and filed with the Securities and Exchange Commission (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>SEC</u></font>&#8221;) on March 10, 2021 a Registration Statement on Form S-3 (Registration No. 333-253756), declared effective by the SEC on September 10, 2021 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Registration Statement</u></font>&#8221;), including a base prospectus dated September 10, 2021, a preliminary prospectus supplement dated September 12, 2023 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Preliminary Prospectus Supplement</u></font>&#8221;), and a final prospectus supplement dated September 12, 2023 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Prospectus
            Supplement</u></font>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For purposes of rendering this opinion, we have examined: (i) the Registration Statement; (ii) the Prospectus Supplement; (iii) the Underwriting
        Agreement; (iv) the form of Pre-Funded Warrant; (v) the Seventh Amended and Restated Certificate of Incorporation of the Company, as amended to date; (vi) the Amended and Restated Bylaws of the Company, as amended to date; and (vii) the resolutions
        adopted by the Board of Directors of the Company (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Board of Directors</u></font>&#8221;) and the Pricing Committee of the Board of Directors (together, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Resolutions</u></font>&#8221;) approving the Registration Statement, the Prospectus Supplement and the issuance of the Shares and the Pre-Funded Warrants. We have relied, without
        independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For the purposes of this opinion letter, we have assumed that: (a) each document submitted to us is accurate and complete; (b) each such document that is
        an original is authentic; (c) each such document that is a copy conforms to an authentic original; (d) all signatures on each such document are genuine; and (e) the Company is and shall remain at all times a corporation duly incorporated, validly
        existing and in good standing under the laws of the State of Delaware. We have further assumed the legal capacity of natural persons, and we have assumed that each party to the documents we have examined or relied on has the legal capacity or
        authority and has satisfied all legal requirements that are applicable to that party to the extent necessary to make such documents enforceable against that party. We have not verified any of those assumptions.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In rendering our opinion below, we also have assumed that: (a) the Company will have sufficient authorized and unissued shares of Common Stock at the
        time of each issuance of a Warrant Share; (b) the Offered Shares and Warrant Shares will be evidenced by stock certificates or the Board of Directors will adopt a resolution providing that all shares of Common Stock shall be uncertificated in
        accordance with Section 158 of the Delaware General Corporation Law (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>DGCL</u></font>&#8221;) prior to the issuance of the Offered Shares and the Warrant Shares; (c) the
        issuance of each Offered Share and Warrant Share will be duly noted in the Company&#8217;s stock ledger upon its issuance; and (d) the Company will receive consideration for each Offered Share and Warrant Share in an amount at least equal to the par
        value of such share of Common Stock and in the amount required by the Resolutions, the Underwriting Agreement and the Pre-Funded Warrant, as applicable.</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our opinions set forth below in numbered paragraph 1, the first sentence of numbered paragraph 2, and numbered paragraph 3 are limited to the Delaware
        General Corporation Law (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>DGCL</u></font>&#8221;) and reported judicial decisions interpreting the DGCL. Our opinion set forth below in the second sentence of numbered
        paragraph 2 is limited to the laws of the State of New York. We express no opinion as to the laws, rules&#160;or regulations of any other jurisdiction, including, without limitation, the federal laws of the United States of America or any state
        securities or blue sky laws. Our opinion is provided as of the date hereof, and we undertake no obligation to advise you of any change in any matter set forth herein.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on the foregoing, we are of the opinion that:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="za1ce4e5200a14940a52046ec6268244c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Offered Shares have been duly authorized for issuance by the Company and, when issued, delivered and paid for as described in the Resolutions, the Prospectus
                Supplement and pursuant to the Underwriting Agreement, will be validly issued, fully paid and non-assessable.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z57140e5e69044ad7964c609d49940f50" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Warrants have been duly authorized for issuance by the Company. The Warrants, when issued, delivered and paid for as described in the Prospectus Supplement and
                pursuant to the Underwriting Agreement, will constitute valid and binding obligations of the Company enforceable against the Company in accordance with their terms, subject to the effects of bankruptcy, insolvency, fraudulent transfer,
                reorganization, receivership, moratorium and other laws affecting the rights and remedies of creditors generally.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z1ba7f45ec7204733a31114c155517e3f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Warrant Shares have been duly authorized for issuance by the Company and, when issued and delivered by the Company against payment therefor as described in the
                Resolutions and Prospectus Supplement, upon exercise of the Pre-Funded Warrants, in accordance with the terms therein and the terms thereof, will be validly issued, fully-paid and non-assessable.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Company&#8217;s Current Report on Form 8-K dated September 15, 2023 and to the
        references to our firm under the caption &#8220;Legal Matters&#8221; in the Preliminary Prospectus Supplement and the Prospectus Supplement. In giving this consent, we do not thereby admit that we are experts with respect to any part of the Registration
        Statement, the Preliminary Prospectus Supplement or the Prospectus Supplement within the meaning of the term &#8220;expert&#8221; as used in Section 11 of the Securities Act or the rules and regulations promulgated thereunder by the SEC, nor do we admit that
        we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the SEC promulgated thereunder.</div>
    </div>
    <br>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z244f66260b8244eea180ed846432fae5">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><u>/s/ K&amp;L Gates LLP</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">K&amp;L GATES LLP</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>rckt-20230912.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.7.1.5162 Broadridge-->
<xs:schema targetNamespace="http://rocketpharma.com/20230912" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:rckt="http://rocketpharma.com/20230912" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="rckt-20230912_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rckt-20230912_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://rocketpharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>rckt-20230912_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.7.1.5162 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>rckt-20230912_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.7.1.5162 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://rocketpharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="rckt-20230912.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://rocketpharma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ny20010507x5_ex1-1img01.jpg
<TEXT>
begin 644 ny20010507x5_ex1-1img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ & "" P$1  (1 0,1 ?_$ '0   (# 0 #
M      8'  0% 0(#" $!                     !   00! P," P4&!P
M     @$#! 4& !$2(1,',11!(C)187$C%9%"@C46"%)B<R14)E81 0
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*_G^GU?Y?30?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ny20010507x5_ex1-1img02.jpg
<TEXT>
begin 644 ny20010507x5_ex1-1img02.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ (@#( P$1  (1 0,1 ?_$ (0   (# 0$!
M       # 0($!08( 0$!                     1   0(#! 4&"P4'!0
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M3. <UE5(W(R*E"Y1,R)ZH!HH:4.!PMA2TW*5:1TP#DH0G92!X! 3 $ 0! $
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GFO@*,;8_07^K? +K>Y5]-T=]L7Z?-!'$=N/TOO$=W?MC9\T#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ny20010507x5_ex1-1img03.jpg
<TEXT>
begin 644 ny20010507x5_ex1-1img03.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ *@"" P$1  (1 0,1 ?_$ (,   (" P$!
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M547=Y:$B)UZIV[Z!OX]ZC^&KK&;5J^-V\MO2++;-DA1.E.B$'Z"T'>7F+BQ
M4URFV[42O[P%:?"M= *Y%ZHN)K6TX,&XG>IJ$H-Q(33A*1UI3<8B-*^*5T G
MB&-9SRCR-:^0<PMA63'K*F^R6MPB%XW$+<V9@M%2A>956E>GAH#KF'EV9ACM
MNL=CM3MXRF]H?\-C"BJVFQ412.G5:*7;0"6/\ WG+;L.5<NSEN<]RA,V%DE&
M(PE*;%05]G=!_3H'A:[7;[3;8ULMS 18$-H6(T<$H(-@FT13X(F@S,QH[&[Z
M+0-;UW'L%!JJ^*T\=!DT$T$T$T$T$T$T$T'QSY"[=OQ=OZ=!4CEG^LEP_P#F
M_P WXOW_ .1/V_\ A^SW4T"N_P#3= _N"OYE_P#G_P#V;^8]U[^[V:"Q:=D_
?O:#2?_F4?]W^4OG_ &_^K]WMT&[H)H)H)H)H)H/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ny20010507x5_ex1-1img04.jpg
<TEXT>
begin 644 ny20010507x5_ex1-1img04.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ (0"" P$1  (1 0,1 ?_$ &P  0 " @,!
M       %!@0' 0(#" $! 0                    $0  $#! $# P0!!0$
M      (! P0 $04&$B$3!S$B%$%1,A4C87&!D4(($0$
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-% H% H% H% H%0?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ny20010507x5_ex1-1img05.jpg
<TEXT>
begin 644 ny20010507x5_ex1-1img05.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ %@"" P$1  (1 0,1 ?_$ ($   $% 0$!
M      0  @,%!@$'" $!                     !   0,# 00%!@83
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/%_0GS;V?]G[+_*^U0?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139693664141680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 12,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Rocket Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001281895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3475813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9 Cedarbrook Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cranbury<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-9100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RCKT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>ny20010507x5_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rckt-20230912.xsd" xlink:type="simple"/>
    <context id="c20230912to20230912">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001281895</identifier>
        </entity>
        <period>
            <startDate>2023-09-12</startDate>
            <endDate>2023-09-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20230912to20230912"
      id="Fact_b57d0eff34e541809504538b1a174f93">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20230912to20230912"
      id="Fact_5dee569895b346e0a1e954aa87aa725a">0001281895</dei:EntityCentralIndexKey>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20230912to20230912"
      id="Fact_7ef3f81ea73945c2946527de70834838">DE</dei:EntityIncorporationStateCountryCode>
    <dei:SecurityExchangeName
      contextRef="c20230912to20230912"
      id="Fact_d20f7e5cf5e1470aa0031ed39447f9ee">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20230912to20230912"
      id="Fact_7b40ef2225874905be846709e250d01e">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20230912to20230912"
      id="Fact_c4ec690db7d84bc3a99069d3c153a40a">2023-09-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20230912to20230912"
      id="Fact_5ee4c53c90304400b1f6e481edd39637">Rocket Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityFileNumber
      contextRef="c20230912to20230912"
      id="Fact_2c7836dffed4401d9e0fccbcc90523c4">001-36829</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20230912to20230912"
      id="Fact_a8e140c6cd5c4cffb1938a216bf12c4d">04-3475813</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20230912to20230912"
      id="Fact_4d771d266cef46d9bc81738f2e8109e9">9 Cedarbrook Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20230912to20230912"
      id="Fact_cced988fae7e4e8197f2e80664985e22">Cranbury</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20230912to20230912"
      id="Fact_58d72708c1dc47179e33bedde4a2e64e">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20230912to20230912"
      id="Fact_97c314c10a114b9e88905dfc4b19ce54">08512</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20230912to20230912"
      id="Fact_36ef56850f9047d8b6c48c693ba42d42">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20230912to20230912"
      id="Fact_97568cdcb17b41bb9d13c9d83e69321b">440-9100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20230912to20230912"
      id="Fact_d488bda2ed454bffa8cb95617738a787">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20230912to20230912"
      id="Fact_25a3b1b2479c4a6c90d2db814274a4a4">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20230912to20230912"
      id="Fact_b903dda86e524e22975cf8629ad77690">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20230912to20230912"
      id="Fact_98a6813b6b4c459280d27af7750bf7c4">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20230912to20230912"
      id="Fact_de6de76c6b5e4726b161c221c9748838">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20230912to20230912"
      id="Fact_23d4872fe63b4ee9a7fee65567e9a008">RCKT</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20230912to20230912"
      id="Fact_86bb798c71fb45fc8bf31d5b0b06b35e">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #& +U<D'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( #& +U=ED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ny20010507x5_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rocketpharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ny20010507x5_8k.htm">ny20010507x5_8k.htm</File>
    <File>ny20010507x5_ex1-1.htm</File>
    <File>ny20010507x5_ex4-1.htm</File>
    <File>ny20010507x5_ex5-1.htm</File>
    <File>rckt-20230912.xsd</File>
    <File>rckt-20230912_lab.xml</File>
    <File>rckt-20230912_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ny20010507x5_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ny20010507x5_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rckt-20230912_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rckt-20230912_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rckt-20230912.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 4,
    "total": 4
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "rckt",
   "nsuri": "http://rocketpharma.com/20230912",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ny20010507x5_8k.htm",
      "contextRef": "c20230912to20230912",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://rocketpharma.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ny20010507x5_8k.htm",
      "contextRef": "c20230912to20230912",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://rocketpharma.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001140361-23-044141-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-044141-xbrl.zip
M4$L#!!0    ( #& +U?#912U<A<  )"0   3    ;GDR,# Q,#4P-W@U7SAK
M+FAT;>T]:U/;R++?;]7]#W/8LWM(%3)Z/TA"%3$FX80 UWAKM^Z74R/-"&LC
M2UI)!OO^^ML](]F27Y@L+(3 5FTL:=33T^_N>>C=L!S%9#**D^)@XN=Q]'YG
M6);9P?[^[>UM!^]TTOQZ7U=58S]*BI(F =^IVL=1\G5#<WSLTV+6?++4_M80
MK37/\_;%TUG3(EK5$,!J^[]_.;L*AGQ$E45\L'LV?[&)C;TO']9-HR(U=<W9
M-%C9HGZAR,M9XY 6OF@(-Z&Q;LR@3M8!U)!Z,$+^^X?^V;QYN;K]O.E^F=.D
M"--\1,LH3; W55%U1=,;0)2"!RU <-VY3F\VPM$L17450ZOAC OEFM)L>9#5
M@]9 &5\@<]TC/&@U#-)Q4N;3U8VKA^T7QGG.DV#=&]73-C)EKI33C!>KB0F/
M]_$QOJ,KJM$<<YFOE0!O'Y[6#1,:!<5JE,2C%CY%%*QN"@_:#<LL7],2GK2:
M\DDP7-T4G[0IR,,UQ.-AJV$>?)W+7YX&7WF9#2E(2"=(1Z*EZLWD;+W>H@'9
M.?SO_R+DW9!3)G[![S(J8W[X;E_^6]W\AZ*0LRC@2<$9*=,#\B%/*<LC=LW)
M292 ,D<T)E=I/$8I+?;(:1)TY+OB[S@-QB.>E"3(.2T!QKB(DNLFE,O^11C%
MG.A&Q^EH'4NS]<;[W32;YM'UL"2 NT44@J-LOJXH-:HC7E*"8U;XG^/HYOU.
M-TU*Z%H9@"SMD$!>O=\I^:3<%S0@^_#NN_V*"/#33]F4%.4TYN]W0FA_0#0U
M*\D@&O&"G/-;TD]'--F3-_;(%<^C$"GYCD4W)&+O=XZO+D\B5-]/$6,\V:F!
ML:C(8CH]($F:\+<[A^^BR0%VRW/Y4[06/Z'!.5 LCP*2T!&^RJ.#(R A0S*>
MQ/1Z1_1T0H/R/[[E,)6'H6%RR]1<U;-4TS)<7Z.:8X:>48UZ4O91Q():0LIT
M+BO2PKS? :MT$$83SI20QN "#L4_[_9;**W'L)> V$R[@&).X].$\<EG/FU@
M:C'.+=MS/<LW3)NK5..>95+J.I0ZND7OQO10!5^BNQJ N"=6())IGJ6Y,*17
M)8AA5]JQ;LIX T>'AT;H:IPZAF=:@>Z9MJ4[C#NJ:YBNX6Z!XW%O:]RN.-A&
MP*X'YH FU_P<GC208;H:.MP*0HMKIJ-2"BY.XPPP,YW0XWP+9,Z/KHZ/_F<)
MH?VVP.4\Y&BB>7'X#CWZ02%\-8 EPL,?#'/L 6V/4L/N3 JV4SU&2_U^IXA&
M60Q2\VZ_#4-VU^Q#7!;I.!=7(H(YJ(8B1K]R*%4[+OA97T4,K\.(YT3TQU>Z
MU.[IY[;L++Y\6-]J0\^ 6BFKKR!NR<MC$)U#1$I1/7#H]7OS9S,TV9JF]9/Z
MNNYDOT6'FF@S*NTWS,4^V!IAK<#D9;5]&='\.DH.B(H<R"K;GM=/_32'5ROC
M0^25XJ=EF8[ PF434J1QQ(@?T^#K['F99@?$7'PXY&B,A5V<O 41C%. ^U,H
M_N!5:'.=@W(Q9?$1CDNA<70-6(([*7G^EDBLE9B' )&.RW1V*Y>]B'O23#='
MNZUIKL$!7:"IN@H)H%>1T:0)62FB_^, WLQ*>.H?_GI^.N@=DZO!T:!W]6[?
M!PKC*W-"/Q%>5[WNK_W3P6GOBAR='Y/>[]U/1^<?>Z1[\>7+Z=75Z<7Y,T!6
MKY#]C19#</QE"M"/N^#%+=-[#/0VH*(B*K_\I-DPAG=^7DD5]/FT%'(K"IU<
M]+^0M=ZBCJ-D+#-W6;X)_E_7=<MU3$^U?.Z:MJ-Z7+=4IFK;> E7^;SL(IZ*
M,<]$6D&Q^KWS >GW+B_Z@V>D1I?CO!A3"*?+%, &&- 0S2 7?:)9N^P-24,R
M&')2Q181H%.'%^0H*/&QYAGFC\U?=,!(B3Z'F+ DN_4UI^"">5$2?H,)2RX>
M<_;FH+89=^GFI7#F/>GB&TH:F#RP/97Y#G--/S"HYZFVQXQ LPQJJEO$OJTH
MG0%T901O#!$%A=&I,@7<%4@W#J]X5O*1#Q&1IN^)7&E9MU\"WQMA#F:H)Q&/
MV0'ICV.N7-)Y5BCRLE:(),,:=19HU%'02DEZNU.[B :<Y@BSLATN?< @"6_+
MH.DMN8U8.<3QJ3_/2=$(X)J_&P/97Q[)]\FG^^FG7H<V=R1T?7X=%5@?*Q>2
M)HMS,[",P%,-U315U=="FYN0TC%(G&S#V<(=]D59A5R*NDK QV440"(LZQI+
MNM2((I"93^XF!"=W>Q.@A2 :FK5\1BQ""U)D/,"LAY$H(5%9$/ .8.7R-Z]V
MX=4N;,^GDOHQ!VK$,=P/(+!_OZ/NB.N,,E9?WQNS%EDDB6OMDMWF]X6Y,U//
M&M2[DM5 JNX,Z^?5^>GVG6RF(5JT9@,L_RO11)%5F(/MBD^'QSRFMS3G-2]:
MQF>%"2K9-F-7_X:Q;[;F)U',X1D$+0U+K@>.:]@L##D#0ZXQCZMA$/@!F'9+
M-P)SJWJAIABVJWN;S?8W4^XQI.:V*J_X:<RJ,O$&R@WHY+0J8P6BN+E$1NIR
MS50#.V!68 9AZ$/X[U)=L_U0TP.3;4-&4S%,QW*UM:'D CE;])/6K,P/U^CQ
M#<^%AZV)".;R/A3<P*;'%.I=444F:4[2<@C!]A^0;14LDOD8^-RH67%^LZ5<
M/2K"W70TBHH"\4-](U)2G@5JI_TKTAME<3H%2K;EF9RGG94X+H@5_A]G<H1;
M>HU?7N.79Q^_/)[=JW"PU([EW-]#R6X*,9R_[MJ/&,MY453_G$4)UQK.R62.
MHS'=M@,>FC;S_,#5',,-=>YJJL>]+9R31[J<T=S/T_0K.<ZCFZ49R[VVGR?K
MRS@ME+OP\R(?I+=)LY 3<.:Y;DBYPTU TG,05]6V3<^UN*YO@7 7$C%_G$^7
MT-P2+^%X+O++/+V)Q$*:>>[K,D>':#'06& ZFN-QP_ A\>4FU;EM;C5A^.^-
ME>"MPB+3ZYC&,Y&[R[0H:?R_4;8PT>LY@:&9@:9233-]C[LN1)4L#$P(CP)N
M;15<NA;.ZGU[8/DR R-@S2Z.N&( QD)9#H(:930F?,*#<0DZ"K?!P_/B680?
M(!X$Y>,USGB-,YX=G[ZE_C>OCO[RDZMKSML"@,0\&Z8))XF(^_<P0XG'&.@0
MFG,*]H[Q>IYC=ZUQ1:=X!,T7S*EA\]"R74L-/=5TF.O;@>D&MF?XU-29N8U;
MM$U[T9B^6>\1SU(PC)<XGJ6$UW, DX %ON;XIN;['M.,P&.NP0$?7?.WP,4T
M5<4#B7N=.7G5_.]+\\'[GJ<EH5D60^@ +NK93$F<I#DH434GD8OI3+BD,DH
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M[$9B-[1>VH6'9EXJ1Q:XD"K-O12\TR&PB7#)5TQ*D?36$006I:-D#&2:-5A
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M7.Y3#]V58XRZ,ED<WU$"KC"<VVG:TU<@^#,]JX76</E:1^-#(@/D\<J+7$M
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M?'T2G<,V+9VK>#Z'*P&GQN^+V:&3X^/3XR.Z/-ZJER\BP2+A!8WW -9';>\
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M/;Y\3K+8/S=%N(%&PGP!3!%6MV *7QJV=9"VJ0 7,G@CHY7DLO&)<.1'.OT
M'+71#60?BZ.:@7O67!<G:P4HB]^O!? ^2MN1^*;V;VAW7QA%D*.[.:.=7FA8
M.-0SCZ/HW;H_^^W7IX[;SJV>'%7)77I#%HE4.L+*D+J(L1]]ZVUU<ML3IDF9
M%SBX!-IB>"",)]QFQ6?7>(C5RRZF4" T?L- !C;&.T9!P&*V=X=33%CD1.5<
M2EFRP/6DL:,VL>0(FXAT%^8>2U!.;CN;-;XG0F.O$-6"L08V^W+=*=1])N9(
M?\4S0TP2VAP=L]V#LV/MHYBL&#@(]SCUG2J]DK<6!8)0>H\-F5.-0'XN4BNX
MT[!T-UFQK&8K5R,42^!\.:N3/.6_(4U&^YF\I!1;#^(P[44R#4EH->4<FBP3
MC9KR%N.TE"R$-B@1"C!99$Y)R'W?ZI;O\_Q_?I[_T3[/O\_S?R9[;4NACEYO
M:"T,4_03 @^_81_TR!=0C;7 I83FLDN%=2@+L?R<5N\*W*D-,G;^"TJ]25%:
MQT5M-?55NDRQZ")A4L[UC_%%CNN>%@T8URK+V@Q;> YT4.]84DF(+LTK)$1^
M #HO\.3X!5&70^?PIHA7ON;R.$3,,4 .MY7?(IKTMH@&IZ)%;9R%&"$B1'S*
M)XD_9?"X\Z/)!#\F1T071>-#TBN<55['P%&UX7]70@6\,CW* G_4.[JR*FL=
MW*KIX7X13M87YB_VAEC;EW_W$=9[!EB)V$V";*D#34^Z!JCMN5R(A!#@&9=5
M^ZQ\=:^8K8=0?:;0;6?,E@_@IP=NNP3!'>.W9NOO&YQU+B!:R5S$\"GQV?B/
M#;XZ'-G&&.S#"+YV[OFG1!GMY6](#%&V^R#CEZ4T7A<U1M%=LPLY&>FTH,J/
M+;8TO#I,E@-240U+W^? 8O0XGPRG?111DS 1F40:V#3^W/<DRA<<][:1W))8
MV9QK ["_JB<D=$++!JYZ916)LT8"'*:%&>MOO\6P9P.(2 H(K,*EO6%=%C9.
MDM21SK+=4):-3E7FP8<=<X]=[8Y5RG*K*>GFJVZPB9!@U&8(OF>FKVG (D0S
MI!80LR.R^M1T@2=R1?R HR/$P6+]$IL9PL+BJOXH&\/4!HWC1+E%,&!'RYF6
MDU?+(3%1Z('N3DKZ..8;/8)O=6/=-$SD,8\<LN:9H&IB%^?RQH,RQ>?<5?LZ
MG9F(J<3)/?)3E>!V,>(0XI'8X6FQDRMS/PH!Y0JRH+(P<PVHL(;-/":=; ]#
MCQ0;'6*\-,_87K(_L*E<\J:QF^K::=Q9+.O!QLZ\+1'=<3PE4FVCU.L$>-QK
M79,K$'>$2IHD:E1T1A5U)N 1]@7W4DT#Z2[PJ[E@*[B&)GO3B,8$PEO+8H-@
M^!=Q>+Z@>_"^SUNE+!130-%A9\GJL^NDFI'^&*/\ >BB"WW:D,1!BZHO8AV_
MH"/Q: >P:01(O_CEZOW/%U?1^4]7%Q>O+EZ_?X<(:?A5].S-J[?GK__!B&@3
MF''@)4Y#^]9$'0?TNR]BK;\<.IJ[-R'J+_7#MK1(B\_1:VX"^N1T,#SH[;.5
M.<ZS/$4.LZ1D9&(BYGRCW5Q3HU(V.%,B]LTO]$?3<SS@LQFY];8'N>5R!8YA
MK-.7:5!K(]\QF -258^=H;V*UU?7'N\L'Y^DJ;.'MY@/<N"AB9"597I3,!>+
M.JLDP/59)EC&;.]I&@1T&&]V<H+O\KP8G7U;GW+_8;_1I@O:]ELGI1#&%K-<
M%B9M7E!;P'%S>5.N7@0[$".'+K#:N4KD9@F'3Y'+K!Z='9_C^L%__^B^WS5?
MI>OS!\U,N+6&CTX?X1JN?2!ULG4Y$ZN$JQ25KX^(#D[SL0<OP,HBO8<Z@(YB
M(HSC=;%*<-+$0%5I'B['0R$_1=X%'#\-Z^%\5-/V$_UE]\8B!R7U4._QMI%F
M,5=GF]:4HL=TG"RM/5&'>E8,9%ZQUGG_A9 /V-Y\^=@9^=BXRCV+PA3N-6N?
MO+$G8.>;';5R;XC)D$YXCH7?P@A\D^Z8\FB)_R9!W[)"F"INLO3V*4-Y;C)!
MB[0R#FZ7^&%9K=Y&Y5ZJTD[VD0X)U;'2&+;<#T>,BSL]YJY@HP)UE+O  EKQ
MN*[FAFQ8]'#%!0$C3#T=?[G$A$D9O< FBK]*A,9\JC%@O?O+,L^JZ[:S1 IE
M5"P(X,\K]M0=;+_((6M8T-B9WS-<63'@$UYM==64."C)S@9C:K1[\N0,A,_@
M=+W\B37]0P2;?.E[!LTM_3QIKXFWP><^"J.FE]N5;GRK?[5.LW-^INBG:YHA
MY3Y2'<81_-<(_^L1S?LQ+4 ;)[T6[=62$>0;%=$,NZ++$@6I?)RS?G[ W"WD
M@;NK@M^0Z].@[&']^C6.O;4W.ON@-WIF5I K!W.)9KE#X6+,ZM*U.MI\!C'@
M:L;]5NJ6"<=.51<+S7N5^DO^-ZIU%/XRYF4EO?;LV5]6CJWG;2E PW(5T.1O
M<8U;@L%-@-^J \;?,(>8X<GJ<)E;:RT<0+9)HU\CO"*)DN1HBT!I)2&D>-HJ
M<=*4?ASW1A\^-NN'9R&MZHY5=S#5N>M;:&2HO/03]5I+Q-*HQQPE2&96!#QE
M*H_,QNF:1Z?KH!A6OLWGY7,>E,:;'-%3<$IBI7?DVP.W#$>#;&D8WD= E'"]
M.@T-ZHXD*<9EAL0$B*_%NSPNDUN/:E<#G19@#ZS\\X&5C_? RCVP\C/TE-Q!
MW"7ZO]]G/UP)QPU&Y?[?GE?E 4UD</>&7%O10#O>"4,S44GR6:H0L",S:9G*
MFE:<YD1^?J.56S:A8UJV&)T[O;/_91M0%S$^A+D;:\GIF@YYL;1?).+'21JV
M2VG8;)[5T7.7YK#GV(<"#'G!@T[0*- TO3?N.\A8U81_=/QX?6QG(&TY6M2\
M$L;JL4/:7;;A6PHLP#^:9"<MK*8/U^^F9/0[N'5T63R1%J/YVI"$]084\:!B
MAQA>)%.?Q"?W1TO7T7>,F6V2M[XF:WG</&;X9SH(]'<^H!M7E0JT\ZX9='7?
M,K3A-/%F%WO>\),GCVALX'5O"!MZ>FRI&%R_DJ;W;/OUP5$'L0/CE(AQ1XP
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M&P[QM?.IA7Y]$:H623\',IZ;4+0Z$G69Y^$=/,:&6&<''>%\%FYC7TA6M.W
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M\HM*A'+"[DA@.BQ91L'E"LL]GD:)B;J^DF=Y"G<.CNS@V^-:\SO]\;X&M>%
M;B/U;7$=R6H&;5"X)>@_RM"4(&_Z$L37X2\++":'*383J,%5]_A5K4>BM>FK
MQ_^OH[>N6^NKHIPFN94Q+U\^H^70O]1)/@,1R1U@GA5'] &)WNA#98*.@5_Q
M. 48T-AEH$PU_(+OON=+#V+I 303>+[_%_HI,?>8M<$?70W"1R3*CX2\J"!'
M7%$4N#88R:K0WXI=+PNL54?"J 7(\2GIA)RZ'+#Y/YO%$>A24!<HG6#$Q2)U
M3<X6\$J483?P9&S3BWV8).^.[ TF5#)/$Z7?XDC0D^3P9'!]T%/[&#M=1UX
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M@X/K@GQA=#;%]!V'#*DRD/XI"3G)?4>S8EJ07T$L@=)H-1U6\,88*_TH]5C
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M0_534.@46[/8D6V&/PK+CS/5O(%B=2F%<_-DC':%5KQ#$P"[<)C<"4V5(PR
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MCBUJ]EU]F^UFOZ,1E1VX\Z(QIWBO9KF R%3K6PZQ4TLENJK-'32R,;3"WY:
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M>7JK@CYJ=[1F,&Z+_S&9^.(<C2.JXG+DKE0L%?CD>[*YFIS5X+)-W":TZS1
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MV7+%E&/XXR0.<!M:.Q8.IL,AKM&226%+X$AMCV+;M]CYD)K/Q;=41HIUS<S
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M"Q2^P\,F2=R(LG5'U/R9*5)@%]$E6L=)'E2%7E?)%K%96'SG!^ [^NK#^R%
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MR1#9\9XUPENNPB34O07?47!KK+Y*\C@RQH4NVXKB2\1*Y\A[A-]N/I//6U7
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MA57^,C2<0\+7,Z#;=G5-32MW@S?.H]SAEQ$YZ79J-WE9D*K1=)\;SFX0>-5
MD!<H\E3Y51DAL3RUJ'((9@S4Q/0_$CUGEBN/@7UG$J6(D>FY=+<Q*#2LT@$;
MKTP0?-8%< E,2!\G&[V"6BL!Z)LJP)67?^FZ4X!*RMEHKK$QSC9,\7YABGMM
MF.(W0 #H;;40 "T$0'.R1YF698.B6$  )T[]$3@9&0&]X@"7=Q9^GY$.8GOF
MR")&,HA;MXIAZE8UM8@0?PU;4>,SCV/&;U%U7?U&_VY7.7BUE[M:0L9$ *P6
M1&D,.%!9"@RHPK=(_G)-8"1?LMJ6D<<P\]P^0OMJ^<+M\N3U7[W?O8_>WSK]
MIV\V?NW__6MV;=#@+MW6[.:]O<V]>Q_#-2.AD+Z7WW@0WP\YY,;]J]JG5/@K
MOR74QT3GM';LJY:N-ET_UM"5BZ4U4M>5I%5PD*VP4KC55%!PB3QKPY;Z#O7[
M-=3WK[@0G3)=58JO::M60]1EAXIB8"@L*^1OXC3%I;SPCJ+$3P*T5;VG0IYY
M6=EN!JJKN@(Z>QM<:2=8DK7(*DDI+$@-4D'MN#V5_&C>S 2+\0H5M98#; YX
M4\,!#@A=H7 LV!"E5LS0;]T:BBR^J#Q[NV3XW:?]I3,\8BLU(C02DXZ6,-3>
M[B[YTY;Q!1F,5)2&P#)U2N/N!^B[I&,D2@J)HD)/Y@7Z4*F\7O I2:]C$5Y0
M?J"<<PT4%5O?*A*@8G8WT,^TM#97&A<ZP#ZT*R65H60*PW\!]$E#O6Q-& I.
M%UB&$DTA,'%SJ]G1J8BI(.%G)/@D5O_4T'UFE099TU)"12[YDD10044'? Z6
M2J:YZJS3 O1I[39E[\>-_+6Q">Q+UG47M.MQHB2W3:-1Q\".H)A/ SQ;8;%H
MO)@-4C&2E 5\-6T&5[RL0>-45)ZRESUF/L)N;MY#_S$0@KU>:T!H#0B-)#RV
MHN3UI=8"[GT/@'L_0&Q!HVG)L209IB;IQU"7!5N>M+L7;^#'N83V*IZ@FT&B
M9>1YO<1P!VR,CH6+9X0>L(/:*)=,,09:Z;534ZA0JH4.+!*-#MQU,Y1*K(JR
M');$499X%:Z:V*".2$4P$;,HX(R]]#JI$(%P^(J\++/$(5YNT4E$*4<<J[(]
M:BW++Z/%35!F[-F>&N#D81ETYY1EG#ERJU[VG4ZXH72O@<K:(UDU3 7GPR"K
M0=/[F_O[.L_2I9-.1*I!*FQ2Z<I OIE*BE7@Y\V:H.6>LL+U;)&-9&U6U2VI
MVBG/ZM;\DBE 5DJP\OB;[\BT/!V:S6(]^^JB,OSQ5C*72&JJ&*A.^*E4W;*3
M53"A-@3M(W<=],!KPL5_I @ '-&F9]<8U@0PX$JLL^?QO*.]GIOIB,J>D/DL
M%?@;F>O=&'D9:7LWL4"'3I!8V]$KL9UZ@QK4YJ+F&E30]V2N;1VNK]F9/IJD
MH]6Q[[LQM4I[RI=3I;)0"DP9+*:UXZKJ9!) XATZ>[N)=&NGU]VH95?0,?&1
M.8A55U8 -0PMWV@GLL/*0O?<MYT8I%N"#F0[4JZ0 U<2&V$697,V,&"<MA^4
MQ8 LXCDQ++Y#VL?.OJCNB%RE8Z*7=6%M=R#'TE*MM2.F)NSZ;N<.I>#2$<*U
M$,K"0*8UH]#U>3<]U_RQ/EI8>%L<#$WS55:X\NJY_:JI9,QE>+Y*$\1]&N+2
MO+,8QLQT[WRV<NGUEIRG>4&1%4 8H-D<),>G_XN\J#[\A2 ?2.3S"188A:FN
MUUEM8/TC1#?@M^WT1(K#\Y,D72:R2%@5":/S[PU#PI#!.=7'\.-$A6?WJ<R&
M'7=OT^9V--?-,AGBEA2#BAN2PTGI+,7J()V=#66>-:>/EMJNWLQIQH@D#'6,
M/=9>U7>8 XDNUD3>K/04)/W<)%,^_\C.(NN#EG&('.=#YWWTN5@]A>$"#3K/
M>K_ERX7:)@AQ$('\H!1A4D.*=/$*CKY$/%51&#U+?Y;(Q+!Q\N*W7Z&UUQ1!
M92+"R/%&N8K<JMPA;NBHN2] (L.B&WS+U(JCAIB@:&T<VY5T]9+DRF1W*Q P
M3T:F2DCSL"2_56;V'L5V:Y)<U>YSJHC),_4&Q_TC5UN'8\\IMZ[KN503<-=S
MZ:@H,[:AT@6$J;QR/_,=[<F;@Q"AWUG8!+>P2?=.O(3,)S?2;)D5LDXQ\:(K
M@^C0<]I7-DX3VHC5!8%WQ7PY5SM""\ET%*Z+F-7@D<+,XK9!M$KEM RAO"T.
M]-'B%#%:WN0"UP'J/UZ(*06MFGW=A'Q1$V**S"'Y[RZ\5(^VO333HFI/==IY
M+!U$.A#>O[4[<T6+$EKZH:-HXRSO%V?YK(VS_&E!L'\ @^[D$:\2XXAT<*BD
MF*FJU=U-KE4V#4OO88RC-*L8+ZT\&"T(L<[,6$L6Q%*9/68C5%>@?<UNI;6$
M@Q%OO.SLRK)6-L9C>5TMZ /'@M%65ZMSC6ZWKM'6-7I#YJMW5(8GU)1NA0>,
M^(5*_)TTJ.K@%MCTB=RJ$B2RV9E$=KNRPOBJ&BC!!Q-[3+37R3&M*G?";=XO
M,Q"SK%6"MS5\$>)9JK%3/A?HVXEU:RY^%[^N8KZ5"X C,CR9YX=G* :V8:8>
MZ&<=RO-7UJMJ)-V&3FZC8[A"B?9LJSO;=MJSK3W;;LGJMX^SOM08I7#&,:RE
M4#2?+Q.)G$K?2W,<BD[:GGX[R"[TH5U#/(@-R_FD[)YEMN#4.M6D%^D"ND[H
MH5(ME0<(*"SHA"-YK.-OE%%Y>,2B1"8]5ETWLSQU9FG;'*\B'T%+"!Y.&$X8
M^$D\G2.LB4YD5@^5B"WJB3#,,*T%;1+1+$+;#2$(ZGS1O9<[6][9YOO-+JW>
MQS3[Y!U$A>4F1;V<P@U],^2W"\?H1GE&&[\8P+G?.1EH3J$ORVE(Q[5OSMV<
M%K2'\K-,-VZBG$$N8#V;8,&&<AKH1DL+EDDO'#6Q-))*.BG8@T;*!N;N7R14
M+AVA=!/"@ U24"S( 9E=(5EYLE2CCE9(PU7CA"5]9?&8<$-&FU#I+0?"F%);
MI?=# @)0='\Z=^WECA>=M@Q- =Z^-"IQW]5"\Q]V@>ZV%VA[@3:24(G0Y&BL
M5%UV<A*32**@XV% A9*OE=.&_)2&&U[+_]+W:",+2'>L8VBM<T.BE<)?+-((
M.X$3YUIU:2&?7>BZD HD@_%^76QS$Z'&:$L.7P;.4>T&C=EC-LAHY>2)Q:K1
M"MV_+#5QO_[*BH:$;[*JZ_*&%DT*5!M7"%]Y<Z6($E"DR)8YE2 @341AY\LC
M/R_/>&/$)<[O;3R@!2C2_Z03">X$7C!9Z;"^,:F%:>0[@MK0/ADK$(%K,F K
M;*9RR9$R?B:%8'7@YF#G+U?VQ:^[F(] OE+"OHO@\G( <XJZ$)\8@3.4((!)
M")>H9DH13A%@)"ZB'*[X]H*JNZ#VV@NJO: :2?@^R@,1QPQ!WH;S?P_A_#_V
M7OJA, N]$4/U4;&4<0F8U819.#'$*!FMK,# 6,G2%U?@+_P@X@(<OE75PBSK
M4;JX'"Q[@E^#^UIYD'0=979AZ2C92[-B!I>@4?"!#G"@,H[**,8N>I(5J'\5
MYT,%0)=Y<XY?*@>91J/GS53B0_$@^AA20(5")(_Q3!2LXDS5>;)KA3CRH"ZQ
M@J3LDEK+Z(+%)6'A44YTHBMP5=#?=,VM2GD@N_H3(XFDLFQIM[9\D/S)J57&
M1<Q@BG,_OO 5P""5 5IQM)>1*++1U;Q0!LW,A4!Q.>_6\XF$F5RP<$W4ZUJ-
M=FT(,AUF9DMF+@IP)>W50.95!9DD9$!3G1DVFRR;$S6=@&0L(7(S@VK1N>1-
M+'TS7[";@"N]^-,HEEY<JSH/PL_4%.G%!SMN69S&O!YKM8@+\QL9M:O#U8ER
MYN@(&CK/A4KZ=]@;O@DR ;1)*Z"8;13-_:)HGK=1-#]M%$TK1WVE*?<5:FE8
MX_Z^/P!5C0I%BK$ZEO!W]=67'12/ 2&RMJ$AV/6]>.91^KVC,JM@(4H(?)E7
M1Y8AN.9#59P5CW[V+:P:K9"&&+QB?%N.BU5'Z6W>PKG$L2&KFU%0 2]A3#>(
M.4H,FC%,?Y0+(A'E4%YTY#H-X:]+8C4*<!::M90',ZXV6XD=*S-4-#"VFJWG
M7Z41T2T7XI.1O<#?(\'2*1H-E7"X$!G!E,K, $-4KJT\T?6FRX(#3C!V%Z$R
MB#FL8A8XUR@O5,A: *^2,PIIGG*A7%F;%7N062C4I?])PI_K9W0!K%S9?LN$
M905O# (H64A3-$,6"IN9A54U?VA3&0D=&!*[L,:%C_'+*/3YZ&I$*?*#R2[*
M7W<A$I$!BY?8ST:@NLF71*M.?X-8T\H16?B9#$N1A'=1>["8I1E$N/!7E'Y(
MD=*HBU53=ZLE$S6<2ZK@<^408.IZ!%VO\V:#T%]<RM^%\&7THYL1C&\21K;,
M-HK%18E,0Q46891^Q&G/29K@)LGS.@@C+?$WU[?$-CH'&]XREV@Y&4=H*@K@
MM*$+;%S,</DI'"F=,MRQGK:\B'Q9-Q;ZFR]T)((\C?+2NR 3RV0"(%9QG:8A
M>CTI!^>?L&WS,-*U/ D^OHZDE'RO5E?3#UF:-ZB#=IG7.7*^M]OGN[X8O^>;
M\0WN;GT<EI>92IVC2#Q9EY<@+JQJ-FYJIK.3\. H$?K4YFC(=*8:[#(!UL0@
MJ[M[;]Y)7(Q8[Z5"%:0T-Q5]6:3=VAURVXY#I38-*4:H>>_=#:GIYS="!ZWR
M]!,I3V/EFV5IJ@_BUT5S8<1QF89)<I),C%"X3%IHO4%*4OGO#WO5!?HP@ L-
M03?VKPG>PGA9P>;0_%P\$@R'<)YEH[@5AN"\6DII+..9&=C*NFME8"OL(,KR
M*WWB=\[.<$:I38[32,-HLD L"Y2427N%:Z16JV"6$KL44:8R$0T 3_PGMYF$
M*9%ONNQ0XG62VI4$HC2=WL%@"JV0F5R:Q*4MURC6<>,,5BPATEWQKR4H9U2O
M!@5Y-$^#9,N8%!1C@%0VLSMMT^^D(759L="<0"2!W.Q>4+&@]=QAC[,K(0"B
MK(FFK=^SK<#[DU\Y?=Q )&\BXW] <TVCQ[/$_RPQRS0FJ<)DJTO;UUI@[NY;
M-Q<$?V;UM12699T!:/0RFB((&CNN0(DW]2KY@GK:B6253_&1$!5=>6#8!_$E
MSFPJG4I.&O:-ETENB.>YC9N5I!Z5)9 %CN;^/T&4+HT-;CU.ZKVV^J9-Q@I>
M1WM4M46)?_:C*L#C!\7-I@-J)&/=*TB_5FJ9QOK0^ :Z8;;@A49--91_XMBV
MI;+LF[!#.J]41&GW8EOB]6??BV\Y:P4NN&/_^I6Y!_&?/QL6&SM?[/C8^]_S
MP7@R/#T9>P>G)P>#T<GPY*TW>3? C^/)Z/P ?^QZ?_2/AX?#R<>N-S@Y.AT=
M#-X/3B9>_^30&YY,!J.ST6#2QR>]TR-X>SCV/O1'HSX\,GZ'O;P9>&]/_X#6
M!X?>FX_TGFP?OL!/LE5LSNL?')R.#OLP&N_#</*.1G/<_S#FM@?>&+H:X(>3
MP0?OX^GH+_38Z?G$&PW>]D>'5EC8*;UR-AJ>' S/C@?4"'1]=#P\F- ':!D?
M&0U.CS:]0?_@G>KFX/3]6?^$!XN?WYT>'PY&'CX*4QB.1H,_3@_Z;XX_>N/S
M-^^'T)KL;/#7@^/S\?"/@??G\]%P?#@\*"FC1H^-'@V@O?XQ='0^@K?'P\D$
MB0\4H.Z!VN8DN]Z;T]'I^5L:W_O^R;O^9-*'E0&ZT?/]PS^?0U>T"B8%X&F<
MQ>%P?'8.'>/PST]P(O >= 6T.!GP /$G(CC\0O_%]R:PBN,^/P#/3@;OSXYA
M H>*#O L-'UP/A[+[Z#-#A#[& 8#DZ%V1H/Q&?2AZ6-PD!R=I(W9V>'IP3D^
M,M[H$K5JZ/ZA#T0>\\_]MZ,!K.[)*79CSK\/(QM-B*].<*F&$WA!KL@(&./T
M8## H7;I]X/C_O ]C*4/;\#_N,&SP6A\>@)\3$O]9V,J[@)S%\!#M*8/Y2>>
ME^[6@PG\,3P@EJ?QCL=Z!R&!<##J^S= _[>660K>E=M*C:V9!K@WW_>'Q_AG
M']H_^ZBVAO?'L(_;:SB&W0[MP6MP6$R&1T/X@*_@-[3#AV_?3;S#P3%,8?31
MZQ ##/X8'@Y.> ;JIPT<-HV'Y^D!R9F/#T<X$QCQX.@(:8T<#LL %*"I#B?F
M@M-2\;282M;DZ?"ADV8X0>Y_>WK*Y\WX_.AH>#!$%FR@+O=8'@WP^1W2!3=!
M?WA2<KL^X0X'P-.'.,3CX?NA9KD/_8_TWQ%1!B>-2Z+[DD_!CCX!;@!:P*L3
M/B;A:+H/"S';6+P/ Z-NB7!]V%]#8"=X%/CV8RL8U0E&%ZU@]!,)1N\$90;G
M;GZ?N4DNY3/*5H$AGC/VGUV))*)"N6B?0/AQLGV;N@KEKU4TG#+W70:0EU5G
M*-R!7/V,(VF$AAAV&NU6:W=H98=>MCOT)]JA8RPFS_'5JR9#PC!A2&+:*PFY
MSPF/N+IOW(UH %-0P R^NDP$UI .!!GV9"T+Z=QA@ZFN/T_P%.KAR Q+R@26
M]*:P)6V$N'4<'*M$_5U+PRL= AR2Q\%1(G1"^C,Q774KEEG'QR-#QQ"2K'"B
MQM!D@O83B4C D[-G%ALT5"D#9;ZK&?1C1OM0=BT?@RITBL?)\5.R6XK<4EG4
M92J'3'[5+93]1XE-@'M#H-6P]KT"9AZKU.G?1@,0C%G5 M&R_W9 NO()BMVD
M2QP/CB;>F^/^R5^J)5@;(_J_)$_@!\X&>-&<#5 ;ZW][CL!=LP%NCO9W<@4>
M'/YO91C<(Q?@42L)@BH"ZMH):B4?6.WI5CPRY"4.[=.-G3KA,B8XM&!9*,=.
MKJ.5\(B;S:* (T7E(4KH+)R.CG[Z@, 4*3[S\<HGFA=.;7E(AO4T>F/W.*;>
MYI@(EUS\_F3K"7U>8-J3_,P+3W]&X>]/_OWLQ:X0O>UP;VO_Q>Y^N W_#H.I
MV/%G81C,=LJ-^X5;IH[[@)=B?Y'#,^JONI"X2L*)V@#&1BC, M7X.53#EOWN
M8;<5I'@$B:_0%CL$"B:_/^F5="["I@[NV&B67JM&RPZVGUBM/B++/'D-:OI?
M!A/O[%U_]+Y_,#B?# _ZQ^,NG.4'F_9IQ)O5FB%\M$I^/XR^\R@,8_'E)%9]
MW*>+!ZQ<4UN*=W=A  WM/@Z]'H4?;R!6??OK8\$WJY>W<EK=V'<;!R\/#B4>
MP&7E4?J$EUU,.UM=#_^W43LEYZMU7TG5\[F<_U?9>S\;+YWX<_'8W'3'0Z-=
MD%JX;DS#_AY61$F;)/^TNDBS+K+?ZB)W6+@O/OK1.'3P;G!X?CSP)!#]5^W<
ML7I^W?Z/3D?OT6PP^.M@=# <#Z0[RAK2M[%J3$C9,_6\!KB&IG)(NA*]5!__
M_O!)/8Z,<>Q3?@N:KMX"E6(,-7KY];J_8<XE6>ZFE)(FNO5L&NZ]V!;/=G;$
M[NRY>#'=VYGN[P@QG8EP]CS4)^KA^.SH.,J+";:]%OWT'DJHJ89698.ZVZ^'
M9NWZZ\_LE^+<;[_1'_5.[_0VZD56YTJOFY:_+-('2B6/*Y=<"MZK,G@_<M&
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M+^W:+RWAB&\0?S_?1\2+^+OVA_\!4$L! A0#%     @ ,8 O5\-E%+5R%P
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M,#(S,#DQ,E]L86(N>&UL4$L! A0#%     @ ,8 O5RD;HKC>!0  ^3X  !4
M             ( !P#P! ')C:W0M,C R,S Y,3)?<')E+GAM;%!+!08
..!P ' -(!  #10@$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
